{"meta":{"query_hash":"929586e20008","filters":{"venue":"Blood Cancer Journal"},"cohort_total":129,"direct_labels_cover":0,"predictions_cover":129,"exported":129,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/929586e20008","api":"https://metacan.xera.ac/api/v1/cohort?venue=Blood+Cancer+Journal"},"results":[{"id":"W1964507957","doi":"10.1038/bcj.2014.75","title":"Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Weill Cornell Medical College","keywords":"Lymphoma; Suppressor; Burkitt's lymphoma; Cancer research; Tumor suppressor gene; Gene; DNA methylation; Medicine; Biology; Immunology; Carcinogenesis; Genetics; Gene expression","score_opus":0.00527948037420535,"score_gpt":0.23228438118724476,"score_spread":0.22700490081303942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964507957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302727,0.0041131387,0.00003184046,0.000874339,0.00033096198,0.00031023295,0.00003932224,0.000010736424,0.0012621544],"genre_scores_gemma":[0.9982186,0.0003868429,0.00013542805,0.0007162552,0.00033225876,0.00003467615,0.0000065034574,0.0000315483,0.00013787471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998288,0.0001799491,0.00047016414,0.00021539713,0.00047218046,0.00037433286],"domain_scores_gemma":[0.99899036,0.00004012734,0.00040668933,0.00023065992,0.00018436479,0.00014778734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041387815,0.00017675078,0.0003812036,0.00013478548,0.00011755857,0.000027507545,0.00015600739,0.000097713986,0.00017344486],"category_scores_gemma":[0.000115969444,0.00012830083,0.00019485297,0.00033050924,0.000072936986,0.0000867483,0.00004060817,0.00024354752,0.0000021373735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007873401,0.00094673777,0.5205089,0.0001056734,0.0004119445,0.00011428408,0.0024697806,0.0009550774,0.42384523,0.000054441505,0.0010600068,0.048740588],"study_design_scores_gemma":[0.012166793,0.00064157986,0.80339104,0.00044719965,0.00063468056,0.00053036516,0.00049135555,0.0005659725,0.17894222,0.0008370462,0.0011059815,0.0002457829],"about_ca_topic_score_codex":0.00037582283,"about_ca_topic_score_gemma":0.00020247548,"teacher_disagreement_score":0.28288212,"about_ca_system_score_codex":0.00018687456,"about_ca_system_score_gemma":0.0005932666,"threshold_uncertainty_score":0.5231956},"labels":[],"label_agreement":null},{"id":"W1974642141","doi":"10.1038/bcj.2012.27","title":"Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Cancer Society Research Institute; Killam Trusts; University of Alberta; Alberta Cancer Foundation","keywords":"SOX2; Anaplastic large-cell lymphoma; Biology; Cancer research; Anaplastic lymphoma kinase; Embryonic stem cell; Stem cell; Carcinogenesis; Cell culture; Cancer stem cell; Molecular biology; Cell biology; Lymphoma; Cancer; Immunology; Pathology; Genetics; Medicine; Gene","score_opus":0.02941579013763417,"score_gpt":0.2718289785923664,"score_spread":0.2424131884547322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974642141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96896154,0.02943284,0.00038831838,0.00006958571,0.000383064,0.00024255282,0.00022189101,0.000010162429,0.00029006234],"genre_scores_gemma":[0.9942727,0.0045751315,0.0004101115,0.00012842566,0.0004012187,0.0000231249,0.000009355621,0.000022616427,0.00015728376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998307,0.00015151047,0.00041919606,0.00025952162,0.0003378778,0.0005248814],"domain_scores_gemma":[0.999034,0.00006522672,0.00023010132,0.00013456574,0.00009380344,0.00044231402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003236648,0.00022120027,0.00047216314,0.00014251683,0.00009668762,0.000020006,0.00009589837,0.0001312998,0.00036544827],"category_scores_gemma":[0.000004732121,0.00016553169,0.00012752328,0.00015725597,0.000079505066,0.00023170358,0.000022792276,0.00030091533,0.000001951122],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011287358,0.0031875954,0.07781842,0.00021586925,0.000073267096,0.00006167359,0.002354454,0.000016034784,0.90578085,0.000024913235,0.00013375813,0.00920444],"study_design_scores_gemma":[0.022730209,0.0018109021,0.4260507,0.0006290846,0.00042502538,0.00043591022,0.0018022908,0.000058658257,0.5405561,0.000021736621,0.005044077,0.00043533937],"about_ca_topic_score_codex":0.000070762646,"about_ca_topic_score_gemma":0.00005958506,"teacher_disagreement_score":0.36522475,"about_ca_system_score_codex":0.0001220296,"about_ca_system_score_gemma":0.0002955549,"threshold_uncertainty_score":0.6750186},"labels":[],"label_agreement":null},{"id":"W2006431669","doi":"10.1038/bcj.2011.50","title":"Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Calpain; Calpastatin; Proteases; Apoptosis; Leukemia; K562 cells; Cancer research; Chemistry; Biology; Immunology; Molecular biology; Biochemistry; Enzyme","score_opus":0.006550593439214601,"score_gpt":0.23700384503349856,"score_spread":0.23045325159428395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006431669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356157,0.001282574,0.004558825,0.00008907084,0.00022355925,0.00018509816,0.000012011714,0.000012003173,0.000075304466],"genre_scores_gemma":[0.9981267,0.0002944546,0.0005492074,0.00014883566,0.00042525827,0.000040931496,0.00003141604,0.000024554633,0.0003586822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989235,0.00016983086,0.00018703066,0.00018153769,0.00018428649,0.00035385092],"domain_scores_gemma":[0.99937075,0.000013472046,0.00016422845,0.0001440903,0.00008180158,0.00022562424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032394455,0.00016131093,0.00014552247,0.00007075315,0.00014422803,0.00002788743,0.000082615596,0.00015828849,0.00009626008],"category_scores_gemma":[0.000033096105,0.000121657264,0.000059206985,0.00013411308,0.000046795794,0.000017331915,0.000029995515,0.00027315714,0.000002931594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008576343,0.00016776663,0.06549687,0.00000961985,0.000111092806,0.000018310333,0.00010990285,0.0005844829,0.9250963,0.0000026753644,0.00079087046,0.0067545064],"study_design_scores_gemma":[0.0035669901,0.00034896366,0.082090646,0.000117340714,0.00012218194,0.0005741745,0.00008785118,0.00027807837,0.90881723,0.000015644899,0.0036774387,0.00030345222],"about_ca_topic_score_codex":0.00009308951,"about_ca_topic_score_gemma":0.00011744948,"teacher_disagreement_score":0.016593777,"about_ca_system_score_codex":0.000099596946,"about_ca_system_score_gemma":0.00032378675,"threshold_uncertainty_score":0.49610394},"labels":[],"label_agreement":null},{"id":"W2007454067","doi":"10.1038/bcj.2013.23","title":"Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity","year":2013,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; Cytolysis; Virology; Leukemia; Immunology; Acute leukemia; Virus; Virotherapy; Biology; Myeloid leukemia; Medicine; Cancer research; Cytotoxicity; In vitro","score_opus":0.013750943640296541,"score_gpt":0.28983553832291326,"score_spread":0.2760845946826167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007454067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686171,0.029294452,0.000020408754,0.00022716406,0.00089347333,0.00026540557,0.00017694577,0.000010784286,0.00049425696],"genre_scores_gemma":[0.869524,0.11947612,0.00028748138,0.00021375492,0.0024350472,0.00017110811,0.00032645,0.00015069242,0.0074153617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977691,0.00023470508,0.0005699885,0.0005095164,0.0004100519,0.0005066128],"domain_scores_gemma":[0.99802506,0.000014849844,0.0007512305,0.00063032773,0.00032697766,0.00025157016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005603477,0.00037379595,0.0005682514,0.00013771644,0.00033782763,0.00012487959,0.00053139153,0.00044464538,0.00012423951],"category_scores_gemma":[0.00005940345,0.0003432083,0.00020629277,0.00019996995,0.00028243609,0.000018549987,0.00020516063,0.0011539112,0.000004554237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037824357,0.00007271073,0.00042656655,0.00006292723,0.0014016898,0.000006263312,0.00006298956,0.0000110561705,0.8593676,1.6025241e-7,0.12872969,0.009480093],"study_design_scores_gemma":[0.0012511702,0.0012547786,0.0009962368,0.00018018731,0.00047767026,0.00013572759,0.000053362925,0.000064068015,0.9802307,0.000016135244,0.014945796,0.00039417786],"about_ca_topic_score_codex":0.00043661884,"about_ca_topic_score_gemma":0.00014183215,"teacher_disagreement_score":0.12086307,"about_ca_system_score_codex":0.00009440004,"about_ca_system_score_gemma":0.0010281813,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W2015577159","doi":"10.1038/bcj.2012.47","title":"Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Receptor tyrosine kinase; Cancer research; KRAS; Somatic cell; Signal transduction; ERBB3; Germline mutation; Mutation; Multiple myeloma; Genetics; Gene; Cell biology; Immunology","score_opus":0.014892732451273484,"score_gpt":0.27513573417818304,"score_spread":0.26024300172690956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015577159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682743,0.01144139,0.0000587286,0.0008201751,0.000049731458,0.00069003395,0.000077896395,0.000025363517,0.000009235104],"genre_scores_gemma":[0.99432075,0.001651647,0.0034116989,0.00018661482,0.00009448556,0.00016986151,0.00003729857,0.000035831235,0.00009180568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985074,0.00010934373,0.0003459827,0.0002842138,0.0003251561,0.00042792308],"domain_scores_gemma":[0.99891025,0.00018990962,0.000119546465,0.00013761895,0.00013403656,0.00050863833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001125176,0.00021951573,0.0003322095,0.00019623904,0.00021665468,0.00012425668,0.000063824016,0.000086592074,0.0005192545],"category_scores_gemma":[0.00024008736,0.00017618538,0.000061144674,0.00015775803,0.00008678588,0.0001724201,0.00004366512,0.00029230316,0.00001977206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019851953,0.00070576294,0.3479345,0.00018040878,0.00037275784,0.00030229735,0.0007239542,0.000026969394,0.6157781,5.3590776e-7,0.0008643318,0.03291183],"study_design_scores_gemma":[0.03367476,0.0013989006,0.33834428,0.0016847879,0.00041269624,0.0014522986,0.00056096487,0.019958386,0.60150826,0.00015662856,0.0002711586,0.0005768515],"about_ca_topic_score_codex":0.0007889593,"about_ca_topic_score_gemma":0.00014362957,"teacher_disagreement_score":0.03347624,"about_ca_system_score_codex":0.00008499035,"about_ca_system_score_gemma":0.00010714678,"threshold_uncertainty_score":0.7184631},"labels":[],"label_agreement":null},{"id":"W2017202925","doi":"10.1038/bcj.2015.14","title":"Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Ontario Ministry of Research and Innovation; University of California, San Diego; National Cancer Institute; Ontario Genomics; National Institutes of Health; National Center for Advancing Translational Sciences; Ontario Institute for Cancer Research; Government of Canada; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada","keywords":"Epigenetics; DNA methylation; Somatic evolution in cancer; Biology; Chronic lymphocytic leukemia; Tumor progression; Genetics; Somatic cell; Methylation; Leukemia; CpG site; Disease; Cancer research; Cancer; DNA; Medicine; Gene; Pathology; Gene expression","score_opus":0.03955269313648678,"score_gpt":0.32959255775537166,"score_spread":0.29003986461888487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017202925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97681534,0.021542253,0.00039999306,0.00033881335,0.000069327,0.0007592602,0.0000028297816,0.000014146688,0.00005800902],"genre_scores_gemma":[0.9816577,0.00024258383,0.017611854,0.000039973347,0.00015725404,0.000073812684,0.000002551298,0.000023648081,0.00019063613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822956,0.00012427999,0.00047157845,0.00022998224,0.0006391873,0.00030542782],"domain_scores_gemma":[0.9982796,0.000085746215,0.00018252087,0.0001828162,0.00032581465,0.0009435583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062003575,0.0001396482,0.00025437254,0.00021960084,0.000117222684,0.00003421729,0.00007385431,0.00006628713,0.000011555015],"category_scores_gemma":[0.0005320694,0.00011301056,0.00002869462,0.0002459349,0.000069813796,0.000064650325,0.00008591769,0.0002113627,0.0000039452007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010426327,0.00045923097,0.9605453,0.002145335,0.00014269316,0.000300226,0.0030597511,0.0005236822,0.01627,0.000014331473,0.00035440284,0.0151424175],"study_design_scores_gemma":[0.02698281,0.00085782737,0.9335361,0.0039849905,0.00067241484,0.0013388505,0.00050101196,0.005033887,0.026012227,0.0006501264,0.00008979454,0.00033995815],"about_ca_topic_score_codex":0.000029649296,"about_ca_topic_score_gemma":0.000012801018,"teacher_disagreement_score":0.027009195,"about_ca_system_score_codex":0.0021006828,"about_ca_system_score_gemma":0.008339125,"threshold_uncertainty_score":0.9972827},"labels":[],"label_agreement":null},{"id":"W2018993327","doi":"10.1038/bcj.2015.11","title":"The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Generalitat de Catalunya; National Cancer Institute; Instituto de Salud Carlos III; Celgene","keywords":"Single-nucleotide polymorphism; Allele; Biology; Myelodysplastic syndromes; Internal medicine; Genotype; Allele frequency; Genetics; Gastroenterology; Bone marrow; Immunology; Medicine; Gene","score_opus":0.05709215149485445,"score_gpt":0.3246878956104926,"score_spread":0.26759574411563813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018993327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98361766,0.010091246,0.0003206287,0.004970914,0.0004970711,0.00029683564,0.000015616984,0.000013840161,0.00017619025],"genre_scores_gemma":[0.99883914,0.00019121531,0.00028006645,0.00020312858,0.00016087266,0.000030326164,0.000002977254,0.000023864206,0.00026841395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863595,0.000083744046,0.00045910908,0.00015869467,0.0004303315,0.00023217528],"domain_scores_gemma":[0.998823,0.00015719893,0.00018235442,0.00018673574,0.00014337312,0.0005073407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044796543,0.00012614421,0.00022875679,0.00021550694,0.00010305174,0.000035219273,0.0000880201,0.000059492537,0.000020681624],"category_scores_gemma":[0.0010731189,0.00009462082,0.000062613064,0.0003246282,0.00007042668,0.00007684955,0.00003309029,0.0003858154,0.000007142613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010641818,0.00017618985,0.9829327,0.00010290879,0.00020396477,0.0009261492,0.0014198176,0.0016372942,0.0016190653,0.00073334516,0.0010780237,0.008106372],"study_design_scores_gemma":[0.0058131143,0.00043245454,0.9875226,0.00069503795,0.00062832097,0.001630157,0.00036737756,0.00031538986,0.0003459588,0.0011702001,0.0009013017,0.00017810026],"about_ca_topic_score_codex":0.00009543114,"about_ca_topic_score_gemma":0.00013146516,"teacher_disagreement_score":0.015221478,"about_ca_system_score_codex":0.0001918892,"about_ca_system_score_gemma":0.0006697953,"threshold_uncertainty_score":0.3858525},"labels":[],"label_agreement":null},{"id":"W2019849294","doi":"10.1038/bcj.2013.50","title":"Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Cathepsin B; Chronic lymphocytic leukemia; Cancer research; Vorinostat; Cathepsin; Apoptosis; Histone deacetylase; Medicine; Immunology; Chemistry; Leukemia; Histone; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.021099606938949234,"score_gpt":0.29001114830507463,"score_spread":0.2689115413661254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019849294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98304373,0.013206369,0.000042507498,0.0017168212,0.00018745275,0.0016638848,0.000015059771,0.00004415351,0.0000800228],"genre_scores_gemma":[0.99540496,0.0012000576,0.00023406852,0.00027932948,0.0013456263,0.0003850474,0.000004824001,0.00008926296,0.0010567971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957845,0.0006187287,0.00086445175,0.0005620683,0.001008926,0.0011612952],"domain_scores_gemma":[0.99744445,0.0005778791,0.00028554676,0.00069959497,0.00026445152,0.0007281008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016327406,0.00044361834,0.0007247436,0.00040016213,0.00034379668,0.00025616295,0.0005024671,0.00022795501,0.0005315512],"category_scores_gemma":[0.0006026759,0.00029819313,0.00017390236,0.00065084785,0.0005421061,0.00029282182,0.00022178957,0.0011841616,0.00011995114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0049404358,0.0004910094,0.021079876,0.0022250419,0.0015807109,0.003219551,0.0036256183,0.0017579882,0.93248063,0.00006616017,0.004547227,0.023985734],"study_design_scores_gemma":[0.1723211,0.0056537353,0.13173836,0.0072059585,0.0033357986,0.010458642,0.0013466647,0.03730498,0.62370175,0.002019094,0.002626974,0.0022869257],"about_ca_topic_score_codex":0.003987858,"about_ca_topic_score_gemma":0.00018511187,"teacher_disagreement_score":0.30877888,"about_ca_system_score_codex":0.035767406,"about_ca_system_score_gemma":0.040212393,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W2024362879","doi":"10.1038/bcj.2012.43","title":"Extremely low-frequency magnetic fields and survival from childhood acute lymphoblastic leukemia: an international follow-up study","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Electromagnetic Fields and Biological Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Electric Power Research Institute; Kræftens Bekæmpelse","keywords":"Hazard ratio; Medicine; Confidence interval; Internal medicine; Lymphoblastic Leukemia; Survival analysis; Overall survival; Proportional hazards model; Prospective cohort study; Survival rate; Leukemia","score_opus":0.008271763767366908,"score_gpt":0.24760234984613883,"score_spread":0.23933058607877192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024362879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992756,0.005148726,0.00008995103,0.000119438395,0.001331276,0.00016363716,0.00002955833,0.000011237846,0.0003501785],"genre_scores_gemma":[0.99513936,0.0018186526,0.0002877215,0.0003456997,0.002148374,0.000025429032,0.000032629625,0.000017871573,0.00018426415],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986655,0.00014529598,0.00025670227,0.0003130933,0.0002187951,0.00040059173],"domain_scores_gemma":[0.99931496,0.000028738361,0.000107698135,0.00020542719,0.000079440615,0.00026374252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002273058,0.00021721322,0.00020693139,0.000035900128,0.00013605403,0.00008683317,0.00030904502,0.00022035802,0.0003181247],"category_scores_gemma":[0.000067354464,0.00016773184,0.00008542338,0.000055276963,0.00004899003,0.000023137427,0.00011082732,0.00029068228,0.000003071197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032687676,0.0011265479,0.29443657,0.000007173689,0.0008022489,0.00006462453,0.00040786076,0.00000660274,0.676491,0.000035630135,0.00041450703,0.025880309],"study_design_scores_gemma":[0.011686122,0.021550348,0.9333249,0.000080268896,0.0009434853,0.00063427986,0.00033392292,0.00005233724,0.029412733,0.00055033393,0.00052756007,0.00090372376],"about_ca_topic_score_codex":0.00019360307,"about_ca_topic_score_gemma":0.00021985684,"teacher_disagreement_score":0.6470783,"about_ca_system_score_codex":0.000027845494,"about_ca_system_score_gemma":0.00013017016,"threshold_uncertainty_score":0.6839906},"labels":[],"label_agreement":null},{"id":"W2031119437","doi":"10.1038/bcj.2013.43","title":"Pharmacological targeting of eIF4E in primary CLL lymphocytes","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"EIF4E; Chronic lymphocytic leukemia; Medicine; Cancer research; Myeloid leukemia; Leukemia; Immunology; PI3K/AKT/mTOR pathway; Oncology; Biology; Translation (biology); Signal transduction; Genetics; Messenger RNA","score_opus":0.018326670456457937,"score_gpt":0.31478625160718254,"score_spread":0.2964595811507246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031119437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572236,0.009815337,0.000011704496,0.00064039015,0.00019955254,0.00033189522,0.0000026351106,0.000016799133,0.0032593084],"genre_scores_gemma":[0.9937187,0.0033643355,0.0011398381,0.00059805124,0.0006988264,0.00005563482,0.0000025364304,0.000022342338,0.00039972833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806535,0.0000950368,0.00055401423,0.00019437597,0.0005815697,0.0005096328],"domain_scores_gemma":[0.9990492,0.00014135918,0.00017504623,0.00011346877,0.00024562454,0.00027533696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052546524,0.00014085828,0.00040942553,0.00017403267,0.000054660493,0.000028539072,0.0002008292,0.00010620418,0.0033917103],"category_scores_gemma":[0.00015054771,0.00010444548,0.000118944554,0.00028454885,0.00012339662,0.0001581595,0.00009596355,0.0005097206,0.000038958213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00121422,0.0018465029,0.12034715,0.00088261045,0.00094695546,0.0021251559,0.0010030717,0.0004600306,0.77489626,0.000038844617,0.04051947,0.055719703],"study_design_scores_gemma":[0.21851915,0.0020380868,0.1816919,0.0023552033,0.0010714707,0.009813863,0.0009655401,0.011585319,0.562879,0.00072318735,0.0074057733,0.0009514919],"about_ca_topic_score_codex":0.0009362663,"about_ca_topic_score_gemma":0.0000082423985,"teacher_disagreement_score":0.21730493,"about_ca_system_score_codex":0.006384425,"about_ca_system_score_gemma":0.008137762,"threshold_uncertainty_score":0.9975193},"labels":[],"label_agreement":null},{"id":"W2038656901","doi":"10.1038/bcj.2011.52","title":"Drug-mediated inhibition of Fli-1 for the treatment of leukemia","year":2012,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Cancer research; Oncogene; Carcinogenesis; Leukemia; Transcription factor; Haematopoiesis; Drug; Biology; Cell growth; Apoptosis; Loss function; Oncogene Proteins; Gene; Medicine; Pharmacology; Regulation of gene expression; Immunology; Stem cell; Phenotype; Cell biology; Cell cycle; Genetics","score_opus":0.030514505918436734,"score_gpt":0.3259653408600217,"score_spread":0.29545083494158497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038656901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436457,0.012989056,0.00013478514,0.0013712406,0.00024057824,0.0005052056,0.00005915658,0.000007496978,0.00032793806],"genre_scores_gemma":[0.9891251,0.008113925,0.00056273007,0.0001055861,0.0013469715,0.00008681916,0.000011125938,0.000022021357,0.0006257314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989049,0.000041138766,0.00033209712,0.0000761793,0.00033184586,0.00031384104],"domain_scores_gemma":[0.99892247,0.00024303605,0.00022029933,0.00016970461,0.00027502447,0.0001694712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039031124,0.000103893806,0.00027572925,0.00009888937,0.00008275136,0.0000062591043,0.00006894665,0.000056510296,0.00023146815],"category_scores_gemma":[0.000073201394,0.000059135935,0.00017452975,0.00016345519,0.00009697059,0.00008237624,0.000011370803,0.00016644213,0.000003663596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051515424,0.005413216,0.16177727,0.00081926276,0.0054305866,0.000058336664,0.014108382,0.00015588345,0.55486274,0.00045451583,0.069075294,0.18269295],"study_design_scores_gemma":[0.024099993,0.0029740883,0.0393816,0.0004076426,0.0020654153,0.00053666555,0.0012748449,0.00046596077,0.86284274,0.000073298164,0.06569188,0.00018586038],"about_ca_topic_score_codex":0.00020088247,"about_ca_topic_score_gemma":0.000021482752,"teacher_disagreement_score":0.30798,"about_ca_system_score_codex":0.00061930186,"about_ca_system_score_gemma":0.00086366636,"threshold_uncertainty_score":0.2534414},"labels":[],"label_agreement":null},{"id":"W2045832601","doi":"10.1038/bcj.2013.24","title":"BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leukaemia and Lymphoma Research; Cancer Research UK; Genome Canada; Wellcome Trust; GlaxoSmithKline; Ontario Ministry of Research and Innovation; Pfizer; Eli Lilly and Company","keywords":"Bromodomain; Downregulation and upregulation; BET inhibitor; Cancer research; Dexamethasone; BRD4; Cytotoxic T cell; Cell cycle checkpoint; Medicine; In vitro; Cell cycle; Biology; Immunology; Epigenetics; Gene; Internal medicine; Genetics; Cancer","score_opus":0.010328341450849276,"score_gpt":0.23233811758586947,"score_spread":0.2220097761350202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045832601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943311,0.002770124,0.00060737017,0.00035343636,0.00026870138,0.000388489,0.000011619823,0.000015327636,0.0012538292],"genre_scores_gemma":[0.9953861,0.0010808049,0.00068996224,0.0011659245,0.00062591163,0.00012019558,0.00007072067,0.00003213629,0.00082823547],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987281,0.00010947166,0.00034918185,0.00026844084,0.00022375441,0.00032105655],"domain_scores_gemma":[0.99936813,0.00001202831,0.00019280556,0.000173356,0.0001113226,0.00014237271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001593325,0.00019144946,0.0001908501,0.00012575302,0.00009951163,0.00010994087,0.00016291041,0.00017209498,0.00020154654],"category_scores_gemma":[0.00003222308,0.00015229033,0.00009730071,0.00023645883,0.000051345305,0.000028595423,0.00006327317,0.0002178398,0.00002501638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005543592,0.00090355705,0.0057000453,0.000060371895,0.00028173707,0.000029585199,0.00012915155,0.000092434384,0.963439,0.000029377316,0.008990292,0.019790107],"study_design_scores_gemma":[0.019038284,0.004314403,0.021763146,0.00024679114,0.0004837801,0.0016810214,0.00026054526,0.00037799595,0.9412185,0.0011845636,0.008154718,0.0012762768],"about_ca_topic_score_codex":0.000034657434,"about_ca_topic_score_gemma":0.000012148634,"teacher_disagreement_score":0.022220507,"about_ca_system_score_codex":0.00010827436,"about_ca_system_score_gemma":0.00043170925,"threshold_uncertainty_score":0.6210219},"labels":[],"label_agreement":null},{"id":"W2048050781","doi":"10.1038/bcj.2012.44","title":"The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"National Cancer Institute","keywords":"Haematopoiesis; Progenitor cell; Suppressor; Cancer research; Hematopoietic cell; Progenitor; Immunology; Stem cell; Hematopoietic stem cell; Biology; Medicine; Cell biology; Internal medicine; Cancer","score_opus":0.009836884992128394,"score_gpt":0.26679489073152185,"score_spread":0.2569580057393935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048050781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912631,0.0046751727,0.000004077268,0.002315758,0.00006693658,0.0006134486,0.0000045479137,0.0000042671572,0.0010526807],"genre_scores_gemma":[0.9987864,0.00027658493,0.0002070027,0.00006969785,0.00028493445,0.000092277005,0.0000010127286,0.00001661181,0.00026546844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840695,0.00016508186,0.0004418938,0.00010139423,0.00060082163,0.0002838372],"domain_scores_gemma":[0.9988996,0.00014969762,0.00027554214,0.00028896413,0.00030629,0.000079920355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065859355,0.00009669475,0.0002188424,0.00008252155,0.00009963711,0.000036882597,0.0003198081,0.000045491433,0.0002672596],"category_scores_gemma":[0.00008229398,0.000049240258,0.00009537223,0.00023536896,0.00013234196,0.00009255619,0.00004124826,0.00047286556,0.000008857134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003474023,0.000556581,0.045369733,0.00025940043,0.0001799708,0.00002890136,0.0034841702,0.000058414167,0.93845373,0.00019544977,0.0051932735,0.0058729635],"study_design_scores_gemma":[0.0035010085,0.0004121047,0.078290895,0.00026236853,0.0001783926,0.0006849549,0.0030233972,0.00087105774,0.9082563,0.0017876999,0.0026362485,0.000095610325],"about_ca_topic_score_codex":0.00027246418,"about_ca_topic_score_gemma":0.00002237469,"teacher_disagreement_score":0.032921158,"about_ca_system_score_codex":0.00007715663,"about_ca_system_score_gemma":0.0004657783,"threshold_uncertainty_score":0.29263052},"labels":[],"label_agreement":null},{"id":"W2070181143","doi":"10.1038/bcj.2013.25","title":"Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University","funders":"Canadian Institutes of Health Research; McGill University","keywords":"EIF4E; PI3K/AKT/mTOR pathway; Initiation factor; Cancer research; Biology; Translation (biology); Eukaryotic initiation factor; Signal transduction; eIF4A; Cell biology; EIF4A1; Eukaryotic translation; Messenger RNA; Genetics; Gene","score_opus":0.012552256503552732,"score_gpt":0.2616538805580792,"score_spread":0.24910162405452646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070181143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932038,0.004262798,0.0014545589,0.0005374498,0.0002612566,0.00015850207,0.00006283412,0.000010185507,0.000048622907],"genre_scores_gemma":[0.9975188,0.00078819337,0.00045407552,0.00062036136,0.0003992259,0.000036081223,0.000029133258,0.000034097724,0.00012005962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988464,0.00014180689,0.00033571495,0.00020335492,0.00023200488,0.0002407187],"domain_scores_gemma":[0.99912775,0.000020943473,0.00031155968,0.00016926668,0.00026476252,0.0001057105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022307731,0.00015330216,0.00016150692,0.00006725315,0.00008964882,0.000046239293,0.0001310448,0.0001511462,0.0005581544],"category_scores_gemma":[0.000074258525,0.00014671369,0.00009825887,0.00010273071,0.000051899573,0.000021290476,0.000023937617,0.0001843249,0.000005284449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029873982,0.00007030196,0.004073363,0.000015540152,0.000112651076,0.0000017042872,0.000110692694,0.00014947954,0.9857697,0.0000010639633,0.0073786275,0.002018135],"study_design_scores_gemma":[0.0017631322,0.0003711824,0.010252425,0.00007490778,0.000030093603,0.000035373352,0.000037330414,0.000074607444,0.9855024,0.000076430115,0.0016004785,0.00018161729],"about_ca_topic_score_codex":0.000053188345,"about_ca_topic_score_gemma":0.0000042356633,"teacher_disagreement_score":0.0061790626,"about_ca_system_score_codex":0.000057016357,"about_ca_system_score_gemma":0.00025378316,"threshold_uncertainty_score":0.61113995},"labels":[],"label_agreement":null},{"id":"W2081446512","doi":"10.1038/bcj.2014.71","title":"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Takeda Pharmaceuticals International; Takeda Oncology; Weill Cornell Medical College","keywords":"Medicine; Ixazomib; Follicular lymphoma; Nausea; Internal medicine; Neutropenia; Tolerability; Adverse effect; Pharmacodynamics; Gastroenterology; Lymphoma; Proteasome inhibitor; Pharmacokinetics; Pharmacology; Multiple myeloma; Toxicity; Carfilzomib","score_opus":0.014046845654841822,"score_gpt":0.27365247284934247,"score_spread":0.25960562719450064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081446512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865896,0.00014003355,0.000004007082,0.00012861274,0.00013678096,0.0008264788,0.000010725105,0.000013400284,0.000081013226],"genre_scores_gemma":[0.999091,0.000017676497,0.00025906638,0.00011545791,0.00032314315,0.00012574717,0.000026857117,0.000024181589,0.000016832413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982742,0.00014433313,0.00048055916,0.00023856842,0.00066008884,0.00020224557],"domain_scores_gemma":[0.9988695,0.000035030447,0.00036752893,0.00020715376,0.00026137542,0.00025943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025349957,0.00018010283,0.00034206014,0.00019479204,0.00009195303,0.000028415272,0.00007290313,0.00006828802,0.000061572304],"category_scores_gemma":[0.00005101791,0.00012844523,0.0000464325,0.00020835378,0.000050558352,0.00030417385,0.000015843205,0.00013664394,0.0000023174011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012608975,0.036151942,0.9324747,0.000024748413,0.0002008756,0.000025237629,0.00086583395,0.000058565518,0.00027066818,0.00001724776,0.00007341853,0.028575864],"study_design_scores_gemma":[0.10328675,0.014472968,0.8798629,0.0003211006,0.00029411592,0.000024967392,0.00011983292,0.000079770616,0.0012385447,0.000048301623,0.00012722788,0.00012349327],"about_ca_topic_score_codex":0.0002102274,"about_ca_topic_score_gemma":0.00014007014,"teacher_disagreement_score":0.10202586,"about_ca_system_score_codex":0.00028441494,"about_ca_system_score_gemma":0.0004819145,"threshold_uncertainty_score":0.52378446},"labels":[],"label_agreement":null},{"id":"W2095588623","doi":"10.1038/bcj.2013.14","title":"The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Internal medicine; Oncology; Myeloid leukemia; Medicine; Univariate analysis; Fms-Like Tyrosine Kinase 3; Cytogenetics; Leukemia; Karyotype; Multivariate analysis; Mutation; Biology; Chromosome; Genetics; Gene","score_opus":0.006879801731779407,"score_gpt":0.26989237800630467,"score_spread":0.26301257627452523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095588623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749607,0.0014173876,0.000016693059,0.00023989653,0.000049122853,0.0006914678,0.0000383191,0.000007201532,0.000043833745],"genre_scores_gemma":[0.99466276,0.0046133157,0.00043046565,0.00003123083,0.00009386242,0.000059089834,0.000007940624,0.000030207655,0.000071115035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985593,0.00010563578,0.00037924165,0.00017894845,0.00039601285,0.0003808924],"domain_scores_gemma":[0.9986639,0.00021804633,0.00025287145,0.0001829117,0.0003940397,0.00028822504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002672308,0.00017149195,0.00028610794,0.00016946324,0.00017473548,0.000085403146,0.0001260859,0.00007946739,0.00005082375],"category_scores_gemma":[0.00023363833,0.00009512582,0.000052156236,0.00025353284,0.00031594932,0.00014585222,0.000070895025,0.000743926,0.0000025406068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041395373,0.000089171284,0.98232585,0.000025230356,0.000552609,0.000026597389,0.00062688,0.000045025703,0.00059069233,0.0000014456311,0.00035288872,0.014949683],"study_design_scores_gemma":[0.00855045,0.0022291357,0.9871119,0.00022382144,0.0004411927,0.00018763254,0.00018436884,0.00040671698,0.00045196622,0.00008850998,0.000018864997,0.00010538883],"about_ca_topic_score_codex":0.00053285056,"about_ca_topic_score_gemma":0.00014400441,"teacher_disagreement_score":0.014844294,"about_ca_system_score_codex":0.00036408062,"about_ca_system_score_gemma":0.0011930586,"threshold_uncertainty_score":0.38791183},"labels":[],"label_agreement":null},{"id":"W2149573012","doi":"10.1038/bcj.2014.51","title":"High DNA-methyltransferase 3B expression predicts poor outcome in acute myeloid leukemia, especially among patients with co-occurring NPM1 and FLT3 mutations","year":2014,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"NPM1; DNMT3B; CEBPA; Methyltransferase; Oncology; Myeloid leukemia; Hazard ratio; Internal medicine; Medicine; Hematology; Transplantation; Biology; Immunology; Cancer research; Genetics; Confidence interval; Mutation; Methylation; Karyotype; Gene","score_opus":0.014389393370973946,"score_gpt":0.28279065290005134,"score_spread":0.2684012595290774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149573012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96151465,0.00045730095,0.0002980853,0.034764834,0.0005887813,0.0014642577,0.0005477278,0.00007863357,0.00028572383],"genre_scores_gemma":[0.65469927,0.0032229712,0.006211876,0.30133414,0.02605481,0.0009606747,0.0025726408,0.0010919791,0.0038516135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940172,0.00040621986,0.0012880566,0.00091652083,0.002098086,0.0012739557],"domain_scores_gemma":[0.99729115,0.00031957228,0.0005972519,0.0005622391,0.0005527999,0.0006770177],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006521956,0.0008342982,0.0014652372,0.0011245573,0.00040513158,0.0002821585,0.00054076343,0.001025631,0.0004671883],"category_scores_gemma":[0.00017094862,0.0006461892,0.00023068256,0.0004431681,0.0003837998,0.0004799669,0.0001141625,0.0076136976,0.000013945171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012966876,0.00030173743,0.737052,0.0008295319,0.0018048477,0.008252209,0.0009826926,0.00013946305,0.0017430112,0.000002000234,0.24445467,0.0031411299],"study_design_scores_gemma":[0.09885628,0.0047336062,0.73396623,0.0135982325,0.008241933,0.0030995414,0.00024152712,0.00021698659,0.014753371,0.00012054982,0.11874142,0.0034303355],"about_ca_topic_score_codex":0.00057921454,"about_ca_topic_score_gemma":0.0001502276,"teacher_disagreement_score":0.30681536,"about_ca_system_score_codex":0.00179801,"about_ca_system_score_gemma":0.0023484663,"threshold_uncertainty_score":0.9995989},"labels":[],"label_agreement":null},{"id":"W2202712680","doi":"10.1038/bcj.2015.104","title":"Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses","year":2015,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Teva Pharmaceutical Industries","keywords":"Logistic regression; Myeloid leukemia; Medicine; Oncology; Internal medicine; Hematology; Immunology","score_opus":0.040615305099031156,"score_gpt":0.31720429007754664,"score_spread":0.2765889849785155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202712680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778693,0.015665563,0.0000119632205,0.0049164696,0.00013922282,0.0008659828,0.00044372134,0.000034339555,0.000053483647],"genre_scores_gemma":[0.98970175,0.0046935063,0.00019832389,0.001473879,0.0018885611,0.00009059377,0.00079215027,0.00017490397,0.0009863536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962507,0.0004859999,0.0007838373,0.00069589174,0.0011524312,0.0006311494],"domain_scores_gemma":[0.99752814,0.00018150298,0.00095132453,0.0004900786,0.00052580266,0.00032316122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005924633,0.0007066341,0.0014401197,0.00067503564,0.0001231497,0.000055279655,0.00014594586,0.0005862304,0.00010466876],"category_scores_gemma":[0.0001203737,0.00043056585,0.000082289414,0.00046501844,0.00030775485,0.00019290624,0.00006421864,0.0020239064,8.631327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06712931,0.0010364614,0.8435975,0.0025872802,0.005682287,0.008633093,0.00040468396,0.00033497074,0.002050674,3.2567493e-7,0.055857144,0.012686286],"study_design_scores_gemma":[0.25329444,0.034152504,0.6630497,0.016142294,0.010369854,0.0030970804,0.000060513976,0.0005768914,0.002443837,0.000008165645,0.015779568,0.0010251382],"about_ca_topic_score_codex":0.0009493298,"about_ca_topic_score_gemma":0.00050448783,"teacher_disagreement_score":0.18616514,"about_ca_system_score_codex":0.006006126,"about_ca_system_score_gemma":0.005657709,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W2294823670","doi":"10.1038/bcj.2016.9","title":"Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Deutsche Forschungsgemeinschaft; National Cancer Institute; Celgene","keywords":"IGHV@; Lenalidomide; Internal medicine; Chronic lymphocytic leukemia; Oncology; Medicine; Refractory (planetary science); Hematology; Fludarabine; Gastroenterology; Leukemia; Multiple myeloma; Chemotherapy; Biology; Cyclophosphamide","score_opus":0.05766062988039832,"score_gpt":0.36183303720276405,"score_spread":0.3041724073223657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294823670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467827,0.010928004,0.000019660778,0.0011842287,0.0005319534,0.0023227548,0.00017099599,0.00003742798,0.00012670807],"genre_scores_gemma":[0.9829667,0.012100332,0.00015570843,0.0002063117,0.0026786516,0.0002815541,0.000023597673,0.00007206082,0.0015150628],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99658716,0.0003356284,0.0007931038,0.000770865,0.00071199186,0.0008012458],"domain_scores_gemma":[0.9967255,0.0013620199,0.00032881106,0.0010583181,0.00013773376,0.0003876247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091381965,0.00038830526,0.00065206015,0.00014985807,0.0003056011,0.00010551524,0.0005573305,0.00019091682,0.00096351595],"category_scores_gemma":[0.0011895488,0.00018060236,0.000119848744,0.0002614279,0.00028034253,0.00031996274,0.00032078425,0.00052383466,0.0000244666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7035703,0.0034494314,0.017466709,0.00023436468,0.004996321,0.00509036,0.0019205454,0.00003979436,0.01867199,0.000009848119,0.015314193,0.22923616],"study_design_scores_gemma":[0.9612621,0.011897773,0.0041218,0.00232411,0.0014170158,0.0012036287,0.00020579355,0.0045609884,0.0021789551,0.00004032299,0.010444485,0.00034303684],"about_ca_topic_score_codex":0.0036122345,"about_ca_topic_score_gemma":0.002839667,"teacher_disagreement_score":0.2576918,"about_ca_system_score_codex":0.092796125,"about_ca_system_score_gemma":0.056786116,"threshold_uncertainty_score":0.99994975},"labels":[],"label_agreement":null},{"id":"W2417787511","doi":"10.1038/bcj.2016.36","title":"Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Fonds de Recherche du Québec - Santé; Deutsche Krebshilfe; Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Genome Canada","keywords":"Chemokine receptor; CX3CR1; Myeloid leukemia; Receptor; G protein-coupled receptor; Biology; CXCR4; Leukemia; Immunology; Myeloid; Cancer research; Chemokine; Genetics","score_opus":0.010879400758837152,"score_gpt":0.2460129510290285,"score_spread":0.23513355027019137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417787511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974395,0.00511645,0.004298659,0.0002122624,0.00021333592,0.0002898134,0.00011245637,0.0000069707894,0.000006106012],"genre_scores_gemma":[0.996366,0.0029497782,0.00028308984,0.000004550286,0.00021867524,0.000022892395,0.000018287132,0.000024213616,0.00011251433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759233,0.00006890226,0.0012399167,0.00025403625,0.0005971542,0.00024767013],"domain_scores_gemma":[0.9983735,0.000025468831,0.0007998993,0.0002518775,0.00035871868,0.00019049869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039612604,0.00017520254,0.00074031873,0.00059239095,0.00003811445,0.000009881937,0.0001693942,0.000086539454,0.00090482045],"category_scores_gemma":[0.00003386148,0.00012481397,0.0004975975,0.000864278,0.00012408373,0.00009719055,0.000016489337,0.00018361332,6.1708465e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074580323,0.00025430563,0.120542966,0.0001224879,0.0017643482,0.000027039607,0.00021402237,0.00017207307,0.8719826,0.0000067332758,0.000026400596,0.0041412734],"study_design_scores_gemma":[0.004097546,0.00017301591,0.40810803,0.0006111666,0.005805746,0.000023058547,0.000057226196,0.0004981423,0.5803185,0.000062448475,0.000078896155,0.00016623813],"about_ca_topic_score_codex":0.00008716402,"about_ca_topic_score_gemma":0.000023971457,"teacher_disagreement_score":0.29166406,"about_ca_system_score_codex":0.00019921744,"about_ca_system_score_gemma":0.00033674575,"threshold_uncertainty_score":0.99071497},"labels":[],"label_agreement":null},{"id":"W2522441445","doi":"10.1038/bcj.2016.74","title":"Amyloid cast tubulopathy: a unique form of immunoglobulin-induced renal disease","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; Canadian Society of Nephrology","funders":"","keywords":"Tubulopathy; Antibody; Disease; Kidney; Medicine; Kidney disease; Amyloid (mycology); Amyloidosis; Immunology; Immunoglobulin A; Immunoglobulin G; Internal medicine; Pathology","score_opus":0.011926368532715604,"score_gpt":0.2677002099911104,"score_spread":0.25577384145839477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522441445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924206,0.0050083427,0.00029645223,0.001500752,0.0002745456,0.00017937443,0.0001467667,0.000011708745,0.00016143826],"genre_scores_gemma":[0.9922533,0.00602751,0.00033232517,0.0002824636,0.0005385374,0.00007721431,0.00001149467,0.000041214906,0.0004359561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853987,0.00008415659,0.00042630293,0.00030295068,0.00025591496,0.00039079253],"domain_scores_gemma":[0.9986885,0.000025579873,0.00035545664,0.0004037043,0.00021573856,0.00031097324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019135443,0.00025227,0.00027224026,0.000074011325,0.000122006546,0.000028526374,0.00032100827,0.00013694272,0.0001765212],"category_scores_gemma":[0.000118549986,0.0001717859,0.0002718978,0.00009231368,0.000080775615,0.000015388545,0.00011479826,0.00013969268,0.000008307817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003959804,0.0003254556,0.14002515,0.00002047456,0.00056946906,0.00008626952,0.00006788881,0.0000056393346,0.8448063,0.00004563952,0.0013512917,0.012300428],"study_design_scores_gemma":[0.0039746794,0.00059433153,0.07603701,0.00025156492,0.00035146222,0.00021334371,0.0000398304,9.932971e-7,0.9113976,0.00020300747,0.0066075153,0.00032866377],"about_ca_topic_score_codex":0.00007273548,"about_ca_topic_score_gemma":0.0000851543,"teacher_disagreement_score":0.066591285,"about_ca_system_score_codex":0.00007814908,"about_ca_system_score_gemma":0.0005671273,"threshold_uncertainty_score":0.70052254},"labels":[],"label_agreement":null},{"id":"W2559984635","doi":"10.1038/bcj.2016.110","title":"MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia","year":2016,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Krebshilfe; Medizinische Fakultät, Universität Ulm; Canadian Institutes of Health Research; Universität Ulm; European Hematology Association; Barncancerfonden; Cancerfonden; Deutsche Forschungsgemeinschaft; Västra Götalandsregionen","keywords":"Myeloid leukemia; Medicine; Leukemia; Cancer research; Hematology; Myeloid; Suppressor; Oncology; Immunology; Internal medicine; Cancer","score_opus":0.016155506416765553,"score_gpt":0.29283192201753755,"score_spread":0.276676415600772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559984635","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041328896,0.004134185,0.000036779486,0.947373,0.0017397414,0.0013356698,0.0010218171,0.00010059499,0.0029293594],"genre_scores_gemma":[0.0017377426,0.009691426,0.001167846,0.90471214,0.039829995,0.00049589167,0.00013955687,0.0005149921,0.04171041],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918755,0.00034614757,0.0014661328,0.0011748674,0.0026675218,0.0024698263],"domain_scores_gemma":[0.9959783,0.0002058448,0.0008084032,0.0012180579,0.0010386797,0.00075071654],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006979853,0.0010530652,0.0018300504,0.0012216566,0.00024772043,0.00023258796,0.0012740887,0.001349274,0.0044243527],"category_scores_gemma":[0.00021631981,0.00075298426,0.00080594316,0.00056709483,0.0003036628,0.00032535885,0.00036274988,0.011669384,0.00045201267],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00068199344,0.00009542701,0.0007161382,0.00044675285,0.0018634207,0.043986518,0.0003226505,0.000001217596,0.0069799833,0.0000020525538,0.94033015,0.0045736902],"study_design_scores_gemma":[0.016709162,0.00074982503,0.0008970439,0.004699199,0.0018286862,0.02238477,0.0000489171,0.000049622828,0.015605695,0.000120628334,0.9358877,0.0010187336],"about_ca_topic_score_codex":0.0008421041,"about_ca_topic_score_gemma":0.000076681536,"teacher_disagreement_score":0.042660818,"about_ca_system_score_codex":0.005593727,"about_ca_system_score_gemma":0.008230497,"threshold_uncertainty_score":0.9999472},"labels":[],"label_agreement":null},{"id":"W2588102416","doi":"10.1038/bcj.2017.10","title":"A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Université de Montréal; Government of Canada; Génome Québec; Compute Canada; Genome Canada","keywords":"Myeloid leukemia; Leukemia; Cancer research; Medicine; Identification (biology); Stem cell; Computational biology; Cancer; Oncology; Biology; Immunology; Internal medicine; Genetics","score_opus":0.01758236777554964,"score_gpt":0.28041359196875115,"score_spread":0.2628312241932015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588102416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97910756,0.0012333352,0.018471543,0.00035682754,0.00020236975,0.00034647834,0.000025504494,0.000002220601,0.00025415837],"genre_scores_gemma":[0.99830467,0.0003768994,0.00064404577,0.000050560986,0.00024550743,0.000064458894,0.000023475479,0.000009086427,0.00028131081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993756,0.000018462772,0.0002572282,0.00012184344,0.00012547975,0.000101403784],"domain_scores_gemma":[0.99919236,0.0000051632915,0.00042142806,0.00024708622,0.00011314872,0.000020789426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042050678,0.00006985881,0.00008516322,0.000034171204,0.0003284445,0.00007659507,0.0002780429,0.000053590637,0.000004049217],"category_scores_gemma":[0.000029274239,0.00005136699,0.00006739132,0.00002446423,0.00007857447,0.000007651627,0.000038874405,0.000086171465,1.3083725e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004197915,0.00012484592,0.00060449104,0.00001178801,0.00009454697,1.2906905e-7,0.00009398548,0.0002851484,0.99662256,0.00016188629,0.00025455104,0.0017040725],"study_design_scores_gemma":[0.002657762,0.00012225188,0.07263322,0.000023050154,0.00006957229,0.00001535812,0.00008943998,0.0006956581,0.92238957,0.000061128216,0.0011413168,0.00010167997],"about_ca_topic_score_codex":0.000022462078,"about_ca_topic_score_gemma":0.0000108801305,"teacher_disagreement_score":0.07423302,"about_ca_system_score_codex":0.000043399785,"about_ca_system_score_gemma":0.00011174633,"threshold_uncertainty_score":0.2526163},"labels":[],"label_agreement":null},{"id":"W2605150999","doi":"10.1038/bcj.2017.29","title":"Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"STAT5; Chronic myelogenous leukemia; T-cell receptor; CD8; T cell; Immunology; Leukemia; Imatinib mesylate; Cancer research; Medicine; Signal transduction; Biology; Imatinib; Internal medicine; Receptor; Immune system; Cell biology","score_opus":0.012434273716650008,"score_gpt":0.280681376245871,"score_spread":0.26824710252922096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605150999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553263,0.0024781441,0.0000031460315,0.00050634687,0.00019314178,0.0009593759,0.000038248927,0.000015133542,0.0002738116],"genre_scores_gemma":[0.9974581,0.0011066918,0.0005693931,0.00013610613,0.00015810055,0.0000803089,0.000009123101,0.00004922279,0.00043298033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783945,0.00013581419,0.0006088817,0.00040707568,0.00043097336,0.00057779386],"domain_scores_gemma":[0.99859697,0.000067450695,0.0004244234,0.0004386024,0.00013769015,0.00033485968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007070697,0.00028699508,0.00047794392,0.00030083783,0.00028002574,0.00014516203,0.00020807452,0.00013868924,0.00012235764],"category_scores_gemma":[0.00028188803,0.00025760644,0.000058561272,0.00015943234,0.00006711516,0.00030691343,0.0001398098,0.00044390568,0.000023890409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006984315,0.00070427667,0.7963655,0.0002637386,0.00017675779,0.0010903941,0.0063029137,0.00041953142,0.086695865,0.0000024281885,0.00032224043,0.100672014],"study_design_scores_gemma":[0.0352616,0.0014202577,0.90349495,0.0012092111,0.00014034682,0.00021327668,0.00006509748,0.00033989543,0.0567042,0.000052593354,0.0007927004,0.00030585943],"about_ca_topic_score_codex":0.0015283967,"about_ca_topic_score_gemma":0.0016379082,"teacher_disagreement_score":0.10712944,"about_ca_system_score_codex":0.0070931558,"about_ca_system_score_gemma":0.0038883612,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W2620976364","doi":"10.1038/bcj.2017.52","title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Interleukin-3 receptor; Transplantation; Medicine; Immunology; Haematopoiesis; Cancer research; Leukemia; Stem cell; Monoclonal antibody; Antibody; Oncology; Internal medicine; Biology","score_opus":0.03181450928796736,"score_gpt":0.3424555418308567,"score_spread":0.31064103254288933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620976364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979053,0.00043678196,0.00010111849,0.000098252785,0.0010860257,0.0002231727,0.000009176209,0.0000034149728,0.00013676251],"genre_scores_gemma":[0.99940085,0.00039707366,0.0000416569,0.0000073945776,0.000022994442,0.000006798435,0.00007390006,0.000007501781,0.000041843334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987857,0.0003734193,0.0004237044,0.0001714874,0.00012631786,0.00011942224],"domain_scores_gemma":[0.9984922,0.00006935118,0.0008979985,0.00017149978,0.00035365473,0.000015313883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008795724,0.00010020541,0.00026697546,0.00015234531,0.00012567727,0.000021448366,0.00010431897,0.00017105717,0.0003173878],"category_scores_gemma":[0.00030040098,0.00008433762,0.000036343903,0.000056975492,0.000085809086,0.00045877724,0.000033740434,0.00038782955,0.0000018163407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007097716,0.0006189453,0.6818359,0.000011786963,0.00006511526,3.5644996e-7,0.00019494153,0.00007682573,0.30598822,0.0000026336206,0.000052297648,0.0104432],"study_design_scores_gemma":[0.0071233977,0.00031907242,0.73867625,0.00031153322,0.00008134478,0.000004807778,0.000037883154,0.00031422486,0.25290886,0.00008392867,0.000072893934,0.00006581302],"about_ca_topic_score_codex":0.0012986369,"about_ca_topic_score_gemma":0.00023760583,"teacher_disagreement_score":0.05684034,"about_ca_system_score_codex":0.000066093744,"about_ca_system_score_gemma":0.00013600766,"threshold_uncertainty_score":0.3475174},"labels":[],"label_agreement":null},{"id":"W2738560661","doi":"10.1038/bcj.2017.64","title":"Malignant T cells activate endothelial cells via IL-17 F","year":2017,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Novo Nordisk Fonden; Kræftens Bekæmpelse","keywords":"Cancer research; Medicine; Immunology; Biology; Cell biology","score_opus":0.027124843449397654,"score_gpt":0.3122429270310163,"score_spread":0.28511808358161866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738560661","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03457512,0.009674898,0.00033477365,0.9187078,0.009894604,0.0036583163,0.003334513,0.00020108609,0.019618902],"genre_scores_gemma":[0.012867924,0.022703204,0.00085909135,0.55981165,0.09526129,0.00038273667,0.00022529908,0.0009966947,0.30689213],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945109,0.00026943616,0.00077003456,0.00083625363,0.002053271,0.0015601119],"domain_scores_gemma":[0.9965485,0.00014069382,0.00092510955,0.0011440257,0.00072698854,0.00051472656],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004508795,0.00081872253,0.0013647003,0.000493269,0.0007795302,0.0005130203,0.0010186974,0.0010488107,0.0053526447],"category_scores_gemma":[0.000077543446,0.00066012447,0.0007503141,0.00012399633,0.0003541079,0.00017385284,0.00020243504,0.0060408744,0.00032111935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037881726,0.00018087284,0.00020274273,0.00032809068,0.0012547382,0.027510917,0.00017366014,0.0000066087855,0.2162743,2.9410273e-7,0.7498381,0.0038508233],"study_design_scores_gemma":[0.0037748974,0.0004919126,0.000020994137,0.00084807613,0.00081676536,0.018255603,0.000019694682,0.000023579229,0.23741217,0.00007331126,0.73771113,0.00055184594],"about_ca_topic_score_codex":0.00044943337,"about_ca_topic_score_gemma":0.000044085737,"teacher_disagreement_score":0.35889614,"about_ca_system_score_codex":0.00060767523,"about_ca_system_score_gemma":0.0029176124,"threshold_uncertainty_score":0.999585},"labels":[],"label_agreement":null},{"id":"W2760214433","doi":"10.1038/bcj.2017.86","title":"Meis2 as a critical player in MN1-induced leukemia","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; Deutsche Krebshilfe; University of British Columbia; BC Cancer Foundation; Vetenskapsrådet; Provincial Health Services Authority; Deutsche Forschungsgemeinschaft; Terry Fox Foundation; Genome British Columbia","keywords":"Biology; Myeloid leukemia; Cancer research; Leukemia; Myeloid; Progenitor cell; Phenotype; Hox gene; Stem cell; Gene expression profiling; Immunology; Genetics; Gene; Gene expression","score_opus":0.02087468825402057,"score_gpt":0.342248153853548,"score_spread":0.32137346559952745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760214433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921797,0.0009839624,0.000045267676,0.0017875424,0.0005930157,0.00006769239,0.0000048589586,0.0000041988196,0.0043337983],"genre_scores_gemma":[0.99704826,0.0003920598,0.00022162404,0.0005431249,0.0011495055,0.000018383776,0.0000024929695,0.000014491774,0.0006100651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991773,0.000042791024,0.0001961854,0.00018649669,0.00015674315,0.00024052098],"domain_scores_gemma":[0.9993814,0.000005510422,0.00010657214,0.00028646833,0.00007949503,0.0001405116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020384464,0.00010774267,0.000113564194,0.00003969801,0.00027086484,0.00015726018,0.00030458707,0.000135124,0.00018456728],"category_scores_gemma":[0.00039382905,0.00009742728,0.000073443836,0.000021902459,0.000058323094,0.0000149269,0.00008250759,0.00026351854,0.000014926478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014358108,0.00011212006,0.015936138,0.000014263953,0.00008308461,0.00012363191,0.000061895684,0.000009750724,0.95987445,0.00044445167,0.008098914,0.015097725],"study_design_scores_gemma":[0.0021603734,0.00027399475,0.010681869,0.000096054275,0.0000326711,0.00034270063,0.00003761305,0.000030043151,0.95087034,0.0004661009,0.03476296,0.00024527078],"about_ca_topic_score_codex":0.00013284256,"about_ca_topic_score_gemma":0.00016788508,"teacher_disagreement_score":0.026664047,"about_ca_system_score_codex":0.00004034964,"about_ca_system_score_gemma":0.00043103236,"threshold_uncertainty_score":0.3972969},"labels":[],"label_agreement":null},{"id":"W2771270080","doi":"10.1038/s41408-017-0020-0","title":"Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma","year":2017,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Oncolytic virus; Immune system; Multiple myeloma; Medicine; Malignancy; Immunotherapy; Virotherapy; Immunology; Clinical trial; Hematologic malignancy; Cancer research; Oncology; Internal medicine","score_opus":0.14036907443041122,"score_gpt":0.4619003633948275,"score_spread":0.3215312889644163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771270080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020287347,0.9956886,0.00007412191,0.000036063484,0.00043072097,0.0013769111,0.00019278866,0.000013862537,0.0001582093],"genre_scores_gemma":[0.0003848766,0.99231833,0.00012353886,0.00018971818,0.0034602867,0.00069972407,0.00013658917,0.00025497944,0.0024319815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713916,0.00037642432,0.00068360503,0.0006709214,0.00037035785,0.00075951807],"domain_scores_gemma":[0.9974407,0.00004671457,0.0007931988,0.0011478462,0.00024882247,0.00032273686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080636214,0.00062203413,0.001176458,0.0001643112,0.00062549184,0.0004181824,0.0015106173,0.0006147469,0.00026210587],"category_scores_gemma":[0.000050550225,0.0005173531,0.00092187594,0.000078387355,0.00015258444,0.00001580788,0.00006779075,0.00068625744,0.000022238728],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010261416,0.0002057476,0.000004745502,0.000818886,0.001829239,0.000020112075,0.00001765777,0.000011176015,0.0064637666,0.0000034017287,0.00026869058,0.9893304],"study_design_scores_gemma":[0.0028496496,0.007850814,0.00000319203,0.001521245,0.0006611572,0.00051500887,0.000012534082,0.000008233695,0.004700452,0.00008125789,0.98116326,0.0006331912],"about_ca_topic_score_codex":0.000042149033,"about_ca_topic_score_gemma":0.00040288595,"teacher_disagreement_score":0.98869723,"about_ca_system_score_codex":0.000119101926,"about_ca_system_score_gemma":0.0037244752,"threshold_uncertainty_score":0.9997278},"labels":[],"label_agreement":null},{"id":"W2771668512","doi":"10.1038/s41408-017-0023-x","title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","year":2017,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Amgen","keywords":"Blinatumomab; Lymphoblastic Leukemia; Medicine; CD19; Oncology; Acute lymphocytic leukemia; Internal medicine; Leukemia; Peripheral blood","score_opus":0.020605197598194517,"score_gpt":0.30439271494368203,"score_spread":0.2837875173454875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771668512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71422255,0.04057791,0.00036361336,0.20358643,0.014411479,0.0062797046,0.0021872392,0.000353124,0.018017957],"genre_scores_gemma":[0.3629694,0.07882334,0.010124859,0.10821888,0.1642715,0.0018191783,0.00082626304,0.002628746,0.27031785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99312794,0.00030752915,0.0014157514,0.0010365624,0.0025129458,0.0015992923],"domain_scores_gemma":[0.9940845,0.00085222686,0.0022326934,0.0014047273,0.00078026985,0.0006456061],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004970841,0.0011415906,0.002284747,0.0010702692,0.0005758156,0.0002296273,0.001167727,0.0015471551,0.0003972297],"category_scores_gemma":[0.00054081844,0.00088701973,0.0015746524,0.00044138567,0.0002843427,0.00032576808,0.00026275349,0.0039593154,0.00011297012],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010367951,0.0006133314,0.0022726317,0.0010725434,0.008245389,0.05139416,0.0007342422,0.000027824008,0.00076952035,9.849404e-7,0.932065,0.0017675447],"study_design_scores_gemma":[0.27335525,0.027022194,0.0037528013,0.011982157,0.19368929,0.034850437,0.00044867338,0.0012329284,0.0681336,0.00078638655,0.37823576,0.006510522],"about_ca_topic_score_codex":0.00045769787,"about_ca_topic_score_gemma":0.000022384791,"teacher_disagreement_score":0.55382925,"about_ca_system_score_codex":0.008864621,"about_ca_system_score_gemma":0.021908075,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W2772253366","doi":"10.1038/s41408-017-0033-8","title":"MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sigrid Juséliuksen Säätiö; National Cancer Institute; Academy of Finland; Helsingin Yliopisto","keywords":"microRNA; Cancer research; Biology; Diffuse large B-cell lymphoma; Signal transduction; MAPK/ERK pathway; Chemoimmunotherapy; Lymphoma; Cancer; Biological pathway; Immunology; Gene expression; Gene; Cell biology; Genetics","score_opus":0.013978233493338417,"score_gpt":0.2677070162185166,"score_spread":0.2537287827251782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772253366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209464,0.0060307574,0.0000012538316,0.0004432524,0.00038165436,0.00021450226,0.000058007558,0.0000169563,0.0007589804],"genre_scores_gemma":[0.99428165,0.004819411,0.00020378098,0.00003724393,0.00034718515,0.000013598776,0.0000046275923,0.000031326108,0.0002612023],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859667,0.0000553496,0.00033363828,0.00027097168,0.0003465358,0.00039684147],"domain_scores_gemma":[0.99852204,0.000032973876,0.0006129887,0.00040307784,0.00014487054,0.00028407155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029924687,0.00023041737,0.00048933574,0.00006439913,0.00051348837,0.000097704564,0.00011970031,0.00010739187,0.000029506093],"category_scores_gemma":[0.000032372813,0.00016963265,0.00015153026,0.000035628316,0.00010293426,0.00015008054,0.00014259461,0.00013021614,0.0000036097542],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005802104,0.00979695,0.57577276,0.00050887506,0.0003354965,0.00181721,0.00087890803,4.0145744e-7,0.3937806,0.000009318546,0.00021791438,0.016301353],"study_design_scores_gemma":[0.03145483,0.00015738478,0.44780025,0.00043265996,0.0003284147,0.00037212446,0.00003746769,0.0000071750273,0.51907426,0.000012021504,0.00021636723,0.000107019594],"about_ca_topic_score_codex":0.00008919818,"about_ca_topic_score_gemma":0.000039981423,"teacher_disagreement_score":0.12797251,"about_ca_system_score_codex":0.00011054941,"about_ca_system_score_gemma":0.00023164948,"threshold_uncertainty_score":0.6917419},"labels":[],"label_agreement":null},{"id":"W2778096288","doi":"10.1038/s41408-017-0035-6","title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","year":2017,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary; Mayo Clinic","keywords":"Medicine; Venous thrombosis; Internal medicine; Thrombosis; Polycythemia vera; Cardiology","score_opus":0.0634775556548781,"score_gpt":0.34844780470417197,"score_spread":0.28497024904929386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778096288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972267,0.00016463007,0.000004464627,0.00025132496,0.0015104758,0.0005540786,0.00010151825,0.000006185768,0.00018059417],"genre_scores_gemma":[0.9985709,0.000511464,0.00016401181,0.00005441709,0.00042029683,0.00023240219,0.000010855935,0.000021746086,0.000013877461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878097,0.000034864355,0.0003239334,0.00024990458,0.00023961591,0.0003707131],"domain_scores_gemma":[0.99916637,0.00007537937,0.0002958482,0.0002273425,0.000081648366,0.00015339664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080584905,0.0001923587,0.0003873873,0.00009636054,0.00029660593,0.00011434724,0.0001384423,0.00007828398,0.00013607656],"category_scores_gemma":[0.00019982351,0.00014908068,0.00011623518,0.000043231197,0.000056151115,0.00019197272,0.00003440877,0.00022686044,0.0000024450196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014015799,0.0027424751,0.9878214,0.000012065477,0.00016222092,0.00003636709,0.0036746198,0.000004368399,0.0005120655,0.0000032577605,0.00013226071,0.0034972953],"study_design_scores_gemma":[0.032067467,0.0020852303,0.9521943,0.0003294395,0.00015529823,0.000012903518,0.0003106816,0.000012607798,0.011749691,0.000020182097,0.0009003228,0.00016191923],"about_ca_topic_score_codex":0.0006030662,"about_ca_topic_score_gemma":0.0011176147,"teacher_disagreement_score":0.035627164,"about_ca_system_score_codex":0.0003586142,"about_ca_system_score_gemma":0.00013418561,"threshold_uncertainty_score":0.60793334},"labels":[],"label_agreement":null},{"id":"W2789913912","doi":"10.1038/s41408-018-0050-2","title":"Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Ottawa; University of Calgary; Ottawa Hospital","funders":"","keywords":"Plerixafor; Hematopoietic cell; Term (time); Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Transplantation; CXCR4; Oncology; Function (biology); Internal medicine; Immunology; Stem cell; Receptor; Biology","score_opus":0.011379354230978871,"score_gpt":0.2886850860899934,"score_spread":0.2773057318590145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789913912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953825,0.0012077497,0.0019342499,0.00013800882,0.00025898198,0.00072914857,0.000024463418,0.000023104461,0.00030181138],"genre_scores_gemma":[0.9985687,0.0009406103,0.00016204326,0.000043064138,0.00015588614,0.00004821309,0.000014528247,0.0000248023,0.000042114338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984785,0.00015066352,0.0005494075,0.00020785506,0.00033464516,0.00027895815],"domain_scores_gemma":[0.9991999,0.00014645279,0.00026102585,0.00013467204,0.00012943974,0.00012848695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004869932,0.00019039659,0.00043065657,0.00018193501,0.000110599176,0.000026597969,0.000082108716,0.00011723491,0.00015744324],"category_scores_gemma":[0.000021771255,0.00012278424,0.00021656824,0.00025500596,0.00021261032,0.00015222494,0.0000069039015,0.0002946809,0.0000016666813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008388098,0.00043217142,0.9114059,0.0010433395,0.00096591754,0.0003000895,0.017062109,0.00014102909,0.058510803,0.000022250057,0.00005902249,0.0016692597],"study_design_scores_gemma":[0.023245582,0.0015294397,0.93398166,0.0013880078,0.0019754206,0.0025935047,0.00045906715,0.0003733648,0.03417,0.00012386146,9.641884e-7,0.00015911473],"about_ca_topic_score_codex":0.0002290504,"about_ca_topic_score_gemma":0.00011054412,"teacher_disagreement_score":0.024340803,"about_ca_system_score_codex":0.00008557561,"about_ca_system_score_gemma":0.00028987337,"threshold_uncertainty_score":0.5006996},"labels":[],"label_agreement":null},{"id":"W2790446180","doi":"10.1038/s41408-018-0064-9","title":"Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; ECOG-ACRIN Cancer Research Group; Harvard T.H. Chan School of Public Health; National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Medicine; Lenalidomide; Diffuse large B-cell lymphoma; Internal medicine; Lymphoma; Oncology; Retrospective cohort study; Clinical trial; Population; Multiple myeloma","score_opus":0.1007839434411648,"score_gpt":0.4406180394919117,"score_spread":0.3398340960507469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790446180","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62249917,0.25868356,0.00024741996,0.1100624,0.0019517661,0.005809359,0.00029212137,0.00002780013,0.0004264431],"genre_scores_gemma":[0.14965725,0.8001264,0.0043583424,0.017826643,0.025905238,0.0017892196,0.00008100182,0.000075121934,0.00018080753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967499,0.0006146341,0.0015722081,0.0003915666,0.00029428667,0.00037739798],"domain_scores_gemma":[0.99591917,0.002668085,0.00069006043,0.0002744366,0.00022615645,0.00022208122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010062859,0.0002513059,0.0015175012,0.000100654834,0.00019513027,0.000035935125,0.00018916873,0.00018636588,0.0002621166],"category_scores_gemma":[0.0016868723,0.00012644076,0.0003720377,0.00015546354,0.00017541769,0.00008246981,0.000027802796,0.00016461831,0.0000041062654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034830237,0.0019745757,0.016361086,0.00059530063,0.0007476876,0.00018032684,0.00070185005,1.2918015e-7,0.0003411587,0.00037240118,0.11437608,0.86086637],"study_design_scores_gemma":[0.12738386,0.015268353,0.2869055,0.010093455,0.007795719,0.008299326,0.0002838283,0.00012765099,0.00035322263,0.0016301073,0.5414108,0.000448164],"about_ca_topic_score_codex":0.00005207023,"about_ca_topic_score_gemma":0.00009588794,"teacher_disagreement_score":0.8604182,"about_ca_system_score_codex":0.00009654181,"about_ca_system_score_gemma":0.00045064543,"threshold_uncertainty_score":0.51561046},"labels":[],"label_agreement":null},{"id":"W2791331105","doi":"10.1038/s41408-017-0039-2","title":"Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition","year":2018,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Faculty of Medicine, McGill University; McGill University","keywords":"Metabolism; Glutamine; Carbohydrate metabolism; Biology; Biochemistry; Medicine; Amino acid","score_opus":0.01505442161798423,"score_gpt":0.28737974831660995,"score_spread":0.27232532669862575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791331105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85903865,0.030205807,0.00015584572,0.107538365,0.0013220472,0.001114164,0.0004857566,0.00006366654,0.00007566806],"genre_scores_gemma":[0.44789737,0.031858213,0.00254415,0.39797,0.110902056,0.0006100026,0.0005293732,0.0008816091,0.006807233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937866,0.0007845764,0.0010535344,0.0011861216,0.0017784539,0.001410724],"domain_scores_gemma":[0.9964105,0.0004680833,0.0005285391,0.0006749287,0.00088128966,0.0010366496],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009822675,0.0009496381,0.0017288788,0.0010596357,0.000462477,0.00050091615,0.00030304393,0.0010254561,0.0005826434],"category_scores_gemma":[0.0004870629,0.00078774546,0.00032439656,0.0004510577,0.00056198693,0.00031303943,0.00052252493,0.002528652,0.000040517705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.033372,0.0005589557,0.00013017465,0.0014781357,0.006067636,0.01661478,0.0037385097,0.0000049421246,0.17163602,0.000020771402,0.7437168,0.022661293],"study_design_scores_gemma":[0.12637863,0.0023724705,0.008280672,0.0052497447,0.010134946,0.054158937,0.00021050716,0.00049088727,0.21491721,0.0003360433,0.57519424,0.0022757351],"about_ca_topic_score_codex":0.0007469886,"about_ca_topic_score_gemma":0.00005533587,"teacher_disagreement_score":0.4111413,"about_ca_system_score_codex":0.005105082,"about_ca_system_score_gemma":0.008172868,"threshold_uncertainty_score":0.99977255},"labels":[],"label_agreement":null},{"id":"W2807346792","doi":"10.1038/s41408-018-0087-2","title":"Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network; McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Stem cell; Leukemia; Myeloid; Haematopoiesis; Cancer research; Medicine; Pharmacology; Oncology; Biology; Immunology; Genetics","score_opus":0.027511754514813476,"score_gpt":0.325757277402375,"score_spread":0.2982455228875615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807346792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98056304,0.011649534,0.001564997,0.0014333625,0.0013358697,0.0004479018,0.000048641217,0.00012801682,0.0028286271],"genre_scores_gemma":[0.97142285,0.0058531933,0.00439021,0.0034782686,0.0070381486,0.00003425716,0.000014488052,0.00016716763,0.007601401],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962194,0.00011804225,0.00075012486,0.0005403933,0.0012151622,0.0011569007],"domain_scores_gemma":[0.99746436,0.0001129542,0.00043246688,0.00049407437,0.00092154805,0.00057458447],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009141611,0.00044061508,0.0005954828,0.00035404554,0.00063613907,0.00025146714,0.00067083724,0.00037870524,0.0007705557],"category_scores_gemma":[0.000027659555,0.00035694952,0.0003099818,0.00058992003,0.0003193839,0.0003267814,0.00020771482,0.002526582,0.00015098085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006063955,0.00021545625,0.0031523025,0.000106219806,0.0013662229,0.00043777598,0.0011717879,0.00004591461,0.95185673,0.000023461906,0.027935691,0.013082063],"study_design_scores_gemma":[0.0185224,0.0020383482,0.009822113,0.0007266247,0.003189176,0.0044796085,0.0011357084,0.0026602885,0.8669276,0.0001440803,0.08928877,0.0010652711],"about_ca_topic_score_codex":0.00012642649,"about_ca_topic_score_gemma":0.000019246885,"teacher_disagreement_score":0.0849291,"about_ca_system_score_codex":0.0019369833,"about_ca_system_score_gemma":0.003941911,"threshold_uncertainty_score":0.99988824},"labels":[],"label_agreement":null},{"id":"W2884841488","doi":"10.1038/s41408-018-0103-6","title":"High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2018,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Medical Research Council; Université de Montréal; King's College London; Cancer Research UK; Compute Canada; National Institute for Health and Care Research; Leukemia and Lymphoma Society; Genome Canada; Blood Cancer UK; McGill University; Génome Québec","keywords":"Internal medicine; Oncology; Medicine; Myeloid leukemia; Cytogenetics; Cohort; Clinical trial; HMGA2; Biology; Gene; Genetics","score_opus":0.030074068534258973,"score_gpt":0.3631047606822544,"score_spread":0.3330306921479954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884841488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956731,0.0005546344,0.00011844195,0.001564141,0.0010227314,0.00039348283,0.000044836903,0.000033358036,0.0005952831],"genre_scores_gemma":[0.98976946,0.002335227,0.0030069875,0.00089067366,0.0021752284,0.000028987079,0.0000072106495,0.000056680597,0.0017295536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613345,0.0002548399,0.0012950043,0.00041836657,0.0012195398,0.00067878026],"domain_scores_gemma":[0.9977711,0.00019122755,0.00049306225,0.000463746,0.0005232795,0.0005575961],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014517086,0.00027375013,0.00093794864,0.0004226607,0.00012388361,0.000039320614,0.0004985539,0.0003715025,0.0010656394],"category_scores_gemma":[0.0004567402,0.00020101883,0.0002887042,0.00039554932,0.0003613089,0.00025793348,0.00025092525,0.0018592962,0.000044436365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022372203,0.0007224733,0.9295992,0.00006415074,0.0008200608,0.00095360127,0.00038088538,0.00000797776,0.034784786,0.000020336325,0.015726533,0.014682752],"study_design_scores_gemma":[0.02518163,0.0028248236,0.7988568,0.0010397161,0.00063589925,0.0011863923,0.00016174917,0.00011849328,0.16762999,0.00020961168,0.0018494253,0.00030549217],"about_ca_topic_score_codex":0.00047131203,"about_ca_topic_score_gemma":0.00015500358,"teacher_disagreement_score":0.13284521,"about_ca_system_score_codex":0.000664908,"about_ca_system_score_gemma":0.0029625185,"threshold_uncertainty_score":0.99984753},"labels":[],"label_agreement":null},{"id":"W2910040477","doi":"10.1038/s41408-018-0168-2","title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxicity; Cancer research; Antibody; Monoclonal antibody; Cell culture; Chemistry; Biology; Immunology; In vitro","score_opus":0.015420752743249182,"score_gpt":0.30757546229849314,"score_spread":0.292154709555244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910040477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852248,0.008848909,0.00022324173,0.00023393461,0.0008309888,0.0011947674,0.00019446634,0.00008557443,0.0031633268],"genre_scores_gemma":[0.9838683,0.008619896,0.00033449195,0.00023818965,0.0006556879,0.000021045253,0.000112095855,0.00013310435,0.006017176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944257,0.00037620842,0.0012393666,0.00074492896,0.0019583043,0.0012554671],"domain_scores_gemma":[0.9966828,0.00026070196,0.0007179352,0.0008221128,0.0008227704,0.00069367024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00136514,0.0005991487,0.0014426707,0.00060351874,0.00024472954,0.00011270428,0.0006580554,0.00034507082,0.014728283],"category_scores_gemma":[0.000085178086,0.0005181312,0.00057475345,0.0006274333,0.00023352052,0.00028922598,0.00019903707,0.0010479752,0.00032641483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010545262,0.0016315221,0.108735986,0.0006403799,0.0005384283,0.0004398767,0.0007480285,0.00004469523,0.8845309,0.000002282208,0.00049611315,0.0011372792],"study_design_scores_gemma":[0.022638975,0.0016903968,0.055517755,0.00041358895,0.00036987665,0.00058778026,0.0004574669,0.00037143956,0.91444826,0.00005230041,0.0028766966,0.00057547796],"about_ca_topic_score_codex":0.0007059641,"about_ca_topic_score_gemma":0.000036218808,"teacher_disagreement_score":0.05321823,"about_ca_system_score_codex":0.0003632189,"about_ca_system_score_gemma":0.0010796767,"threshold_uncertainty_score":0.999727},"labels":[],"label_agreement":null},{"id":"W2920738037","doi":"10.1038/s41408-019-0190-z","title":"Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","year":2019,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research UK","keywords":"Myeloid leukemia; Medicine; Myeloid; Internal medicine; Expression (computer science); MEDLINE; Bioinformatics; Computer science; Biology; Political science; Law","score_opus":0.024372206675235007,"score_gpt":0.3449138785461871,"score_spread":0.3205416718709521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920738037","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56553394,0.021784015,0.00021453816,0.005788119,0.3696617,0.004803791,0.0010336818,0.00026610275,0.030914128],"genre_scores_gemma":[0.095943294,0.072614856,0.0009993382,0.0017996059,0.02130296,0.00018644409,0.00046221758,0.00046249223,0.8062288],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99225324,0.00053349434,0.0025306644,0.00094073534,0.002674559,0.0010672933],"domain_scores_gemma":[0.99523383,0.00043107767,0.0017543281,0.0009742389,0.0008533588,0.00075317756],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018104382,0.0007601663,0.0028198424,0.0010921265,0.00014475234,0.0000934344,0.000996499,0.0022342806,0.001672707],"category_scores_gemma":[0.00083483726,0.0005942003,0.0008950425,0.00060393254,0.0002624703,0.00031355952,0.0004820804,0.012465343,0.00008046488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014908091,0.000576502,0.15218455,0.0003147968,0.0016312799,0.0013972054,0.00012693994,0.000025013333,0.0005498062,0.000001515439,0.83546793,0.0062336717],"study_design_scores_gemma":[0.058412787,0.0066713193,0.65024734,0.020614522,0.0061444067,0.0077553685,0.00042718163,0.00065347727,0.010425079,0.000097870856,0.23664966,0.0019009861],"about_ca_topic_score_codex":0.0009672157,"about_ca_topic_score_gemma":0.0002507138,"teacher_disagreement_score":0.7753147,"about_ca_system_score_codex":0.0025223778,"about_ca_system_score_gemma":0.016552197,"threshold_uncertainty_score":0.99965096},"labels":[],"label_agreement":null},{"id":"W2923666301","doi":"10.1038/s41408-019-0196-6","title":"Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; National Institute for Health and Care Research; National Institutes of Health; American Society of Hematology; Cancer Research UK; National Cancer Institute; University College London; Celgene; University College London Hospitals NHS Foundation Trust; Sanofi; GlaxoSmithKline; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Internal medicine; Refractory (planetary science); Multiple myeloma; Interim analysis; Lenalidomide; Transplantation; Phases of clinical research; Clinical trial; Oncology; Gastroenterology; Surgery; Adverse effect; Biology","score_opus":0.02122107329605373,"score_gpt":0.35036038003859094,"score_spread":0.3291393067425372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923666301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957554,0.0019528967,0.000006100634,0.0002757844,0.00032902398,0.0012965895,0.00015031412,0.00003677527,0.00019712246],"genre_scores_gemma":[0.99680525,0.0019582596,0.00022965018,0.0002150479,0.00036688772,0.000022784641,0.00015251525,0.0000544095,0.00019521762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971724,0.0003538014,0.0005850344,0.000593145,0.000734115,0.0005614877],"domain_scores_gemma":[0.99823934,0.0002359313,0.00021375337,0.0004917064,0.00013038128,0.00068891206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005277405,0.00033808255,0.00065377646,0.00031289738,0.00020200967,0.00008865875,0.00017449797,0.00009896996,0.0007309141],"category_scores_gemma":[0.00011622639,0.00025624453,0.00009609563,0.00021100871,0.00006195488,0.0002863882,0.000074391384,0.00096790324,0.00007181878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021684848,0.01526343,0.8520634,0.000035200832,0.00067784224,0.0028922847,0.0017974754,0.00008845536,0.038723253,0.0000022735549,0.000086367036,0.06668517],"study_design_scores_gemma":[0.14476517,0.0050633196,0.8435265,0.00052527006,0.00023966465,0.000108206244,0.00093127164,0.0008136119,0.0026695416,0.000013346191,0.0010629434,0.0002811598],"about_ca_topic_score_codex":0.0012383226,"about_ca_topic_score_gemma":0.0005033737,"teacher_disagreement_score":0.12308031,"about_ca_system_score_codex":0.00019362361,"about_ca_system_score_gemma":0.00033082903,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W2925264218","doi":"10.1038/s41408-019-0200-1","title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Carfilzomib; Multiple myeloma; Intensive care medicine; Population; Clinical trial; Ixazomib; Internal medicine","score_opus":0.01894229791230373,"score_gpt":0.29470740091309067,"score_spread":0.27576510300078694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925264218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967177,0.0016219976,0.000011265447,0.00020597542,0.00007037598,0.0010224342,0.000038493243,0.000017346234,0.0002944337],"genre_scores_gemma":[0.99680555,0.0005728981,0.0018160973,0.00004818209,0.0001852295,0.00007163123,0.000024979303,0.000045228935,0.0004301849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834156,0.000052419928,0.00025350912,0.0002480626,0.00071549084,0.00038894726],"domain_scores_gemma":[0.9988592,0.000053284533,0.0002404438,0.00026088164,0.00030198423,0.0002841995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052114447,0.00024363709,0.0004551225,0.00014291136,0.00009730189,0.00003564965,0.00007298293,0.000048544265,0.00027893056],"category_scores_gemma":[0.00000992737,0.0001238939,0.000099767836,0.00013186914,0.00006364544,0.00010277895,0.000007385771,0.00016185369,0.00001302668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01865733,0.003106871,0.88176656,0.000032486365,0.0013638821,0.00019443274,0.00019547011,0.00004199845,0.0006135198,0.0000012054004,0.000025324149,0.09400091],"study_design_scores_gemma":[0.0897256,0.022606013,0.85807514,0.0006075067,0.00021977969,0.00012786307,0.000055980832,0.000084438325,0.026632907,0.000002273189,0.0017011012,0.00016141903],"about_ca_topic_score_codex":0.000107861844,"about_ca_topic_score_gemma":0.00004699497,"teacher_disagreement_score":0.0938395,"about_ca_system_score_codex":0.00020454283,"about_ca_system_score_gemma":0.00038743805,"threshold_uncertainty_score":0.50522465},"labels":[],"label_agreement":null},{"id":"W3021689191","doi":"10.1038/s41408-020-0321-6","title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Chromosomal translocation; Venetoclax; Amyloidosis; AL amyloidosis; Medicine; Internal medicine; Oncology; Cancer research; Leukemia; Immunology; Biology; Genetics","score_opus":0.025811673003337074,"score_gpt":0.29806781107969577,"score_spread":0.2722561380763587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021689191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430174,0.037870586,0.0026943148,0.015152267,0.0003679745,0.00068183825,0.00016727866,0.000011499953,0.000036790585],"genre_scores_gemma":[0.96383595,0.033058133,0.00056164915,0.0013355769,0.000762159,0.0003144442,0.00002471855,0.000029925408,0.00007742426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99910223,0.000039403218,0.00027952454,0.00021907469,0.00014440688,0.00021535426],"domain_scores_gemma":[0.9993559,0.00004193963,0.00019339545,0.00018076239,0.00010868183,0.000119292985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007015306,0.0001745279,0.0002116601,0.00002042244,0.00014641571,0.000026114176,0.00019102961,0.00007619227,0.0000536426],"category_scores_gemma":[0.000025527257,0.00011782586,0.00028880168,0.000077352764,0.00005444453,0.000005091073,0.000010964142,0.000048937934,0.0000016091262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013869524,0.0015320603,0.15045103,0.000097901044,0.006133357,0.0000141319615,0.002814026,0.005289704,0.6198913,0.00010981165,0.033736583,0.17854318],"study_design_scores_gemma":[0.0048066555,0.0022433999,0.005779,0.000024777546,0.00077754713,0.000024859435,0.00018780431,0.00012835214,0.7435266,0.00001456464,0.24230415,0.00018228433],"about_ca_topic_score_codex":0.00006726233,"about_ca_topic_score_gemma":0.0001249123,"teacher_disagreement_score":0.20856757,"about_ca_system_score_codex":0.0000637869,"about_ca_system_score_gemma":0.0002449535,"threshold_uncertainty_score":0.48047993},"labels":[],"label_agreement":null},{"id":"W3023905358","doi":"10.1038/s41408-020-0319-0","title":"The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Multiple myeloma; Bone marrow; Internal medicine; Cohort; Gastroenterology; Retrospective cohort study; Biopsy; Renal function; Pathology; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.014517996752799115,"score_gpt":0.24561186572125138,"score_spread":0.23109386896845227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023905358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593395,0.0007228455,0.000004991258,0.0018225446,0.000021859638,0.0011242449,0.00010463827,0.00001122553,0.00025368386],"genre_scores_gemma":[0.99867153,0.00011324945,0.00078603206,0.00011957052,0.000070261514,0.0001090659,0.000034949393,0.000040130348,0.00005523207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977845,0.000074657466,0.0003667019,0.00026203194,0.0010061825,0.0005059308],"domain_scores_gemma":[0.9988595,0.000034308203,0.00026311167,0.00018505653,0.00022949473,0.00042852364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010908715,0.00023449774,0.00034448976,0.000099849996,0.0001260788,0.00004463905,0.00016039678,0.000064892374,0.00009372669],"category_scores_gemma":[0.00004268523,0.00012609691,0.000074214215,0.0003017972,0.00011485935,0.00012582996,0.000052572675,0.0005033031,0.000003183629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009004161,0.0016852013,0.97681165,0.00006563549,0.00043430325,0.000060892165,0.00039759005,0.000020847781,0.0008701477,0.000003169232,0.00007837742,0.010568003],"study_design_scores_gemma":[0.05067732,0.006671833,0.926513,0.00042765058,0.00028218658,0.00001874765,0.00031377695,0.0002935277,0.011632005,0.00003000756,0.0028595182,0.00028043293],"about_ca_topic_score_codex":0.0002703516,"about_ca_topic_score_gemma":0.00026785838,"teacher_disagreement_score":0.05029868,"about_ca_system_score_codex":0.000096387506,"about_ca_system_score_gemma":0.00036879955,"threshold_uncertainty_score":0.51420826},"labels":[],"label_agreement":null},{"id":"W3024544545","doi":"10.1038/s41408-020-0324-3","title":"Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"LEO Fondet; Kom op tegen Kanker; Kræftens Bekæmpelse; Novo Nordisk Fonden; H. Lundbeck A/S; Lundbeckfonden; Novo Nordisk","keywords":"FOXP3; Immunology; Staphylococcus aureus; Lymphoma; Biology; Immune system; Cancer research; Antigen; MHC class II; T cell","score_opus":0.027901647223077017,"score_gpt":0.3006441397954133,"score_spread":0.2727424925723363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024544545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924287,0.002385664,0.000042191383,0.003809352,0.00017963418,0.00071846455,0.000029434777,0.000021259735,0.0003852703],"genre_scores_gemma":[0.9968427,0.0008340149,0.00010538896,0.0016784224,0.00027966927,0.00008153368,0.0000035359255,0.00004585135,0.00012892945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763304,0.00016101499,0.00054478797,0.0003617769,0.0006529822,0.00064637157],"domain_scores_gemma":[0.999007,0.0000842312,0.000114478426,0.00016727838,0.00011945125,0.0005075991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002356802,0.000239626,0.0005207537,0.0003893453,0.00006903079,0.00006683067,0.00024893475,0.00012632327,0.00095736433],"category_scores_gemma":[0.00018544898,0.00022015061,0.000116500065,0.00073293585,0.00007071522,0.00012798433,0.000090546826,0.0012837003,0.00005174527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015106917,0.0011952097,0.7254556,0.00034072733,0.00029192076,0.029058665,0.004359542,0.00091748073,0.23171858,0.00000736027,0.0022938396,0.002850405],"study_design_scores_gemma":[0.09305622,0.014229127,0.64815164,0.0057118665,0.000696398,0.038132027,0.0068139993,0.00808138,0.17104511,0.0005541514,0.0108800735,0.002648042],"about_ca_topic_score_codex":0.00026111898,"about_ca_topic_score_gemma":0.00068668596,"teacher_disagreement_score":0.09154552,"about_ca_system_score_codex":0.00034127128,"about_ca_system_score_gemma":0.0011043279,"threshold_uncertainty_score":0.9999559},"labels":[],"label_agreement":null},{"id":"W3083502363","doi":"10.1038/s41408-020-00357-4","title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Internal medicine; Multiple myeloma; Regimen; Hazard ratio; Clinical endpoint; Oncology; Adverse effect; Randomized controlled trial; Confidence interval","score_opus":0.10023944158936043,"score_gpt":0.37622240002227375,"score_spread":0.2759829584329133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083502363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98396355,0.005628549,0.00003911597,0.008340861,0.00014624874,0.0013419818,0.00013043953,0.000019220626,0.00039005172],"genre_scores_gemma":[0.995623,0.002309217,0.0003323585,0.00064566167,0.0007826367,0.00009530854,0.000023475202,0.000027030299,0.0001613138],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996747,0.0009383159,0.0007028774,0.00040077046,0.000760844,0.00045017042],"domain_scores_gemma":[0.99776775,0.0011173584,0.00023173596,0.00023331266,0.00011759344,0.0005322321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014536452,0.00025193466,0.0008650795,0.00007878869,0.0001780157,0.00013037623,0.00018604546,0.00006084463,0.00037225353],"category_scores_gemma":[0.001419674,0.0001487032,0.00016968814,0.00021416518,0.00012529442,0.00011603418,0.00008979256,0.000811171,0.000010057854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80655813,0.003736213,0.13421941,0.00003015385,0.004291557,0.0057042176,0.008488241,0.000030142915,0.001444546,0.000027066602,0.0017069805,0.033763323],"study_design_scores_gemma":[0.9235181,0.0012700958,0.07107956,0.00018510908,0.0008425472,0.00013501878,0.0011025107,0.00053800025,0.0004355516,0.000109861496,0.00061536755,0.00016823158],"about_ca_topic_score_codex":0.004713737,"about_ca_topic_score_gemma":0.0006499786,"teacher_disagreement_score":0.11696,"about_ca_system_score_codex":0.00010301464,"about_ca_system_score_gemma":0.00046953346,"threshold_uncertainty_score":0.71257913},"labels":[],"label_agreement":null},{"id":"W3095225774","doi":"10.1038/s41408-020-00375-2","title":"Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Lenalidomide; Internal medicine; Daratumumab; Medicine; Oncology; Hazard ratio; Population; Multiple myeloma; Confidence interval","score_opus":0.03944056650698583,"score_gpt":0.3211153016057787,"score_spread":0.28167473509879287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095225774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259723,0.015616567,0.000047872596,0.0011766065,0.00003873259,0.00020997788,0.000045627014,0.000009963447,0.0002573947],"genre_scores_gemma":[0.9950911,0.0035317442,0.00083966536,0.00025477383,0.00016544832,0.000017510101,0.000008552612,0.000021745,0.000069494956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981836,0.00014605657,0.0004937704,0.00028753775,0.0005186494,0.00037040454],"domain_scores_gemma":[0.9987982,0.000105827676,0.00020789634,0.00017758424,0.00013162446,0.0005788613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027698005,0.00018219803,0.00071453606,0.0005180159,0.0000748017,0.000029176781,0.00011133567,0.00008770283,0.000452995],"category_scores_gemma":[0.00022655993,0.00014673432,0.00020419553,0.0011838934,0.00010370102,0.000072002265,0.000053675358,0.0004912331,0.0000033695324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021032149,0.00049244345,0.93595856,0.000118107426,0.0050119944,0.0011643209,0.00084167236,0.00010187557,0.032725006,0.00000998285,0.00013172756,0.021341074],"study_design_scores_gemma":[0.017374882,0.0011021668,0.9666425,0.00017463163,0.0036848497,0.00020601998,0.00022053676,0.0011347862,0.008929801,0.000018132578,0.00034956346,0.00016212088],"about_ca_topic_score_codex":0.00034163438,"about_ca_topic_score_gemma":0.00035718252,"teacher_disagreement_score":0.03068393,"about_ca_system_score_codex":0.00009835474,"about_ca_system_score_gemma":0.00032392805,"threshold_uncertainty_score":0.59836525},"labels":[],"label_agreement":null},{"id":"W3112832052","doi":"10.1038/s41408-020-00391-2","title":"Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Proteinuria; Medicine; Receiver operating characteristic; Gold standard (test); Albuminuria; Urine; Urology; Creatinine; Internal medicine; Renal function; Cohort; Cutoff; Area under the curve; Gastroenterology; Kidney","score_opus":0.013394281776035879,"score_gpt":0.2685380778017706,"score_spread":0.2551437960257347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112832052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966792,0.0019059123,0.000043209817,0.0006042151,0.00011001899,0.00048909656,0.000067674315,0.0000073259357,0.00009334664],"genre_scores_gemma":[0.9957021,0.003424999,0.0001655753,0.00022107344,0.00026302747,0.00009332968,0.000042742915,0.000026543205,0.000060650305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987118,0.000098854944,0.00047338626,0.00028409564,0.00021482936,0.00021700564],"domain_scores_gemma":[0.99921256,0.000018686223,0.0003719263,0.000135232,0.00010135132,0.00016023948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001375824,0.0001815831,0.000333114,0.00007507352,0.000054432345,0.000022481845,0.000114250586,0.00009682657,0.000028468334],"category_scores_gemma":[0.00006115981,0.00016482577,0.00008256414,0.00016411237,0.00004313603,0.000012016954,0.00007874641,0.00017514713,0.0000016861112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094811585,0.000104529485,0.9867587,0.00004812173,0.00030927564,0.0000067411834,0.00014443746,0.00006427116,0.010224701,0.0000030644835,0.00069962436,0.001541736],"study_design_scores_gemma":[0.0035584623,0.00048813695,0.96050555,0.00021407133,0.0002752282,0.000014225064,0.000047749003,0.000018577304,0.03403139,0.0000069356697,0.00065535353,0.00018431003],"about_ca_topic_score_codex":0.00027590664,"about_ca_topic_score_gemma":0.00018138424,"teacher_disagreement_score":0.026253127,"about_ca_system_score_codex":0.000056548422,"about_ca_system_score_gemma":0.0001139633,"threshold_uncertainty_score":0.67214},"labels":[],"label_agreement":null},{"id":"W3132537256","doi":"10.1038/s41408-021-00429-z","title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Minimal residual disease; Medicine; Cancer research; Leukemia; Hematology; Drug development; Immunology; Oncology; Pharmacology; Drug; Internal medicine; Tyrosine kinase; Receptor","score_opus":0.02705962028518334,"score_gpt":0.34454831379110384,"score_spread":0.3174886935059205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132537256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98681515,0.009067826,0.0010813127,0.002036762,0.00015170692,0.00045959264,0.00018933027,0.000015353033,0.00018297312],"genre_scores_gemma":[0.99425685,0.00094081333,0.0032546727,0.00006535317,0.0006982219,0.00008058974,0.000117722484,0.000022875305,0.0005628686],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99886155,0.000050691142,0.00034361723,0.00020757658,0.00031611454,0.00022043967],"domain_scores_gemma":[0.99874973,0.00011732307,0.00018010414,0.00024009559,0.00040883757,0.00030392193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025267684,0.00009167493,0.00019462233,0.000068313806,0.0001470713,0.000032346605,0.000069211506,0.00005180182,0.00016304538],"category_scores_gemma":[0.00027425398,0.000084406136,0.000077574085,0.0001525072,0.000074950534,0.00006344439,0.000032693264,0.00015351875,0.0000013177613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008754495,0.003007512,0.33967867,0.0076595726,0.0032745535,0.00079710234,0.0028096656,0.0040920307,0.4902923,0.008790012,0.07066985,0.06017419],"study_design_scores_gemma":[0.06099929,0.00076995435,0.5493747,0.0012706788,0.002834584,0.0020869577,0.00028458252,0.021925893,0.29732862,0.00749926,0.055003952,0.0006214987],"about_ca_topic_score_codex":0.0001075216,"about_ca_topic_score_gemma":0.00003241504,"teacher_disagreement_score":0.20969602,"about_ca_system_score_codex":0.001563724,"about_ca_system_score_gemma":0.009989754,"threshold_uncertainty_score":0.9956227},"labels":[],"label_agreement":null},{"id":"W3135629194","doi":"10.1038/s41408-021-00440-4","title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Mayo Clinic","keywords":"Immune system; Immunology; Multiple myeloma; Immunosurveillance; Tumor microenvironment; Immunotherapy; Cancer research; Biology; Immunosuppression; Stem cell; Medicine; Cell biology","score_opus":0.012191571370281424,"score_gpt":0.2555898192621097,"score_spread":0.2433982478918283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135629194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751148,0.02385271,0.000042669715,0.00039912845,0.00012096394,0.00021917891,0.000154337,0.000010692664,0.00008550807],"genre_scores_gemma":[0.98721594,0.011359299,0.00070443226,0.000030950334,0.00009306135,0.000024487279,0.0000857273,0.000028007777,0.0004580763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830085,0.000119761695,0.00050874613,0.00026082012,0.0004181954,0.00039163628],"domain_scores_gemma":[0.9989477,0.000118204676,0.00024080717,0.0002516411,0.000114140385,0.00032750162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015956305,0.00020014543,0.0004004584,0.00008038612,0.00016538097,0.00003714647,0.000086793676,0.00008360778,0.0006701334],"category_scores_gemma":[0.00009437727,0.00014923711,0.00014417204,0.00009342269,0.00007985606,0.000076570206,0.00010469471,0.000355958,0.000006551217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029288686,0.0005303116,0.48333603,0.000122285,0.00028022638,0.0009164657,0.000097786055,0.0000017169898,0.50988036,3.6398586e-7,0.000039638424,0.004501917],"study_design_scores_gemma":[0.0077328244,0.00025479897,0.5453913,0.0005469645,0.00020574947,0.0008999454,0.00020657452,0.000065430344,0.44439563,0.000004105393,0.00020880827,0.00008786649],"about_ca_topic_score_codex":0.00018118176,"about_ca_topic_score_gemma":0.00003677315,"teacher_disagreement_score":0.06548475,"about_ca_system_score_codex":0.00007483569,"about_ca_system_score_gemma":0.00025302518,"threshold_uncertainty_score":0.73374903},"labels":[],"label_agreement":null},{"id":"W3154921500","doi":"10.1038/s41408-021-00463-x","title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); McGill University Health Centre; McGill University; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Polycythemia vera; Thrombosis; Hematology; Medicine; Internal medicine; Phenotype; Gastroenterology; Immunology; Biology; Genetics","score_opus":0.048162946961059695,"score_gpt":0.3147656740675299,"score_spread":0.2666027271064702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154921500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5999117,0.030656362,0.0000018938614,0.3666224,0.0012722606,0.00032768253,0.0001248637,0.000021497985,0.0010613705],"genre_scores_gemma":[0.50827134,0.10567311,0.001278829,0.3625448,0.019827072,0.00060456624,0.00028325358,0.00024491805,0.001272075],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9974985,0.00017046292,0.0005725304,0.00060093537,0.00057740643,0.0005801479],"domain_scores_gemma":[0.9987048,0.00039180423,0.0002694948,0.00025130497,0.0001532565,0.00022932499],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000115795156,0.0005459551,0.0012536262,0.00023251823,0.00019979583,0.00021003591,0.0001354734,0.0006075638,0.0029989805],"category_scores_gemma":[0.00006280172,0.00041395114,0.00024800788,0.00020067385,0.00014535522,0.000116229145,0.00008600609,0.0031745692,0.000008538802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009816135,0.00087961345,0.38663244,0.00070763926,0.0058253994,0.007192076,0.00097472285,7.2446227e-7,0.00034438932,0.000026840247,0.5781273,0.018307185],"study_design_scores_gemma":[0.04237162,0.0032440426,0.71124613,0.006847692,0.007073366,0.003236165,0.0005922759,0.000015092842,0.011542537,0.00032369068,0.21179494,0.0017124321],"about_ca_topic_score_codex":0.00018499815,"about_ca_topic_score_gemma":0.00026449564,"teacher_disagreement_score":0.3663324,"about_ca_system_score_codex":0.00030991854,"about_ca_system_score_gemma":0.001087728,"threshold_uncertainty_score":0.99983126},"labels":[],"label_agreement":null},{"id":"W3168326299","doi":"10.1038/s41408-021-00507-2","title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; bluebird bio; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Oncology; Surgery","score_opus":0.036563343465977595,"score_gpt":0.3583077447515886,"score_spread":0.321744401285611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168326299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936924,0.0042434167,0.00000852203,0.00077435124,0.00008255966,0.00021988947,0.000024382725,0.000014069175,0.0009403945],"genre_scores_gemma":[0.99477863,0.0016589296,0.0020991727,0.00008966745,0.000100281635,0.000024322042,0.000010511892,0.0000303965,0.001208088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814993,0.00012084565,0.00050896924,0.00026802073,0.00056740054,0.00038481786],"domain_scores_gemma":[0.99871224,0.00018100586,0.00022943971,0.00025697352,0.00025141754,0.00036891422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021158783,0.00019372084,0.00067175337,0.00025602127,0.00009736461,0.00003143166,0.00008159413,0.00006583794,0.00022129131],"category_scores_gemma":[0.00014429084,0.00013953331,0.000085221145,0.0003510096,0.000089191075,0.000092414404,0.0000517582,0.0005275256,0.0000028511074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010551172,0.0011495367,0.96326804,0.00009685605,0.0006124,0.001561552,0.00047205872,0.0000257563,0.017528096,0.000007221895,0.00016288062,0.014060508],"study_design_scores_gemma":[0.017686306,0.0005745741,0.93548083,0.00045585932,0.00021062752,0.00027119162,0.00043550486,0.00018188165,0.04403504,0.000015433647,0.0005212486,0.0001314877],"about_ca_topic_score_codex":0.00095676346,"about_ca_topic_score_gemma":0.008316752,"teacher_disagreement_score":0.027787171,"about_ca_system_score_codex":0.00015236049,"about_ca_system_score_gemma":0.00060495164,"threshold_uncertainty_score":0.5690003},"labels":[],"label_agreement":null},{"id":"W3175478791","doi":"10.1038/s41408-021-00505-4","title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Internal medicine; Medicine; Gastroenterology; Biomarker; Cohort; Hematology; Oncology; Monoclonal; Immunology; Monoclonal antibody; Antibody; Biology","score_opus":0.029876526239525292,"score_gpt":0.31746582814420443,"score_spread":0.28758930190467913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175478791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955742,0.0025719388,0.0000074302893,0.0010199089,0.0001970689,0.00017983848,0.000056654353,0.000013447445,0.00037953086],"genre_scores_gemma":[0.99759454,0.00080630055,0.00044173733,0.00021127486,0.0001466016,0.000021361988,0.0000062844742,0.00002067389,0.0007512193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859476,0.000061866915,0.00028028726,0.00021292071,0.00044128674,0.000408892],"domain_scores_gemma":[0.9992318,0.00004408708,0.00006945259,0.00014233624,0.00015647546,0.0003558205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012356359,0.00014736361,0.00031792195,0.00012721088,0.00010511529,0.00006241941,0.000058536643,0.00006059515,0.00042760302],"category_scores_gemma":[0.00015608134,0.000115117466,0.00007288078,0.00015197044,0.0000313832,0.0001298135,0.0000724587,0.00035995725,0.000005101486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007774375,0.0003831401,0.940128,0.000052178653,0.00033743255,0.0016441197,0.00015259156,0.000002861881,0.0004948398,0.0000024916399,0.00007598004,0.05664859],"study_design_scores_gemma":[0.011971124,0.00022956434,0.98158723,0.0002966593,0.000099275094,0.0004888129,0.00007738059,0.000041624124,0.0047626826,0.000037286292,0.0003124171,0.000095945456],"about_ca_topic_score_codex":0.000075014024,"about_ca_topic_score_gemma":0.00019923283,"teacher_disagreement_score":0.056552645,"about_ca_system_score_codex":0.00011982142,"about_ca_system_score_gemma":0.00033597625,"threshold_uncertainty_score":0.4694354},"labels":[],"label_agreement":null},{"id":"W3177665412","doi":"10.1038/s41408-021-00522-3","title":"Drug importation: limitations of current proposals and opportunities for improvement","year":2021,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Panacea (medicine); Business; Drug prices; Authorization; Drug; International trade; Law; Public economics; Economic policy; Medicine; Economics; Pharmacology; Political science; Computer security; Alternative medicine","score_opus":0.18921442342185205,"score_gpt":0.34818537186670157,"score_spread":0.15897094844484952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177665412","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040859776,0.14466165,0.00030769117,0.0054711215,0.8318887,0.0006296435,0.011242264,0.000013188717,0.0016998092],"genre_scores_gemma":[0.0035056786,0.34860322,0.00045477637,0.00044766083,0.6449021,0.00031181777,0.0003294555,0.00008126015,0.0013640301],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819005,0.000014436208,0.0011561937,0.0002953573,0.000070188,0.0002737751],"domain_scores_gemma":[0.99776405,0.00030736285,0.0012859826,0.00015064291,0.00029339385,0.0001985489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065389933,0.00021276184,0.00063715427,0.00020417469,0.00013974519,0.00017991061,0.00018679924,0.00015612894,0.00014183378],"category_scores_gemma":[0.00027871254,0.00024202191,0.0002195378,0.000051664574,0.000068519534,0.00016649779,0.000053099426,0.00048268042,0.0000017091613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019340796,0.00013130136,0.000087178996,0.00040871478,0.00043245932,0.0000030094832,0.00028170773,0.00000841103,0.000010552569,0.013667286,0.9621394,0.02281063],"study_design_scores_gemma":[0.0012778768,0.00009589959,0.0000132171745,0.00013242546,0.00014698638,0.0000028813527,0.00009073844,0.00008821197,0.00016024188,0.014405115,0.9833281,0.00025829792],"about_ca_topic_score_codex":0.00003341833,"about_ca_topic_score_gemma":0.00006219655,"teacher_disagreement_score":0.20394155,"about_ca_system_score_codex":0.00009892012,"about_ca_system_score_gemma":0.00091737614,"threshold_uncertainty_score":0.9869367},"labels":[],"label_agreement":null},{"id":"W3198880734","doi":"10.1038/s41408-021-00544-x","title":"A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Singapore General Hospital; National University of Singapore; Onyx Pharmaceuticals; Duke-NUS Medical School","keywords":"Carfilzomib; Dexamethasone; Medicine; Cyclophosphamide; Internal medicine; Phase (matter); Oncology; Intensive care medicine; Chemotherapy; Lenalidomide; Chemistry","score_opus":0.025987748150059484,"score_gpt":0.3327062772657641,"score_spread":0.30671852911570463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198880734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93938464,0.03434584,0.0000506293,0.02147835,0.00021483348,0.0028952814,0.0015526783,0.000026652084,0.000051118765],"genre_scores_gemma":[0.8770474,0.07297055,0.007260112,0.017582871,0.0082250135,0.002336751,0.0015786767,0.00042262816,0.012575988],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99657625,0.00023176441,0.00063245714,0.00072384346,0.0009903202,0.00084537547],"domain_scores_gemma":[0.99769443,0.0003152429,0.00054761244,0.00048453663,0.00049863296,0.00045951782],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022776228,0.00069438503,0.0016797052,0.00033523605,0.00030309724,0.0001031129,0.00017055053,0.00039931247,0.00021043574],"category_scores_gemma":[0.000061615254,0.00044548078,0.0002980271,0.00020796589,0.00010939648,0.000088832785,0.000029296905,0.0015530124,0.0000012488899],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08208594,0.052751888,0.23514593,0.004235024,0.11319391,0.16578408,0.010305162,0.00009008663,0.0040003164,0.000006381589,0.23007151,0.102329776],"study_design_scores_gemma":[0.59979177,0.15074788,0.023255737,0.0044796295,0.044611927,0.013345097,0.0022258959,0.00002576282,0.046909872,0.00009647275,0.11284496,0.00166501],"about_ca_topic_score_codex":0.011120502,"about_ca_topic_score_gemma":0.001611044,"teacher_disagreement_score":0.5177058,"about_ca_system_score_codex":0.00030009644,"about_ca_system_score_gemma":0.0013018001,"threshold_uncertainty_score":0.99979967},"labels":[],"label_agreement":null},{"id":"W3204092402","doi":"10.1038/s41408-021-00555-8","title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Genentech; Aptitude Health; AbbVie","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine","score_opus":0.011538544988294298,"score_gpt":0.27638876329451056,"score_spread":0.26485021830621625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204092402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965754,0.0013534339,0.000051229894,0.0012367612,0.000078617835,0.0005841429,0.000031780535,0.000009626757,0.00007899428],"genre_scores_gemma":[0.9964891,0.0010816982,0.0013698628,0.00037935108,0.0001165439,0.00003316555,0.000023947261,0.000039755687,0.00046657768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987398,0.000040887764,0.00035783328,0.00024221186,0.00024972134,0.0003695716],"domain_scores_gemma":[0.997846,0.00010331486,0.00017620133,0.00016190192,0.0015253178,0.0001872432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016775216,0.00017057238,0.00048419234,0.00015891831,0.00010014603,0.000030354573,0.000079190606,0.000092463684,0.000075481454],"category_scores_gemma":[0.00024391981,0.00012479397,0.00007260736,0.00037856947,0.00009366134,0.00010490835,0.00003548668,0.00037310825,3.471125e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012774601,0.0012004314,0.89679086,0.00026264144,0.0012979157,0.00015254894,0.0012923421,0.000024039195,0.07090185,0.000009479849,0.0015293519,0.013763926],"study_design_scores_gemma":[0.18593921,0.00463375,0.45410895,0.0014633185,0.00067868293,0.00042388355,0.0012148913,0.0006588741,0.3497736,0.00008171214,0.0006305141,0.00039262796],"about_ca_topic_score_codex":0.0002371683,"about_ca_topic_score_gemma":0.00026288084,"teacher_disagreement_score":0.4426819,"about_ca_system_score_codex":0.00016812608,"about_ca_system_score_gemma":0.0012105531,"threshold_uncertainty_score":0.508895},"labels":[],"label_agreement":null},{"id":"W3206224016","doi":"10.1038/s41408-021-00561-w","title":"Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Acute promyelocytic leukemia; NPM1; Retinoic acid receptor alpha; Myeloid leukemia; Retinoic acid; Cancer research; Retinoic acid receptor; Leukemia; Myeloid; Hematology; Medicine; Arsenic trioxide; Internal medicine; Biology; Oncology; Immunology; Genetics; Karyotype","score_opus":0.010544463350792267,"score_gpt":0.2419341986136415,"score_spread":0.23138973526284923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206224016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96171695,0.017997313,0.00040339807,0.016961254,0.0015496861,0.000274655,0.00048601138,0.000018848801,0.00059190777],"genre_scores_gemma":[0.52336806,0.2250409,0.008616763,0.17582105,0.04143274,0.0001926257,0.005933722,0.0008685762,0.018725546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974091,0.00018461628,0.0007484141,0.0006262691,0.0005323855,0.00049923843],"domain_scores_gemma":[0.9978424,0.000019796622,0.0010162729,0.0005271701,0.0004489327,0.00014544996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028315152,0.00052944483,0.00076273526,0.00009771719,0.00019055168,0.00013414903,0.0004885444,0.001049661,0.00018040555],"category_scores_gemma":[0.000051527044,0.00043370915,0.00019688443,0.00012782103,0.00020003675,0.000012779577,0.00023041756,0.0018193638,0.000001940082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004340107,0.00008105632,0.045843627,0.0012549653,0.0023227374,0.001491558,0.0001356267,0.0000035315554,0.73108226,0.0000021809133,0.21268305,0.004665361],"study_design_scores_gemma":[0.0027219728,0.0010951217,0.0033432401,0.0011578635,0.0020099783,0.0038022245,0.000043882457,0.0000040995455,0.6081906,0.000023777415,0.37651142,0.0010958188],"about_ca_topic_score_codex":0.000022924794,"about_ca_topic_score_gemma":0.000009357409,"teacher_disagreement_score":0.43834883,"about_ca_system_score_codex":0.00009691717,"about_ca_system_score_gemma":0.001128032,"threshold_uncertainty_score":0.9998115},"labels":[],"label_agreement":null},{"id":"W3208012644","doi":"10.1038/s41408-021-00565-6","title":"Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","year":2021,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Intensive care medicine; Pediatrics","score_opus":0.01351894866652132,"score_gpt":0.28720051549605913,"score_spread":0.2736815668295378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208012644","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96947503,0.010604035,0.00010494165,0.0030058483,0.012581903,0.00310056,0.0002457355,0.000046899808,0.0008350637],"genre_scores_gemma":[0.43671155,0.028588014,0.0043985755,0.002383243,0.010167708,0.0009517791,0.0026398269,0.00106994,0.51308936],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99745935,0.000092620794,0.00074369635,0.00053521525,0.00054757664,0.0006215515],"domain_scores_gemma":[0.9955081,0.00015578096,0.0006394003,0.00031314362,0.0030588275,0.00032474304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030856737,0.00046864,0.0013110322,0.0004926337,0.00020882252,0.00007809241,0.00018084008,0.0005357617,0.00016512541],"category_scores_gemma":[0.00051707745,0.00035643176,0.00019692765,0.0006687738,0.00017575105,0.00012743469,0.00006821754,0.0019973244,4.9539136e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0201164,0.0015643697,0.09920411,0.0011236287,0.004062903,0.00024336482,0.001535967,0.000019756826,0.0022859932,0.0000017019477,0.8533177,0.016524142],"study_design_scores_gemma":[0.45301992,0.031819683,0.28279004,0.03368616,0.008648158,0.0030476379,0.0051240316,0.0044959947,0.050289515,0.00007467562,0.123647384,0.0033567974],"about_ca_topic_score_codex":0.0007298398,"about_ca_topic_score_gemma":0.0007406848,"teacher_disagreement_score":0.7296703,"about_ca_system_score_codex":0.00058775104,"about_ca_system_score_gemma":0.004460967,"threshold_uncertainty_score":0.9998888},"labels":[],"label_agreement":null},{"id":"W3208762835","doi":"10.1038/s41408-021-00568-3","title":"A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Menzies Centre for Australian Studies, King's College London, University of London; Gillings School of Public Health; Sidney Kimmel Comprehensive Cancer Center; King's College London; CHILDREN with CANCER UK; Johns Hopkins University","keywords":"Mitoxantrone; Cytarabine; Myeloid leukemia; Medicine; Biomarker; Internal medicine; Oncology; Refractory (planetary science); Hematology; Leukemia; Myeloid; Cancer research; Chemotherapy; Chemistry; Biology","score_opus":0.01458154797642146,"score_gpt":0.28983538762658784,"score_spread":0.27525383965016637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208762835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7309856,0.07091937,0.000094295545,0.19291441,0.00086996873,0.0017240319,0.0015328481,0.00006192904,0.00089754444],"genre_scores_gemma":[0.38545468,0.22830683,0.004471084,0.2928491,0.015339953,0.0015084893,0.004927352,0.001532198,0.065610304],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99342006,0.00053275627,0.0015389078,0.0011967839,0.0020837518,0.0012277563],"domain_scores_gemma":[0.9965597,0.00030458492,0.0010484534,0.0008415704,0.0007988197,0.00044691315],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010142758,0.00082650094,0.0028975373,0.0022177128,0.00016459107,0.00013255312,0.0005096432,0.0013940298,0.0011962729],"category_scores_gemma":[0.00022462466,0.00071862683,0.0008840174,0.002333803,0.00034155318,0.00024595644,0.0002868633,0.00745647,0.0000070345554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014870317,0.000512254,0.05333966,0.00045205027,0.049522042,0.015479155,0.00055509224,0.000013767176,0.08081774,0.000001065995,0.79578567,0.002034497],"study_design_scores_gemma":[0.11387697,0.0055047437,0.18231386,0.0072797756,0.18714596,0.013210463,0.001086883,0.0014296331,0.058448695,0.00013293244,0.42435062,0.005219458],"about_ca_topic_score_codex":0.0014081367,"about_ca_topic_score_gemma":0.00039731388,"teacher_disagreement_score":0.37143502,"about_ca_system_score_codex":0.0043115737,"about_ca_system_score_gemma":0.0049707764,"threshold_uncertainty_score":0.99990237},"labels":[],"label_agreement":null},{"id":"W3216448276","doi":"10.1038/s41408-021-00569-2","title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Risk stratification; Medicine; Stratification (seeds); Internal medicine; Oncology; Intensive care medicine; Biology","score_opus":0.043779452069503774,"score_gpt":0.3397416861487298,"score_spread":0.295962234079226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216448276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995727,0.0023338522,0.00022312604,0.0006316091,0.00015200583,0.00046051093,0.00005194127,0.000018441122,0.00040148592],"genre_scores_gemma":[0.99657923,0.0011059876,0.0017322164,0.000045196903,0.0003214645,0.00014019213,0.000029186222,0.00002050784,0.000026012045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.00018417306,0.00041885837,0.00024002542,0.00053442473,0.0003108637],"domain_scores_gemma":[0.9982791,0.00038229013,0.0003082115,0.00030633048,0.00052639813,0.00019765118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044002337,0.00015040342,0.0002782915,0.000060781713,0.00035709233,0.00019344762,0.00012663317,0.00006119163,0.00052404474],"category_scores_gemma":[0.0009731088,0.000100796715,0.00012582794,0.00024003877,0.000096296135,0.00016023376,0.000049956507,0.0004116236,0.0000040639525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016153169,0.0005507601,0.8711827,0.00011182756,0.0005342002,0.00013215175,0.00025997718,0.000023946328,0.042922262,0.000009552728,0.000059096597,0.08405202],"study_design_scores_gemma":[0.0026567583,0.00010181792,0.8588909,0.00026364622,0.0004309007,0.00018344262,0.00051164767,0.0003358012,0.13641906,0.00006859662,0.00006229543,0.00007516524],"about_ca_topic_score_codex":0.0002618844,"about_ca_topic_score_gemma":0.00036432443,"teacher_disagreement_score":0.0934968,"about_ca_system_score_codex":0.000052796084,"about_ca_system_score_gemma":0.0009537202,"threshold_uncertainty_score":0.5737922},"labels":[],"label_agreement":null},{"id":"W344822596","doi":"10.1038/bcj.2015.35","title":"NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates; Killam Trusts; University of Alberta; Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; MSH2; Cancer research; Phosphorylation; Tyrosine kinase; Tyrosine phosphorylation; Anaplastic large-cell lymphoma; Transfection; Tyrosine; Molecular biology; Chemistry; Biology; Cell biology; Signal transduction; DNA mismatch repair; Biochemistry; DNA repair; Lymphoma; Medicine; DNA; Gene; Internal medicine; Immunology","score_opus":0.024010159222079917,"score_gpt":0.26744182695403806,"score_spread":0.24343166773195815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W344822596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719725,0.02564793,0.000037595833,0.00061207055,0.00041135948,0.00022250335,0.000010113117,0.000010359933,0.0010755684],"genre_scores_gemma":[0.9976466,0.0009782006,0.00081462465,0.000094250245,0.00024921857,0.000018373754,0.0000027966787,0.000015859412,0.00018011883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836516,0.0000863963,0.00056893274,0.00016808904,0.0006119869,0.00019942071],"domain_scores_gemma":[0.9987405,0.000197109,0.00039208613,0.00015115671,0.00039195883,0.00012716763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097487145,0.00013143537,0.00036723484,0.000101756545,0.000072271825,0.000009350768,0.00007940755,0.00008107067,0.00021738041],"category_scores_gemma":[0.00045438227,0.00008771355,0.00009721961,0.00027268604,0.0002754648,0.000058633206,0.00006084738,0.00026626236,9.054069e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027894296,0.00020046272,0.9763733,0.00017033162,0.00013504192,0.000017980581,0.0041648466,0.0011559778,0.012251841,0.00008061095,0.00139126,0.0012689176],"study_design_scores_gemma":[0.030909669,0.0015534156,0.84395665,0.0012046387,0.00094286905,0.0016647312,0.0021248993,0.0024762985,0.11234001,0.0016875853,0.00080340507,0.00033582895],"about_ca_topic_score_codex":0.00040508664,"about_ca_topic_score_gemma":0.0002954557,"teacher_disagreement_score":0.13241665,"about_ca_system_score_codex":0.00019602665,"about_ca_system_score_gemma":0.00053336675,"threshold_uncertainty_score":0.3576855},"labels":[],"label_agreement":null},{"id":"W4200418432","doi":"10.1038/s41408-021-00584-3","title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","year":2021,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Leukemia & Lymphoma Society of Canada; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; University of British Columbia; Genome British Columbia; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Genome Canada; Terry Fox Research Institute","keywords":"Myeloid leukemia; Myeloid; Azacitidine; Medicine; Differentiation therapy; Acute promyelocytic leukemia; Myelodysplastic syndromes; Immunology; Haematopoiesis; Cancer research; Stem cell; Biology; Retinoic acid; Bone marrow; DNA methylation","score_opus":0.06473534785784331,"score_gpt":0.3828485920994154,"score_spread":0.3181132442415721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200418432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042724132,0.99559826,0.00045829755,0.0003574579,0.0007062531,0.0019811722,0.00024940306,0.00003880056,0.00018310048],"genre_scores_gemma":[0.000015547956,0.9902039,0.000901147,0.00041036238,0.004514318,0.00080984813,0.00025557316,0.00016872218,0.0027205793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996564,0.00026649152,0.0010109642,0.00056624826,0.0008251897,0.0007671398],"domain_scores_gemma":[0.99730444,0.00026528153,0.0007443187,0.0005081855,0.0007373676,0.00044039206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007128397,0.00058701634,0.0025982284,0.00038177834,0.0003263428,0.00020728477,0.0004142919,0.00054579356,0.0011305664],"category_scores_gemma":[0.00021671169,0.00042045914,0.0015268682,0.00049924396,0.00007604506,0.00012201772,0.00009155741,0.0016898104,0.000015929554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088820816,0.00041652325,0.000046509325,0.009680831,0.0029540353,0.00021393057,0.000091412614,5.6059486e-7,0.00018905353,0.000053496507,0.017053513,0.96921134],"study_design_scores_gemma":[0.0038166207,0.00051169354,0.000035800567,0.017517483,0.0030916862,0.0026255792,0.000032579243,0.0000073606693,0.00045834546,0.000040500032,0.9714541,0.00040826452],"about_ca_topic_score_codex":0.000018447045,"about_ca_topic_score_gemma":0.0000091020665,"teacher_disagreement_score":0.96880305,"about_ca_system_score_codex":0.0011056464,"about_ca_system_score_gemma":0.006742927,"threshold_uncertainty_score":0.9998247},"labels":[],"label_agreement":null},{"id":"W4206490155","doi":"10.1038/s41408-021-00600-6","title":"Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Université de Montréal","keywords":"Multiple myeloma; Immunoglobulin light chain; Medicine; Antibody; Immunoglobulin A; Internal medicine; Myeloma protein; Immunology; Immunoglobulin G; Oncology","score_opus":0.03656930127434755,"score_gpt":0.31523575146382365,"score_spread":0.2786664501894761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206490155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6928144,0.011278521,0.000009864594,0.28812444,0.0033964193,0.0020922548,0.00034290075,0.00011476909,0.0018264034],"genre_scores_gemma":[0.91079426,0.00812568,0.00089011533,0.03775839,0.020643188,0.0024361312,0.002003609,0.0004825435,0.016866082],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.995324,0.00043582323,0.0010437346,0.0006272152,0.0015530513,0.00101615],"domain_scores_gemma":[0.99827576,0.00007944279,0.00054410007,0.00068075064,0.00012901898,0.00029096016],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052077154,0.00059777376,0.0010390562,0.0009849792,0.00043034108,0.0001877432,0.00037655502,0.000514124,0.001486953],"category_scores_gemma":[0.00015635442,0.00050146336,0.0006220834,0.000528702,0.000032036376,0.0003412735,0.00013044104,0.0034235884,0.000028752887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036236076,0.002936594,0.45894474,0.00068451394,0.012009639,0.08631444,0.0034711065,0.00010141381,0.0029512388,0.000004522106,0.39117333,0.03778484],"study_design_scores_gemma":[0.08791029,0.013791889,0.2818684,0.0036008663,0.0056908904,0.00929865,0.0006224698,0.00010044637,0.005144285,0.0003760395,0.5896712,0.0019245838],"about_ca_topic_score_codex":0.0025817011,"about_ca_topic_score_gemma":0.00010434432,"teacher_disagreement_score":0.25036603,"about_ca_system_score_codex":0.0038724283,"about_ca_system_score_gemma":0.0013269036,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W4210625548","doi":"10.1038/s41408-021-00602-4","title":"Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study","year":2022,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"Hamilton Health Sciences Foundation; Cancer Care Ontario; Hamilton Health Sciences","keywords":"Multiple myeloma; Medicine; Outcome (game theory); Population; Internal medicine; MEDLINE; Health care; Intensive care medicine; Environmental health; Biology","score_opus":0.03334740798546452,"score_gpt":0.329829562829504,"score_spread":0.29648215484403945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210625548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9013726,0.0021452687,0.0000045413362,0.00013567603,0.09253065,0.002545522,0.0011927168,0.000063170446,0.000009855398],"genre_scores_gemma":[0.9660578,0.00008315131,0.000019059065,0.00016744115,0.02760831,0.0004596511,0.0054507474,0.00011206865,0.000041767493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954332,0.00040271415,0.0010569578,0.0005527757,0.0020416614,0.00051270827],"domain_scores_gemma":[0.9967319,0.00017465313,0.0017149944,0.00024173282,0.00087568094,0.00026107734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029121255,0.0005125369,0.0011973828,0.00053505064,0.0003751085,0.00004797678,0.00012473715,0.00024358442,0.00021249104],"category_scores_gemma":[0.0001338151,0.000383431,0.00012649127,0.00064042304,0.00002079013,0.000091310016,0.000017082384,0.001462692,2.6709347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066942177,0.004383028,0.9561067,0.00017555777,0.0016044641,0.00045611986,0.0022821173,0.0010286637,3.933666e-7,1.7657314e-8,0.02655767,0.00071105],"study_design_scores_gemma":[0.061431266,0.008288915,0.918487,0.0010194338,0.002820135,0.000007981371,0.0007654324,0.0000112046555,0.0000051505526,2.4296585e-7,0.0067496593,0.0004135425],"about_ca_topic_score_codex":0.00389378,"about_ca_topic_score_gemma":0.036445595,"teacher_disagreement_score":0.06492234,"about_ca_system_score_codex":0.0027569765,"about_ca_system_score_gemma":0.0034264743,"threshold_uncertainty_score":0.9998618},"labels":[],"label_agreement":null},{"id":"W4220863985","doi":"10.1038/s41408-022-00639-z","title":"Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Karyotype; Leukocytosis; Essential thrombocythemia; Internal medicine; Gastroenterology; Medicine; Clinical significance; Biology; Pathology; Chromosome; Genetics; Polycythemia vera; Gene","score_opus":0.019627244049158665,"score_gpt":0.3221583252107662,"score_spread":0.30253108116160754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220863985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812419,0.017339481,0.0000073652327,0.00074498804,0.00013833618,0.00038595818,0.000026056381,0.000007047253,0.00010891319],"genre_scores_gemma":[0.98781115,0.011239826,0.00022204156,0.0004055293,0.00008197403,0.00019537816,0.0000058097785,0.000013527328,0.000024792571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858403,0.00016432047,0.0005450397,0.00019459304,0.00026087897,0.00025114988],"domain_scores_gemma":[0.9991904,0.0003811136,0.00015813866,0.0000817922,0.00005469234,0.00013388398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034921902,0.00016013312,0.00040886726,0.00013622762,0.00014609858,0.000040060604,0.000047094767,0.00005253329,0.00011975055],"category_scores_gemma":[0.00020234259,0.00013447397,0.000051882627,0.00015362201,0.00014010559,0.000110817884,0.0000945302,0.0006608574,7.1802833e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030362673,0.00040233528,0.9908928,0.00006280437,0.00016244625,0.0026010766,0.0017469611,0.00019677376,0.0000759396,0.0001339145,0.00006778754,0.0033534968],"study_design_scores_gemma":[0.0144758485,0.0031599833,0.95879394,0.0006812997,0.0005308242,0.013680518,0.0029229652,0.0006192282,0.0037101593,0.00063624355,0.0004716722,0.0003173226],"about_ca_topic_score_codex":0.000106021456,"about_ca_topic_score_gemma":0.00017271965,"teacher_disagreement_score":0.0320989,"about_ca_system_score_codex":0.00008047718,"about_ca_system_score_gemma":0.00027927884,"threshold_uncertainty_score":0.54836893},"labels":[],"label_agreement":null},{"id":"W4224221548","doi":"10.1038/s41408-022-00668-8","title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; AbbVie","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cytarabine; Placebo; Myeloid leukemia; Visual analogue scale; Oncology; Physical therapy","score_opus":0.008543927453387928,"score_gpt":0.2656750802293543,"score_spread":0.2571311527759664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224221548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964409,0.00016907515,0.0000613474,0.0021211216,0.00007398422,0.0006757152,0.00005898829,0.000009836278,0.00038903632],"genre_scores_gemma":[0.9973413,0.00006004727,0.0004142402,0.00073802605,0.00009758102,0.00021077966,0.000027678723,0.000031906075,0.0010784537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982289,0.00015524591,0.00034522222,0.00016549088,0.00081298855,0.0002921473],"domain_scores_gemma":[0.99908125,0.00005257369,0.00018212665,0.00023478015,0.00030273723,0.00014651814],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004315206,0.0001208812,0.00023746748,0.0002648617,0.00028420525,0.000029754023,0.0002767347,0.000034851528,0.0010604135],"category_scores_gemma":[0.000038368857,0.00008424003,0.000055365825,0.000732022,0.000054370186,0.00010732469,0.0001327197,0.000741308,0.000017699365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018122662,0.0045925896,0.56601024,0.00023097856,0.005402052,0.0023177594,0.016677856,0.057738382,0.11832852,0.00037198333,0.09399683,0.116210155],"study_design_scores_gemma":[0.060746793,0.016309835,0.8557125,0.0006684293,0.0015707331,0.0029153598,0.0009698566,0.007243062,0.010720068,0.00044900473,0.04173838,0.0009560197],"about_ca_topic_score_codex":0.00018870732,"about_ca_topic_score_gemma":0.00006774978,"teacher_disagreement_score":0.28970224,"about_ca_system_score_codex":0.0023197755,"about_ca_system_score_gemma":0.0026798313,"threshold_uncertainty_score":0.9998528},"labels":[],"label_agreement":null},{"id":"W4224221896","doi":"10.1038/s41408-022-00671-z","title":"Financial toxicity in hematological malignancies: a systematic review","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Malignancy; Internal medicine; Intensive care medicine","score_opus":0.0827086563937685,"score_gpt":0.3040631644147532,"score_spread":0.22135450802098466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224221896","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018409788,0.99297696,0.0000362385,0.00015518474,0.0014737019,0.0017546392,0.00053950044,0.000031186046,0.0030141461],"genre_scores_gemma":[0.000014077412,0.9955839,0.00006161007,0.0015494571,0.000553437,0.0014504333,0.000017744456,0.00009216321,0.00067715894],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99355733,0.00021200166,0.0043821135,0.0007982794,0.00014190789,0.0009083644],"domain_scores_gemma":[0.99480134,0.00021186743,0.0040742937,0.0006393555,0.000041759486,0.00023139136],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027193967,0.0007358157,0.007987108,0.0005979477,0.00027206365,0.00017098631,0.0012812894,0.00044763772,0.0058612237],"category_scores_gemma":[0.0015602218,0.00068841357,0.0015603706,0.0008026995,0.000083023326,0.00035628796,0.0002373663,0.0019258569,0.00028485744],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007805329,0.000296515,0.00008037232,0.9561973,0.00038450272,0.00041197328,0.000089754285,0.0000031502389,1.1479105e-8,0.01759095,0.006875966,0.01806169],"study_design_scores_gemma":[0.00038391002,0.0000828175,0.0000059403233,0.27977976,0.0006917178,0.00095866306,0.000007875602,0.0000013558591,7.9415436e-8,0.0028125965,0.71460867,0.00066658907],"about_ca_topic_score_codex":0.00009649133,"about_ca_topic_score_gemma":0.0000630422,"teacher_disagreement_score":0.70773274,"about_ca_system_score_codex":0.0012174873,"about_ca_system_score_gemma":0.0010809264,"threshold_uncertainty_score":0.9995567},"labels":[],"label_agreement":null},{"id":"W4224245023","doi":"10.1038/s41408-022-00659-9","title":"Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Monoclonal gammopathy of undetermined significance; Internal medicine; Medicine; Hazard ratio; Gastroenterology; Macroglobulinemia; Population; Waldenstrom macroglobulinemia; Body mass index; Proportional hazards model; Univariate analysis; AL amyloidosis; Multiple myeloma; Amyloidosis; Confidence interval; Oncology; Lymphoma; Immunology; Monoclonal; Multivariate analysis; Antibody; Immunoglobulin light chain; Monoclonal antibody","score_opus":0.016868981811633883,"score_gpt":0.3038341216571848,"score_spread":0.28696513984555094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224245023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962503,0.0019737745,0.000030165638,0.000404312,0.00018359403,0.00062795717,0.00007729957,0.000026229734,0.00042638564],"genre_scores_gemma":[0.9984308,0.00029434974,0.000163829,0.00011116037,0.00018857699,0.00021169247,0.000023591298,0.000054562206,0.00052143243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961825,0.00027540507,0.00065820105,0.0003595327,0.0018842089,0.0006401518],"domain_scores_gemma":[0.9983951,0.00016112153,0.00054240035,0.00030174621,0.0003365724,0.00026305314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010702945,0.00023652508,0.00057581026,0.00034794465,0.00019243029,0.000034868495,0.00034421956,0.00010159907,0.0006556546],"category_scores_gemma":[0.00014589065,0.00019222984,0.00010694062,0.00095793593,0.00016729202,0.0001315952,0.00012652446,0.0010987347,0.0000010540298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0145532,0.0043063345,0.85234857,0.00068095874,0.0015570031,0.013584154,0.0013642055,0.004236714,0.09663174,0.000051630668,0.0028760857,0.007809427],"study_design_scores_gemma":[0.35847214,0.015159074,0.40796933,0.008562436,0.0018832545,0.016020121,0.003375228,0.10714594,0.074316464,0.00046899257,0.0045027295,0.0021243151],"about_ca_topic_score_codex":0.00049617764,"about_ca_topic_score_gemma":0.00021280487,"teacher_disagreement_score":0.44437924,"about_ca_system_score_codex":0.010131232,"about_ca_system_score_gemma":0.014916939,"threshold_uncertainty_score":0.9936687},"labels":[],"label_agreement":null},{"id":"W4255030439","doi":"10.1038/s41408-020-00374-3","title":"Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients","year":2020,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Cancer Research Society","keywords":"Imatinib mesylate; Chronic myelogenous leukemia; Leukemia; Medicine; Imatinib; STAT5; Cancer research; Immunology; Pharmacology; Oncology; Internal medicine; Receptor","score_opus":0.009923411100285665,"score_gpt":0.25646876323930656,"score_spread":0.2465453521390209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255030439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964833,0.018703133,0.000005678388,0.00090062217,0.011465851,0.0023196759,0.00015675194,0.000056531313,0.0015587219],"genre_scores_gemma":[0.88908124,0.027782643,0.0009126854,0.0014218639,0.005424296,0.00070918154,0.0007833082,0.0005680307,0.073316775],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958056,0.00035120823,0.0012533814,0.0008727428,0.0008851655,0.0008318982],"domain_scores_gemma":[0.99788254,0.00013598478,0.00073288806,0.00036889972,0.00027315484,0.000606498],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006135091,0.0007121898,0.001208266,0.0007199612,0.0001687013,0.00012767238,0.00022770785,0.00063058763,0.00032396376],"category_scores_gemma":[0.00038652372,0.00068464846,0.0001468844,0.0008687926,0.00006405092,0.0002063232,0.00017669165,0.002467821,0.000048831986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0216216,0.0016295055,0.06443198,0.0024578911,0.0010699044,0.005192247,0.01593244,0.0012949065,0.010349991,7.2629825e-7,0.75863856,0.11738027],"study_design_scores_gemma":[0.13220404,0.01611116,0.4432266,0.027420247,0.0026168607,0.0030071407,0.0005823471,0.0047198124,0.024280196,0.000074702584,0.34228894,0.00346792],"about_ca_topic_score_codex":0.0012533912,"about_ca_topic_score_gemma":0.0019580608,"teacher_disagreement_score":0.4163496,"about_ca_system_score_codex":0.02105527,"about_ca_system_score_gemma":0.017591218,"threshold_uncertainty_score":0.9998335},"labels":[],"label_agreement":null},{"id":"W4283698909","doi":"10.1038/s41408-022-00695-5","title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"National Cancer Institute; National Institutes of Health","keywords":"Multiple myeloma; Medicine; Clinical trial; Carfilzomib; Lenalidomide; Refractory (planetary science); Transplantation; Oncology; Salvage therapy; Intensive care medicine; Internal medicine; Chemotherapy; Biology","score_opus":0.15640130480209158,"score_gpt":0.3700564653846089,"score_spread":0.21365516058251732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283698909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019931601,0.97593766,7.1132143e-7,0.00082015217,0.0003620702,0.0017498486,0.00079271465,0.00001083422,0.0003944277],"genre_scores_gemma":[0.015874475,0.9825934,0.00015749465,0.000045907786,0.00019392632,0.0004976376,0.00008775459,0.000060189657,0.000489223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625784,0.0010528942,0.0011908389,0.00030724984,0.00073912315,0.0004520392],"domain_scores_gemma":[0.996027,0.0019466614,0.0010204953,0.0006635043,0.00013384449,0.0002085231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006493866,0.0004650629,0.0015944418,0.00038062464,0.0004078117,0.000037731526,0.00038884455,0.00015729835,0.00027276287],"category_scores_gemma":[0.00027278988,0.0002537756,0.0006162358,0.00034559448,0.00028278268,0.000056961984,0.00012353118,0.00096210354,0.0000010425496],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018431786,0.0017786167,0.007603991,0.0030273837,0.0019027671,0.00040264268,0.0015235096,0.0000031948523,0.000013388925,0.000016207145,0.00084389694,0.9827001],"study_design_scores_gemma":[0.0075289933,0.0011296353,0.004109029,0.0058809705,0.0022708927,0.001362787,0.0018332681,0.000019280335,0.000040890256,0.000008032944,0.9756024,0.00021382974],"about_ca_topic_score_codex":0.00066525507,"about_ca_topic_score_gemma":0.00066794665,"teacher_disagreement_score":0.98248625,"about_ca_system_score_codex":0.00051417586,"about_ca_system_score_gemma":0.0014145372,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W4288046493","doi":"10.1038/s41408-022-00706-5","title":"Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Pharmacyclics; Amgen; U.S. Department of Health and Human Services","keywords":"Haematopoiesis; Distribution (mathematics); Biology; Race (biology); Immunology; Plasma cell; Plasma cell neoplasm; Hematology; Internal medicine; Cancer research; Medicine; Stem cell; Genetics; Plasmacytoma; Antibody; Multiple myeloma","score_opus":0.009441518617760419,"score_gpt":0.23951033742045671,"score_spread":0.2300688188026963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288046493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872798,0.00014627991,0.000007502659,0.008866182,0.00012466546,0.00057418447,0.0029435789,0.000007980196,0.000049856182],"genre_scores_gemma":[0.9941812,0.00012076661,0.00009563884,0.0030804388,0.00023794408,0.00006664068,0.0016100626,0.00006779111,0.0005395297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961863,0.00020374387,0.0006459227,0.00034916433,0.002040516,0.0005743287],"domain_scores_gemma":[0.99788254,0.00010273513,0.0011047357,0.00025415214,0.00049293647,0.00016289107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020942303,0.00036744156,0.0009417682,0.0003125668,0.000119585726,0.000025407555,0.00022061417,0.0003117224,0.00083045574],"category_scores_gemma":[0.000049938822,0.0002659169,0.00019164039,0.0003803426,0.00013263003,0.000100461104,0.000080233985,0.0022137403,0.000001228458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01438048,0.0032143642,0.9110579,0.0010421363,0.0039190613,0.005495282,0.00042622548,0.00010063942,0.00022154847,2.9837548e-7,0.058495052,0.0016470321],"study_design_scores_gemma":[0.076628625,0.009988057,0.87352294,0.0031887735,0.0031336502,0.00054925715,0.00009472234,0.00014613656,0.02718364,0.000009025267,0.0048488965,0.00070630293],"about_ca_topic_score_codex":0.00030261674,"about_ca_topic_score_gemma":0.000066962115,"teacher_disagreement_score":0.062248144,"about_ca_system_score_codex":0.0005516484,"about_ca_system_score_gemma":0.0010777264,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W4289836925","doi":"10.1038/s41408-022-00710-9","title":"Venetoclax ex vivo functional profiling predicts improved progression-free survival","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Winship Cancer Institute; Emory University; Multiple Myeloma Research Foundation; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; American Cancer Society","keywords":"Ex vivo; Venetoclax; Profiling (computer programming); In vivo; Medicine; Oncology; Computational biology; Internal medicine; Biology; Bioinformatics; Cancer research; Leukemia; Computer science; Genetics","score_opus":0.038656709197645085,"score_gpt":0.31966684938514667,"score_spread":0.2810101401875016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289836925","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058219515,0.049962275,0.00020231004,0.83560044,0.024566092,0.010098733,0.005514004,0.0007350681,0.015101539],"genre_scores_gemma":[0.022029612,0.014147959,0.013482368,0.4959159,0.30070797,0.009464448,0.009879764,0.00215522,0.13221677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942407,0.00029962359,0.00067638874,0.00069893524,0.0029170949,0.0011672662],"domain_scores_gemma":[0.9975192,0.00016969227,0.00052511034,0.000739531,0.0004911493,0.00055533194],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057226693,0.00056680833,0.00080580654,0.00040438783,0.000621208,0.00017966364,0.00053638965,0.00052308483,0.011006197],"category_scores_gemma":[0.00032369333,0.00044210785,0.00048682807,0.00029632443,0.000118616765,0.00016110782,0.00036915526,0.0060402644,0.00002198037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018714718,0.00034418883,0.017995656,0.0006273415,0.0034448022,0.01144202,0.000048824346,0.00002000494,0.0017105236,0.0000024303108,0.9558996,0.00659315],"study_design_scores_gemma":[0.022408891,0.0028352924,0.004814675,0.0011416163,0.0019549006,0.0055483254,0.00006128559,0.00042915344,0.0029348747,0.00016022666,0.95700413,0.00070660753],"about_ca_topic_score_codex":0.00012839,"about_ca_topic_score_gemma":0.000018843326,"teacher_disagreement_score":0.33968458,"about_ca_system_score_codex":0.0012707385,"about_ca_system_score_gemma":0.0050245654,"threshold_uncertainty_score":0.99980307},"labels":[],"label_agreement":null},{"id":"W4311358889","doi":"10.1038/s41408-022-00765-8","title":"Management of patients with lower-risk myelodysplastic syndromes","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Myelodysplastic syndromes; Medicine; Internal medicine; Disease; Myeloid leukemia; Oncology; Dysplasia; Hematologic disease; International Prognostic Scoring System; Intensive care medicine; Bone marrow","score_opus":0.03015095816860201,"score_gpt":0.3252116550783994,"score_spread":0.29506069690979736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311358889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001255225,0.99585927,0.000017888227,0.00002357109,0.000490142,0.0011190082,0.00023740968,0.000019241776,0.0009782418],"genre_scores_gemma":[0.00006986382,0.99689764,0.00048364006,0.000015778543,0.00026989062,0.00021543412,0.00007318055,0.00012887275,0.0018457046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965128,0.00022493218,0.0007419677,0.0004077803,0.0015709886,0.0005415854],"domain_scores_gemma":[0.9977927,0.00012769522,0.0010510158,0.0005077736,0.00018662757,0.00033414137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044056954,0.0004554637,0.001881309,0.00049735885,0.0002012801,0.000035379424,0.00050472637,0.00013727727,0.00514721],"category_scores_gemma":[0.00003919107,0.0003007678,0.0004946423,0.0007335711,0.000102458594,0.00006953256,0.00027370147,0.0021824422,0.000021989166],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002587398,0.0006889771,0.001421928,0.027258947,0.007772211,0.0027531746,0.000024902345,0.000006674117,1.2275096e-8,0.00000838728,0.0024245023,0.95738155],"study_design_scores_gemma":[0.0038844177,0.001679717,0.0006395148,0.02354094,0.01616796,0.0011809359,0.00003009846,0.0000015107219,2.428058e-7,0.000003918438,0.9525807,0.0002900408],"about_ca_topic_score_codex":0.000020420579,"about_ca_topic_score_gemma":0.0000021902194,"teacher_disagreement_score":0.9570915,"about_ca_system_score_codex":0.0009806369,"about_ca_system_score_gemma":0.0018268094,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W4311587513","doi":"10.1038/s41408-022-00757-8","title":"Second- and third-line treatment strategies in multiple myeloma: a referral-center experience","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Multiple myeloma; Referral; Medicine; Center (category theory); Internal medicine; Oncology; Family medicine; Intensive care medicine","score_opus":0.0614510644982715,"score_gpt":0.3488668860152637,"score_spread":0.28741582151699224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311587513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331445,0.0038417843,0.0000053976305,0.0006400531,0.00014171918,0.0003465732,0.00006428406,0.00001966685,0.0016260635],"genre_scores_gemma":[0.9961751,0.0016116748,0.00026561358,0.00012409802,0.00016848007,0.0003506329,0.000014483878,0.000019972602,0.001269941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985149,0.00010485075,0.00028685288,0.0002681159,0.0003982848,0.00042700977],"domain_scores_gemma":[0.9993683,0.00004004571,0.00008663828,0.00016818674,0.000048545957,0.0002882988],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013362025,0.00018163696,0.00029837093,0.0001838109,0.00032036836,0.00007250077,0.00009101289,0.000032894182,0.0017392498],"category_scores_gemma":[0.00002017459,0.00013708526,0.000078152654,0.00016840486,0.000064783584,0.00017927558,0.00008366433,0.00039942947,0.0000034033333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028192939,0.003512837,0.9102622,0.00007340785,0.00056442514,0.0057020066,0.007846161,0.00011598031,0.013704076,0.000047495894,0.00052036095,0.054831706],"study_design_scores_gemma":[0.093997106,0.008403483,0.79830617,0.0002964429,0.00026401057,0.012464612,0.016902309,0.0016478417,0.012385196,0.00027670318,0.05442435,0.00063177047],"about_ca_topic_score_codex":0.00038316773,"about_ca_topic_score_gemma":0.0010918243,"teacher_disagreement_score":0.111956075,"about_ca_system_score_codex":0.0003808146,"about_ca_system_score_gemma":0.00041999342,"threshold_uncertainty_score":0.9991733},"labels":[],"label_agreement":null},{"id":"W4312114026","doi":"10.1038/s41408-022-00760-z","title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"Cilag; Pharmacyclics; Kite Pharma; Canadian Institutes of Health Research; Ipsen; MorphoSys; Associazione Italiana per la Ricerca sul Cancro; Aptitude Health; Cancer Research UK; Ascentage Pharma; BeiGene; Celltrion; Hairy Cell Leukemia Foundation; Adaptive Biotechnologies; Astex Pharmaceuticals; TG Therapeutics; Genentech; Blood Cancer UK; Amicus Therapeutics; Incyte; Pfizer; Biogen; University of Rochester; CancerCare Manitoba Foundation; MEI Pharma; Daiichi-Sankyo; MacroGenics; Sunesis; University of Pittsburgh; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Sanofi; Ipsen Biopharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; GlaxoSmithKline","keywords":"Minimal residual disease; Oncology; Medicine; Bone marrow; Internal medicine; Leukemia; Flow cytometry; Hematology; Hairy cell leukemia; Disease; Cancer research; Immunology","score_opus":0.10005170867196604,"score_gpt":0.40304154366956174,"score_spread":0.3029898349975957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114026","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066538807,0.9892236,0.0000012735244,0.000101156846,0.0017812136,0.0006475861,0.0004413215,0.000020001631,0.00112995],"genre_scores_gemma":[0.0010488941,0.9955352,0.00013379495,0.00010754151,0.0021813738,0.00017864596,0.0004002547,0.00010352095,0.00031077754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522793,0.0006159568,0.0011686976,0.0006108104,0.0018827778,0.0004938127],"domain_scores_gemma":[0.9974758,0.00045792438,0.00068482454,0.0006468394,0.00013416902,0.00060043077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007997653,0.00042678387,0.0014536527,0.0006107761,0.00011060123,0.00005855854,0.00066217734,0.0002232799,0.0029608416],"category_scores_gemma":[0.00029647935,0.00035678805,0.00044586646,0.00031842245,0.000115078175,0.00010360535,0.00018690943,0.0015081145,0.000008642129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037770343,0.0026071023,0.00089079223,0.013014449,0.001889317,0.009071021,0.0006882688,0.000434878,0.000031402404,0.00005226619,0.01416187,0.9533816],"study_design_scores_gemma":[0.019044666,0.0005708353,0.00013916973,0.024337335,0.0009616673,0.00080323714,0.00013849323,0.00031204804,0.00002759673,0.000042762564,0.95318586,0.00043632582],"about_ca_topic_score_codex":0.003605387,"about_ca_topic_score_gemma":0.00011752515,"teacher_disagreement_score":0.9529453,"about_ca_system_score_codex":0.026828036,"about_ca_system_score_gemma":0.04025908,"threshold_uncertainty_score":0.9998884},"labels":[],"label_agreement":null},{"id":"W4312114807","doi":"10.1038/s41408-022-00769-4","title":"Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy","year":2022,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Flatiron Health","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Chromosomal translocation; Internal medicine; Oncology; CD38; Daratumumab; Hematology; Bortezomib; Stem cell; Biology","score_opus":0.01845025648032841,"score_gpt":0.2758553600145342,"score_spread":0.2574051035342058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620049,0.0050264625,0.000009963637,0.030919697,0.00038678467,0.0013981111,0.000116508876,0.000022009173,0.00011556411],"genre_scores_gemma":[0.9739771,0.0061532296,0.00035991555,0.0166445,0.0014864003,0.00029592653,0.0005095027,0.00017342837,0.00040001053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628526,0.00037051868,0.0006622282,0.0004209566,0.0016481869,0.00061286293],"domain_scores_gemma":[0.99838895,0.0001628154,0.0005580843,0.00035867016,0.00035971223,0.00017175946],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035122377,0.000385023,0.00076853944,0.00059232523,0.00015825217,0.000039346574,0.0002579966,0.0002967744,0.0010636657],"category_scores_gemma":[0.00009168472,0.00028597013,0.00018584251,0.00043528999,0.000087117995,0.00015896244,0.000026119162,0.0028743052,0.0000026691164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014690938,0.0015112573,0.94150305,0.00034984894,0.001220836,0.0013814761,0.0004672407,0.00003751969,0.000119522534,4.464633e-7,0.020864213,0.03107547],"study_design_scores_gemma":[0.025403839,0.003631566,0.9302943,0.0021770652,0.00042023204,0.00017491053,0.000032029857,0.0000157422,0.0004048653,0.000011062245,0.03711301,0.00032138097],"about_ca_topic_score_codex":0.00033290542,"about_ca_topic_score_gemma":0.000059404625,"teacher_disagreement_score":0.03075409,"about_ca_system_score_codex":0.00042733038,"about_ca_system_score_gemma":0.0012709264,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W4313545228","doi":"10.1038/s41408-022-00779-2","title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Ottawa Hospital; McMaster University","funders":"National Institute on Aging; National Cancer Institute; Hamilton Health Sciences Foundation; Cancer Research UK; Hamilton Health Sciences","keywords":"Medicine; Clinical trial; Population; Randomized controlled trial; Frailty syndrome; Multiple myeloma; Psychological intervention; Gerontology; MEDLINE; Internal medicine; Frailty Index","score_opus":0.19399017801219695,"score_gpt":0.4970273322898045,"score_spread":0.3030371542776076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313545228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00084381364,0.9913276,4.016144e-7,0.00023698418,0.00022980398,0.0072485246,0.000093641014,0.000009924113,0.000009303258],"genre_scores_gemma":[0.00022243682,0.9975991,0.000033703105,0.000050445946,0.00016308046,0.0013913496,0.0000068287595,0.000050598097,0.00048244026],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9877411,0.0048513785,0.0057000895,0.0004126519,0.0008006751,0.0004940892],"domain_scores_gemma":[0.9860284,0.010469551,0.00245843,0.0005463484,0.00017688479,0.00032042395],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017819408,0.00041509248,0.008143899,0.00032366565,0.00008030222,0.00004464582,0.00036955497,0.0002516518,0.000045553446],"category_scores_gemma":[0.032275226,0.00019529316,0.0011846878,0.00054445484,0.00012614623,0.000060114915,0.000120616074,0.0013397292,0.000014833169],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073885516,0.00027198522,0.02931353,0.77077824,0.0014882473,0.0003720619,0.00003868036,1.5667815e-8,1.2328672e-8,0.0000010324104,0.00012136883,0.19754092],"study_design_scores_gemma":[0.0068169194,0.00016836521,0.029930122,0.95323753,0.00703031,0.00036042833,0.00002637007,0.0000061283145,1.3559794e-7,0.000004861085,0.002266748,0.00015209209],"about_ca_topic_score_codex":0.000112888214,"about_ca_topic_score_gemma":0.00042509337,"teacher_disagreement_score":0.19738883,"about_ca_system_score_codex":0.00015654934,"about_ca_system_score_gemma":0.0011844456,"threshold_uncertainty_score":0.97587633},"labels":[],"label_agreement":null},{"id":"W4318191396","doi":"10.1038/s41408-022-00781-8","title":"DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease","year":2023,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Government of Canada; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Hyperactivation; Drug; Chronic lymphocytic leukemia; Biomarker; DNA; Disease; Leukemia; Cancer research; Hematology; Medicine; Immunology; Biology; Pharmacology; Internal medicine; Genetics","score_opus":0.03328712576353946,"score_gpt":0.3199920189238956,"score_spread":0.28670489316035613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318191396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74796176,0.06943563,0.000115836934,0.17773679,0.00101424,0.0030258016,0.000528765,0.00011866094,0.00006248382],"genre_scores_gemma":[0.5986544,0.06055364,0.0006579264,0.30081755,0.021906285,0.0025640584,0.0010250442,0.0011577408,0.012663362],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962873,0.00018710358,0.0007376021,0.0007937104,0.0009949752,0.0009993311],"domain_scores_gemma":[0.9980488,0.0005027926,0.0004007853,0.00041457667,0.00022835685,0.00040471123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071940914,0.0005392331,0.00080007716,0.0007223658,0.0002602356,0.00021326225,0.00020613219,0.0004845965,0.00016110098],"category_scores_gemma":[0.00017430518,0.00046372588,0.00021807048,0.0004422297,0.00022309693,0.00017355946,0.000093218245,0.0013834637,0.000007630924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006250067,0.00012542306,0.0022064461,0.009827525,0.0027797346,0.006516484,0.0010392711,0.00020053438,0.0062369625,0.000014207465,0.9394373,0.025366023],"study_design_scores_gemma":[0.13982414,0.0013904017,0.017599622,0.011222055,0.0047584875,0.0038851958,0.00027672478,0.082842216,0.0018451029,0.0019185523,0.7322425,0.0021949806],"about_ca_topic_score_codex":0.0014097008,"about_ca_topic_score_gemma":0.00016380861,"teacher_disagreement_score":0.2071948,"about_ca_system_score_codex":0.06437015,"about_ca_system_score_gemma":0.052109465,"threshold_uncertainty_score":0.9997814},"labels":[],"label_agreement":null},{"id":"W4319161971","doi":"10.1038/s41408-023-00791-0","title":"Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"European Regional Development Fund; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Shota Rustaveli National Science Foundation; Ostravská Univerzita v Ostravě; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"RNA splicing; Biology; Alternative splicing; Transcriptome; Gene; RNA; Computational biology; Disease; Cancer research; Bioinformatics; Genetics; Gene expression; Messenger RNA; Medicine; Internal medicine","score_opus":0.029960230637768478,"score_gpt":0.33604121860853825,"score_spread":0.30608098797076977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319161971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930531,0.002321849,0.00025549703,0.0036288854,0.00007394131,0.0004232722,0.00016298637,0.000022865257,0.00005764176],"genre_scores_gemma":[0.9984325,0.0009213231,0.00011105624,0.00010901026,0.00003753118,0.00007201122,0.000047464036,0.000018514364,0.00025057272],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987897,0.00007846112,0.00037583662,0.00016581484,0.00033991298,0.00025023313],"domain_scores_gemma":[0.9993418,0.00004311396,0.00008848263,0.00013975581,0.00012011917,0.00026671847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022425322,0.00011598803,0.00019386139,0.00025747073,0.00008323875,0.00007009327,0.00007453442,0.00004190062,0.000072157294],"category_scores_gemma":[0.00002410162,0.000093503346,0.00005998065,0.0004420394,0.000047835412,0.00013164444,0.000006955078,0.00018418895,0.0000063064817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013651596,0.0007630129,0.06133994,0.00019180652,0.0006704531,0.00030623516,0.0026920724,0.0014041456,0.9194706,0.00009759153,0.00048268557,0.01121627],"study_design_scores_gemma":[0.011880198,0.00058599084,0.87555516,0.0004734511,0.0004576859,0.00004599308,0.00079482957,0.011149569,0.09753076,0.00081568706,0.00048665973,0.00022400536],"about_ca_topic_score_codex":0.000080900776,"about_ca_topic_score_gemma":0.00008431125,"teacher_disagreement_score":0.8219399,"about_ca_system_score_codex":0.000045626162,"about_ca_system_score_gemma":0.0003789288,"threshold_uncertainty_score":0.38129556},"labels":[],"label_agreement":null},{"id":"W4323316666","doi":"10.1038/s41408-023-00794-x","title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Minimal residual disease; Oncology; Positron emission tomography; Internal medicine; Negativity effect; Multiple myeloma; Nuclear medicine; Bone marrow","score_opus":0.06746045659604068,"score_gpt":0.32278984922358334,"score_spread":0.2553293926275427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323316666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998437,0.00079775415,0.000006992328,0.00024337375,0.00004914901,0.00018876759,0.00022829327,0.000013189122,0.000035488156],"genre_scores_gemma":[0.9970877,0.0021285585,0.0001882843,0.000034058867,0.00010591566,0.00002470856,0.00033156833,0.000013237781,0.000085925756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985669,0.000093936294,0.00036912202,0.0002058229,0.00045947498,0.00030469435],"domain_scores_gemma":[0.99922884,0.00003600304,0.000102400525,0.00011220988,0.00016787255,0.00035265382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023217611,0.00012871671,0.0003330978,0.0008558999,0.0000879535,0.000043854867,0.000057961493,0.00003113658,0.00012210083],"category_scores_gemma":[0.00007515523,0.00009957818,0.000094685165,0.00108753,0.000043031123,0.00013346941,0.00001594582,0.00020101525,0.0000018687954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079275883,0.00018491701,0.9686492,0.000059971062,0.0012903096,0.0010641093,0.00053867325,0.00028453633,0.018087376,0.0000027119097,0.00018765572,0.008857792],"study_design_scores_gemma":[0.004869115,0.0002810815,0.97027904,0.0002444084,0.0016487746,0.000033704364,0.00019740696,0.017826667,0.0044984976,0.00000784436,0.000019539708,0.000093948904],"about_ca_topic_score_codex":0.0009922031,"about_ca_topic_score_gemma":0.0017329709,"teacher_disagreement_score":0.017542131,"about_ca_system_score_codex":0.00016206631,"about_ca_system_score_gemma":0.0005452043,"threshold_uncertainty_score":0.40606803},"labels":[],"label_agreement":null},{"id":"W4323362510","doi":"10.1038/s41408-023-00805-x","title":"Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS","year":2023,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development; National Cancer Institute; Amgen","keywords":"Daratumumab; Carfilzomib; Pleiades; Dexamethasone; Medicine; Oncology; Multiple myeloma; Internal medicine; Refractory (planetary science); Lenalidomide; Biology; Computer science","score_opus":0.07917735754631587,"score_gpt":0.36156698615345484,"score_spread":0.28238962860713895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323362510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94081724,0.018289672,0.000004858237,0.039520435,0.00023313043,0.00046914333,0.00046692742,0.000028869203,0.00016969992],"genre_scores_gemma":[0.8321374,0.08873775,0.0040298114,0.04311846,0.0076966956,0.0004522682,0.0009682054,0.0005058956,0.022353536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968763,0.00025672143,0.00074282475,0.00054270064,0.00090778444,0.0006736441],"domain_scores_gemma":[0.9981012,0.00055057363,0.00045599035,0.00035456894,0.0002181554,0.00031955025],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005088415,0.00041243577,0.0015209848,0.0018511718,0.00013400469,0.00007563999,0.0001659823,0.0005599114,0.00037673555],"category_scores_gemma":[0.00040984165,0.0002978799,0.000250078,0.0012231515,0.00023766008,0.00008749229,0.000114400595,0.0027562745,0.0000029691853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007214236,0.00089284935,0.56504095,0.0026909958,0.045001786,0.077855915,0.0014667996,0.000031826024,0.0021914095,0.0000034899501,0.21788225,0.07972752],"study_design_scores_gemma":[0.032154214,0.0029485452,0.89170146,0.002780171,0.020685136,0.0023418292,0.00028029742,0.00055718835,0.00056134386,0.000058341353,0.04513438,0.0007971118],"about_ca_topic_score_codex":0.0013536594,"about_ca_topic_score_gemma":0.0018117349,"teacher_disagreement_score":0.3266605,"about_ca_system_score_codex":0.0002400365,"about_ca_system_score_gemma":0.000786429,"threshold_uncertainty_score":0.9999473},"labels":[],"label_agreement":null},{"id":"W4353014868","doi":"10.1038/s41408-023-00804-y","title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Seagen; bluebird bio; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Lenalidomide; Medicine; Daratumumab; Multiple myeloma; Intensive care medicine; Clinical trial; Bortezomib; Oncology; Internal medicine","score_opus":0.5237619651572638,"score_gpt":0.5617298454699142,"score_spread":0.037967880312650415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353014868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004328791,0.98872674,0.0004943975,0.00021363089,0.000947942,0.005093975,0.00015646189,0.000034767592,0.0000033245979],"genre_scores_gemma":[0.007573978,0.9852162,0.00209846,0.000013877008,0.0013715214,0.003528339,0.000044366643,0.00014134239,0.000011901717],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99469084,0.0004915609,0.00232096,0.00079030194,0.00073200325,0.00097433716],"domain_scores_gemma":[0.9892424,0.008736896,0.00082511344,0.0004978161,0.000372445,0.00032534002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003604755,0.00061183947,0.0027551595,0.0008492319,0.00014249633,0.00014480308,0.00049888727,0.00038332865,0.000028642775],"category_scores_gemma":[0.002863365,0.00042897137,0.0014067205,0.00045914002,0.00008962937,0.00020010436,0.00006895098,0.0014817794,0.00000838586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021792976,0.0009812287,0.0039279996,0.010844643,0.0006646424,0.00035139042,0.00007515578,0.000028481412,9.100099e-7,0.000010536655,0.0000320117,0.9809037],"study_design_scores_gemma":[0.055851694,0.005631359,0.029365204,0.64092755,0.002113986,0.00026789473,0.00025643763,0.0014207003,0.000014752781,0.0010926841,0.26175648,0.0013012433],"about_ca_topic_score_codex":0.00008283874,"about_ca_topic_score_gemma":0.0011781387,"teacher_disagreement_score":0.97960246,"about_ca_system_score_codex":0.00061616296,"about_ca_system_score_gemma":0.0048748897,"threshold_uncertainty_score":0.9998162},"labels":[],"label_agreement":null},{"id":"W4362614405","doi":"10.1038/s41408-023-00820-y","title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; Minimal residual disease; Gastroenterology","score_opus":0.036904548148674894,"score_gpt":0.3457851510166651,"score_spread":0.30888060286799024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362614405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915948,0.0055416776,0.000016589072,0.0011887511,0.00028981108,0.00097118923,0.000042247455,0.00003294673,0.00032198665],"genre_scores_gemma":[0.9868065,0.008351543,0.0003424587,0.00015170369,0.00075437216,0.00021565183,0.000009626798,0.0000720672,0.0032960884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788386,0.000095188334,0.0004560862,0.00022015713,0.00064984825,0.00069488114],"domain_scores_gemma":[0.9988742,0.00020668875,0.00014923904,0.00022129499,0.00028656263,0.0002620032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008148252,0.00015907429,0.0004349918,0.00043602163,0.000071277536,0.000037050457,0.0001411761,0.0000958839,0.00091069704],"category_scores_gemma":[0.00014202383,0.00013278921,0.00019303815,0.000715657,0.000076826196,0.000078384386,0.0000291548,0.00048306203,0.00000788551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003351037,0.0003809493,0.49447685,0.00019976369,0.00051031535,0.00038862988,0.0018275607,0.00007735031,0.3705435,0.000050357525,0.0022674338,0.12592623],"study_design_scores_gemma":[0.020988008,0.003912775,0.8950074,0.00068684324,0.00017835625,0.0003755989,0.0004164707,0.00030920774,0.061198454,0.00073701906,0.015915193,0.00027470218],"about_ca_topic_score_codex":0.00039738303,"about_ca_topic_score_gemma":0.00011123107,"teacher_disagreement_score":0.40053052,"about_ca_system_score_codex":0.0001426784,"about_ca_system_score_gemma":0.0009496724,"threshold_uncertainty_score":0.9971494},"labels":[],"label_agreement":null},{"id":"W4366822278","doi":"10.1038/s41408-023-00823-9","title":"Management of chronic myeloid leukemia in 2023 – common ground and common sense","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Dasatinib; Nilotinib; Ponatinib; Medicine; Imatinib; Oncology; Imatinib mesylate; Internal medicine; Myeloid leukemia; Intensive care medicine","score_opus":0.04700418793668781,"score_gpt":0.35556062656842063,"score_spread":0.3085564386317328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366822278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009163806,0.9879308,7.1217386e-7,0.000048996553,0.00053130346,0.0011864702,0.00009092603,0.000035901914,0.0010111209],"genre_scores_gemma":[0.00039365137,0.9957544,0.00008416923,0.000027417693,0.00067022257,0.00016631764,0.000080022815,0.00014561805,0.0026781685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653083,0.00021565969,0.0014734089,0.0005083174,0.00063447363,0.00063729886],"domain_scores_gemma":[0.99797964,0.00015871371,0.00093203166,0.00058015063,0.00005467773,0.000294789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005946244,0.0006285968,0.002934435,0.000561639,0.000101146215,0.00004978041,0.00023587856,0.0003660785,0.0002021045],"category_scores_gemma":[0.000010084492,0.0005152506,0.00046241836,0.0007371962,0.00012777346,0.00008481888,0.00026097632,0.0014721231,0.000046341203],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054833825,0.00016313023,0.00032588487,0.05667026,0.0037363733,0.008883324,0.00006771093,0.000013323831,0.0000016392981,0.00003486424,0.00082560524,0.92922306],"study_design_scores_gemma":[0.014313979,0.0007614488,0.0029564898,0.25646636,0.017706597,0.012083238,0.00014320287,0.000053778815,0.00001062533,0.00012629479,0.6945491,0.0008289149],"about_ca_topic_score_codex":0.001547206,"about_ca_topic_score_gemma":0.0011016834,"teacher_disagreement_score":0.92839414,"about_ca_system_score_codex":0.009049076,"about_ca_system_score_gemma":0.0029341893,"threshold_uncertainty_score":0.99972993},"labels":[],"label_agreement":null},{"id":"W4367300469","doi":"10.1038/s41408-023-00840-8","title":"An atlas of the bone marrow bone proteome in patients with dysproteinemias","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Bone marrow; Atlas (anatomy); Medicine; Bone marrow transplantation; MEDLINE; Pathology; Internal medicine; Bioinformatics; Biology; Anatomy","score_opus":0.013879807561555286,"score_gpt":0.2832907785892708,"score_spread":0.26941097102771555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367300469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977928,0.00026377465,0.0000016069879,0.00085058867,0.000057782698,0.00087576534,0.0000268794,0.000015228954,0.00011559131],"genre_scores_gemma":[0.9989283,0.00008419501,0.00022091981,0.00004061118,0.00012916904,0.00010348,0.00001013364,0.000023578714,0.0004596202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984116,0.00007885135,0.00026538043,0.00015656199,0.0007277672,0.0003598438],"domain_scores_gemma":[0.9991756,0.000014416433,0.00014888716,0.00026722005,0.00017774399,0.0002161097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023908533,0.00012197076,0.00025585695,0.00017845139,0.00009059738,0.000019162233,0.00012038376,0.000048130856,0.00016560355],"category_scores_gemma":[0.000062760715,0.00006588291,0.000061056926,0.00056354015,0.00006656014,0.00009898728,0.000037274905,0.00037928345,0.000008886029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011886252,0.0006757597,0.9835508,0.00006953305,0.0001343071,0.00029021854,0.00015305544,0.000032964854,0.006197957,0.0000023942055,0.0002394508,0.007464961],"study_design_scores_gemma":[0.013439851,0.0011949331,0.9721574,0.00046487857,0.00007337637,0.00007416755,0.00004062542,0.00004476419,0.012267846,0.000029312903,0.00013925237,0.00007357663],"about_ca_topic_score_codex":0.0002805315,"about_ca_topic_score_gemma":0.00022023219,"teacher_disagreement_score":0.012251225,"about_ca_system_score_codex":0.00009162777,"about_ca_system_score_gemma":0.0003528484,"threshold_uncertainty_score":0.2686627},"labels":[],"label_agreement":null},{"id":"W4376133376","doi":"10.1038/s41408-023-00843-5","title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Frailty in Older Adults","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Medicine; Cohort; Confidence interval; Cohort study; Population; Epidemiology; Multiple myeloma; Gerontology; Internal medicine; Demography","score_opus":0.009676987236834574,"score_gpt":0.2988752424923265,"score_spread":0.2891982552554919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376133376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957272,0.00015582438,0.00038078683,0.0008181793,0.000490732,0.0020068288,0.00007593237,0.00024107452,0.00010347544],"genre_scores_gemma":[0.99681145,0.00010943569,0.0013786895,0.00014326887,0.0002979301,0.00040020153,0.0000981515,0.000093998875,0.00066688505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968361,0.00017710186,0.00060307706,0.00052881986,0.001273272,0.00058159145],"domain_scores_gemma":[0.99803,0.00017315522,0.00046007804,0.0005188438,0.00041198978,0.00040593673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060967536,0.00034918636,0.0005573367,0.0003385124,0.00041041564,0.00010609829,0.00020588972,0.00011493937,0.00041757588],"category_scores_gemma":[0.00016756797,0.00026952167,0.00015136263,0.00073561573,0.000061168816,0.00020849756,0.000044320397,0.0010206908,0.00002377173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002625773,0.000958468,0.98851997,0.00007691247,0.0008247702,0.0005785792,0.00064741797,0.002731924,0.000028063023,2.673189e-7,0.00086037675,0.004510654],"study_design_scores_gemma":[0.019103799,0.00079529005,0.9530234,0.0009932236,0.0011862633,0.00013321331,0.0010240679,0.023335604,0.000040574287,0.0000067854758,0.000046672543,0.00031113904],"about_ca_topic_score_codex":0.0028466296,"about_ca_topic_score_gemma":0.011186983,"teacher_disagreement_score":0.035496622,"about_ca_system_score_codex":0.0004279196,"about_ca_system_score_gemma":0.00056211714,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W4377287471","doi":"10.1038/s41408-023-00851-5","title":"Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Phenotype; Biology; Multiple myeloma; Mass cytometry; Malignancy; Genetic heterogeneity; Meta-analysis; Cancer research; Oncology; Internal medicine; Immunology; Genetics; Medicine; Gene","score_opus":0.03962556086710801,"score_gpt":0.30440145318038375,"score_spread":0.26477589231327575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377287471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834085,0.00026018888,0.000048664806,0.0007486134,0.00006806394,0.0002952804,0.0001187646,0.00004878721,0.00007080773],"genre_scores_gemma":[0.99818426,0.00063519477,0.00014356062,0.00014387134,0.00008077159,0.000023845218,0.000029123483,0.000023482677,0.0007358872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982929,0.00012521462,0.00022994449,0.00023767712,0.00059524586,0.0005189767],"domain_scores_gemma":[0.9990247,0.00022495854,0.00011870972,0.00013301642,0.00013229312,0.0003663517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041698225,0.00018158913,0.0004062393,0.00040104613,0.00040656445,0.00003627366,0.00010963577,0.00009005057,0.00013187346],"category_scores_gemma":[0.0002614178,0.00013097428,0.00007101008,0.00051840575,0.00005759148,0.00012534572,0.00017725542,0.0004887525,0.0000071509176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040066804,0.00023158093,0.9926725,0.000043440345,0.0007705469,0.0024947047,0.00032022526,0.0000063078805,0.0008857884,0.0000032281546,0.00009005369,0.002080974],"study_design_scores_gemma":[0.011488044,0.00033066794,0.9865989,0.00033306325,0.00014898802,0.00012016838,0.00016237766,0.00013102553,0.00045206537,0.00009103842,0.000011430594,0.0001322032],"about_ca_topic_score_codex":0.00051990215,"about_ca_topic_score_gemma":0.001019095,"teacher_disagreement_score":0.011087376,"about_ca_system_score_codex":0.00023646711,"about_ca_system_score_gemma":0.00015691161,"threshold_uncertainty_score":0.5340976},"labels":[],"label_agreement":null},{"id":"W4378188863","doi":"10.1038/s41408-023-00856-0","title":"Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Minimal residual disease; Medicine; Multiple myeloma; Oncology; Internal medicine; Residual; Medical physics; Bone marrow; Computer science; Algorithm","score_opus":0.05230070476117005,"score_gpt":0.3153324173812251,"score_spread":0.26303171262005504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378188863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890475,0.004253596,0.000009387696,0.00021258822,0.0046945703,0.00043651118,0.00096781674,0.000026116184,0.00035189072],"genre_scores_gemma":[0.94468755,0.024314104,0.00014620839,0.00006843282,0.00206763,0.000113642214,0.0056784004,0.00009148629,0.022832545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972494,0.00018795845,0.0007439988,0.00044766662,0.0009131828,0.00045777668],"domain_scores_gemma":[0.9983651,0.00006273481,0.00036747835,0.00021923128,0.000442206,0.0005432606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029066802,0.00033889976,0.00088149455,0.001665076,0.00015607658,0.00010301339,0.00011647911,0.00016927983,0.00027880445],"category_scores_gemma":[0.00018506624,0.0002766414,0.0002461311,0.0013355382,0.000077914825,0.00015317471,0.000029701307,0.0010903169,0.000002485373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027662267,0.00070098555,0.7185475,0.0005559849,0.009861562,0.004697767,0.00093699654,0.00036652372,0.0015729287,0.0000010816213,0.2453716,0.014620836],"study_design_scores_gemma":[0.008238513,0.0009890574,0.9389329,0.003550756,0.012835092,0.00021252508,0.00035158635,0.032186586,0.0007489844,0.000004793,0.0015076497,0.00044158625],"about_ca_topic_score_codex":0.0031777222,"about_ca_topic_score_gemma":0.010418064,"teacher_disagreement_score":0.24386394,"about_ca_system_score_codex":0.0005934019,"about_ca_system_score_gemma":0.0025623117,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W4383197462","doi":"10.1038/s41408-023-00866-y","title":"Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Clinical decision making; Immune system; Intensive care medicine; Oncology; Immunology; Internal medicine","score_opus":0.27779533924331146,"score_gpt":0.4866892149139586,"score_spread":0.20889387567064716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383197462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10733599,0.78543466,0.0029901473,0.003307803,0.092206575,0.008099594,0.00035328654,0.00014739526,0.00012453932],"genre_scores_gemma":[0.42044914,0.5607273,0.001971666,0.00007509478,0.010945028,0.0037018578,0.00018772787,0.00026143205,0.0016807378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951816,0.0003273894,0.001704656,0.000840469,0.0009478365,0.0009980195],"domain_scores_gemma":[0.9923173,0.0054879696,0.00069577346,0.0004834421,0.0006898732,0.00032563703],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002754862,0.00055910135,0.0014018746,0.00084894244,0.00021542847,0.00018360178,0.00042199733,0.00055409176,0.000055534387],"category_scores_gemma":[0.003984046,0.00044530275,0.0007881585,0.00041512973,0.000109419714,0.00024181065,0.00006132204,0.0026041663,0.000006580154],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016182339,0.0020770119,0.05221006,0.0010568701,0.0007941279,0.00067446684,0.00033226996,0.00039348422,0.00002402638,0.000005790427,0.03630991,0.88993967],"study_design_scores_gemma":[0.08179574,0.01018839,0.7085099,0.09498421,0.00072652573,0.0002689895,0.0010188088,0.02588466,0.00023392252,0.0012685779,0.07376065,0.0013596218],"about_ca_topic_score_codex":0.00025815683,"about_ca_topic_score_gemma":0.006146518,"teacher_disagreement_score":0.88858,"about_ca_system_score_codex":0.00073327514,"about_ca_system_score_gemma":0.00528563,"threshold_uncertainty_score":0.99979985},"labels":[],"label_agreement":null},{"id":"W4384923381","doi":"10.1038/s41408-023-00883-x","title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; McGill University; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Juravinski Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"Janssen Canada","keywords":"Attrition; Medicine; Multiple myeloma; Internal medicine; Cohort; Surgery; Oncology","score_opus":0.12362651348174936,"score_gpt":0.38956669331827093,"score_spread":0.2659401798365216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384923381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069774,0.0022180795,0.000010776447,0.0041998117,0.00016282,0.0004940004,0.00011103071,0.00006215362,0.0020436086],"genre_scores_gemma":[0.9958534,0.0016702767,0.0004884461,0.00012903662,0.0005243628,0.00020102304,0.00017614524,0.000047706413,0.00090957247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956457,0.00039775632,0.0005468483,0.0004937816,0.0013300903,0.0015858478],"domain_scores_gemma":[0.9975043,0.00026253017,0.0000990274,0.00038497866,0.00040429496,0.0013448688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002118209,0.000230642,0.0005477298,0.0044987584,0.0007008989,0.00016877585,0.00025145325,0.00018157624,0.0008113692],"category_scores_gemma":[0.0006892188,0.00020828059,0.00029057593,0.0060352134,0.0001199153,0.00019337276,0.000080319296,0.0012731386,0.00018854985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047814514,0.00026282316,0.94640064,0.00006488319,0.001870691,0.00804945,0.0006078631,0.00012145137,0.0029172443,0.000045955512,0.003770166,0.035410687],"study_design_scores_gemma":[0.0076541714,0.00043368535,0.9816019,0.00038240472,0.00047198628,0.0003616082,0.000820023,0.003239325,0.0006871642,0.00015894476,0.0039778207,0.00021099776],"about_ca_topic_score_codex":0.13823693,"about_ca_topic_score_gemma":0.5454202,"teacher_disagreement_score":0.40718332,"about_ca_system_score_codex":0.0011259221,"about_ca_system_score_gemma":0.001401066,"threshold_uncertainty_score":0.8883924},"labels":[],"label_agreement":null},{"id":"W4386202664","doi":"10.1038/s41408-023-00888-6","title":"Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2023,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; McGill University; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; Juravinski Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Medicine; Attrition; Internal medicine; Oncology; Family medicine","score_opus":0.09519958533312171,"score_gpt":0.37304994375816725,"score_spread":0.2778503584250455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386202664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25908455,0.18880905,0.00016640336,0.04400514,0.23161167,0.014449402,0.006604274,0.0014801921,0.2537893],"genre_scores_gemma":[0.59013224,0.03190238,0.00059807155,0.0003883135,0.016720021,0.0013643635,0.005096579,0.00052497385,0.35327306],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9919568,0.0007981759,0.0011295844,0.0010904756,0.0026758432,0.0023491764],"domain_scores_gemma":[0.9952602,0.00045408733,0.0003733462,0.0007617282,0.0010849356,0.0020656951],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002527209,0.0006289103,0.001509213,0.008450868,0.0012039565,0.00040495122,0.000510176,0.0010329353,0.0016004395],"category_scores_gemma":[0.0017262569,0.0005977854,0.0007726727,0.006943825,0.00021770172,0.00021916571,0.00015162153,0.0072371275,0.0002343679],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00064378243,0.0003924074,0.1610242,0.0002442856,0.005821531,0.013539818,0.00039980205,0.000052138035,0.0000706664,0.000005708879,0.7906758,0.027129857],"study_design_scores_gemma":[0.011105534,0.0013393357,0.7303987,0.005448794,0.0035451355,0.00187918,0.0011820549,0.0049350755,0.00008343828,0.00009178252,0.23911184,0.0008791103],"about_ca_topic_score_codex":0.34100294,"about_ca_topic_score_gemma":0.88146967,"teacher_disagreement_score":0.5693745,"about_ca_system_score_codex":0.004245675,"about_ca_system_score_gemma":0.0070222365,"threshold_uncertainty_score":0.9996474},"labels":[],"label_agreement":null},{"id":"W4386441220","doi":"10.1038/s41408-023-00905-8","title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Memorial University of Newfoundland; Saint John Regional Hospital; McGill University; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; University of British Columbia; Institute of Cancer Research; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre; McMaster University; Western University; Hôpital Maisonneuve-Rosemont; Université Laval","funders":"","keywords":"Multiple myeloma; Medicine; Transplantation; Stem cell; Autologous stem-cell transplantation; Oncology; Internal medicine; Biology; Genetics","score_opus":0.07226150521320708,"score_gpt":0.361496175435274,"score_spread":0.28923467022206695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386441220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913163,0.0008417762,0.0000043414416,0.0033387153,0.00024921223,0.0009214923,0.0014883603,0.000038896214,0.0018009008],"genre_scores_gemma":[0.99310285,0.0039814515,0.00036996868,0.00005504863,0.00040791603,0.00016296907,0.00085331406,0.00004269097,0.0010237707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957677,0.00057946006,0.0008742921,0.00048096635,0.0013205037,0.0009770717],"domain_scores_gemma":[0.9968132,0.0012172626,0.00026035673,0.00062808715,0.0003628975,0.0007182022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024948157,0.00021771196,0.00043494254,0.00089774764,0.00046851233,0.000079937316,0.00034625668,0.00012446965,0.0000911001],"category_scores_gemma":[0.00036042393,0.0001564806,0.0001264015,0.0016202182,0.00017027534,0.00016736028,0.000053799176,0.0011435904,0.000032810163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046880245,0.00052094454,0.8375113,0.00017923983,0.00043148105,0.09630194,0.0037170972,0.000090687114,0.009278611,0.000014429396,0.014269887,0.03299635],"study_design_scores_gemma":[0.015877385,0.00026879483,0.9706919,0.0006558993,0.00015311044,0.0005185917,0.00075982563,0.00045833923,0.008594894,0.0000410356,0.0018380105,0.00014220671],"about_ca_topic_score_codex":0.7319516,"about_ca_topic_score_gemma":0.9515372,"teacher_disagreement_score":0.21958561,"about_ca_system_score_codex":0.00062106695,"about_ca_system_score_gemma":0.0027787434,"threshold_uncertainty_score":0.6381094},"labels":[],"label_agreement":null},{"id":"W4386704631","doi":"10.1038/s41408-023-00918-3","title":"The expanding CML treatment landscape: an introspective commentary","year":2023,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Toronto","keywords":"Introspection; Medicine; MEDLINE; Intensive care medicine; Psychology; Political science; Law; Cognitive psychology","score_opus":0.015809717900934883,"score_gpt":0.3357773604501388,"score_spread":0.3199676425492039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386704631","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075823893,0.017998636,0.0000034980171,0.0029317923,0.96987575,0.00064737693,0.00045900757,0.00014242984,0.00035912805],"genre_scores_gemma":[0.00065804843,0.062885754,0.00007064958,0.000118116775,0.9319846,0.00028844556,0.00040020395,0.00017644599,0.003417712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968296,0.00015838155,0.00057662063,0.00050459604,0.001170006,0.0007607869],"domain_scores_gemma":[0.997258,0.00090726995,0.0004958278,0.00059951976,0.00026479777,0.00047456968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004308867,0.0005660059,0.0008114875,0.00016518052,0.00089262816,0.00026156797,0.0003424318,0.00044661644,0.00029866674],"category_scores_gemma":[0.00020661985,0.00034096997,0.00035811702,0.00021649041,0.00009564125,0.00012754397,0.00008785065,0.0016413152,0.000047110403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054695696,0.0003650475,0.0016358625,0.000047830286,0.003827903,0.0009658406,0.0006094986,0.000007663012,0.00003880246,0.0000017971788,0.98039675,0.011556025],"study_design_scores_gemma":[0.017206308,0.0026232018,0.00049011415,0.0009390113,0.003516548,0.0002779863,0.0007246434,0.000021559594,0.0003520374,0.00006526798,0.97343415,0.00034917312],"about_ca_topic_score_codex":0.0009797366,"about_ca_topic_score_gemma":0.0014520262,"teacher_disagreement_score":0.044887114,"about_ca_system_score_codex":0.006251157,"about_ca_system_score_gemma":0.002763141,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W4388495570","doi":"10.1038/s41408-023-00939-y","title":"MRD negativity: considerations for older adults with multiple myeloma","year":2023,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University","funders":"National Cancer Institute; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Multiple myeloma; Medicine; Negativity effect; Internal medicine; Oncology; Gerontology; Psychology; Developmental psychology","score_opus":0.02538720888301478,"score_gpt":0.3279142641090423,"score_spread":0.3025270552260275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495570","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015125225,0.0034393065,0.0003244129,0.0029003879,0.9679655,0.004324877,0.0054089325,0.00024903307,0.0002623251],"genre_scores_gemma":[0.022248624,0.0026111347,0.004204366,0.000100382764,0.9623008,0.001754439,0.00075455895,0.00029289423,0.0057328152],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965194,0.00009263302,0.0005101488,0.00057457224,0.0014613201,0.000841949],"domain_scores_gemma":[0.9938381,0.0031513376,0.00038503527,0.00038515325,0.001545577,0.0006948437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032960868,0.00047936666,0.0008503522,0.00032621907,0.00056939694,0.00023093485,0.00014309054,0.0004979454,0.00036410344],"category_scores_gemma":[0.0038372735,0.0003461621,0.00030914944,0.00022767752,0.00011447922,0.00015125441,0.000052698346,0.0015039563,0.000038283986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023340434,0.00046687332,0.002401364,0.0005667927,0.002793715,0.0014911448,0.00033650603,0.0000076335555,0.000036855647,0.0000022033269,0.9811,0.008462839],"study_design_scores_gemma":[0.1310802,0.004872656,0.01378616,0.011632796,0.0053696577,0.0010689825,0.00051815604,0.00050033093,0.0024761911,0.00026266996,0.82708865,0.0013435393],"about_ca_topic_score_codex":0.0004911015,"about_ca_topic_score_gemma":0.003150523,"teacher_disagreement_score":0.15401137,"about_ca_system_score_codex":0.00029704583,"about_ca_system_score_gemma":0.0039922534,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W4389485135","doi":"10.1038/s41408-023-00946-z","title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institutes of Health Research; University of British Columbia; Memorial University of Newfoundland; McGill University; McGill University Health Centre; London Health Sciences Centre; Western University; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Juravinski Cancer Centre; Jewish General Hospital; Alberta Cancer Foundation; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Saint John Regional Hospital; BC Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Dalhousie University","funders":"Pfizer Canada; Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Cohort; Lenalidomide; Salvage therapy; Bortezomib; Daratumumab; Oncology; Surgery; Chemotherapy","score_opus":0.15252260014164173,"score_gpt":0.41818446379962954,"score_spread":0.26566186365798783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389485135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904856,0.00021311252,0.0000103052835,0.0017638505,0.00035802845,0.001165748,0.0054716696,0.00005894187,0.00047273136],"genre_scores_gemma":[0.9895496,0.0006098894,0.0008733786,0.00009728034,0.0005214644,0.00007257071,0.0076443544,0.000074200965,0.00055731233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940037,0.0004406902,0.0008287602,0.0008696633,0.002645453,0.0012117024],"domain_scores_gemma":[0.995263,0.0007539026,0.00044863828,0.0016832238,0.0008294244,0.0010218408],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0019844389,0.00042024258,0.00078609993,0.0010668987,0.001646564,0.00016667838,0.00090646686,0.000116603354,0.00014274142],"category_scores_gemma":[0.0015437055,0.0002441274,0.00014864632,0.0017060041,0.00055039144,0.0004756939,0.00044382663,0.0014763513,0.000039537656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001460702,0.0012163753,0.97857827,0.00003505008,0.0016791564,0.006504037,0.00014081615,0.000014104964,0.0014771625,0.000019197843,0.0049171015,0.003958015],"study_design_scores_gemma":[0.01627404,0.00057299924,0.97424334,0.0006375653,0.00031789287,0.00012448104,0.00016809454,0.0007349847,0.0005484893,0.0000057940338,0.0061369278,0.00023541684],"about_ca_topic_score_codex":0.41972598,"about_ca_topic_score_gemma":0.7097068,"teacher_disagreement_score":0.28998083,"about_ca_system_score_codex":0.0009565397,"about_ca_system_score_gemma":0.0031229823,"threshold_uncertainty_score":0.99965316},"labels":[],"label_agreement":null},{"id":"W4390875111","doi":"10.1038/s41408-023-00974-9","title":"Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Occupational Safety and Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; National Cancer Institute; National Institutes of Health; Alexander and Margaret Stewart Trust; Vanderbilt University Medical Center; Vanderbilt University; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Zygosity; Loss of heterozygosity; Germline mutation; Biology; Internal medicine; Uniparental disomy; Mutation; Oncology; Genetics; Medicine; Allele; Chromosome; Gene; Karyotype","score_opus":0.017966603771226337,"score_gpt":0.3262525614460847,"score_spread":0.3082859576748584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390875111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897968,0.0033824916,0.00083985314,0.0048827976,0.00030281415,0.00024371113,0.00013484238,0.000039506085,0.00037715334],"genre_scores_gemma":[0.99705887,0.0016481958,0.00046404157,0.00026891814,0.000434575,0.00006803885,0.000008053308,0.000016559834,0.000032729517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987074,0.00007116086,0.00038308505,0.00019570663,0.0004063047,0.00023635691],"domain_scores_gemma":[0.99942344,0.00017041889,0.000055748675,0.000065375934,0.00012091239,0.00016407756],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019877347,0.00015076238,0.00024425276,0.00017395851,0.00016046224,0.000119134886,0.000036300655,0.00008414461,0.0010922691],"category_scores_gemma":[0.00008304726,0.0001160208,0.00014223403,0.00018769324,0.000033428227,0.0003311278,0.000007560114,0.0004979005,0.000019262741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001808348,0.00064150203,0.95458233,0.00046272634,0.00069297745,0.001000075,0.012996421,0.000045970268,0.0006780008,0.00072447496,0.00091533875,0.027079348],"study_design_scores_gemma":[0.0055130315,0.0008045512,0.92708033,0.002872554,0.0015855709,0.0032649937,0.0008517131,0.0066419854,0.04816784,0.0012017558,0.0016961119,0.00031956652],"about_ca_topic_score_codex":0.00012478819,"about_ca_topic_score_gemma":0.000120937664,"teacher_disagreement_score":0.047489837,"about_ca_system_score_codex":0.00022529664,"about_ca_system_score_gemma":0.0002737377,"threshold_uncertainty_score":0.9998209},"labels":[],"label_agreement":null},{"id":"W4390893554","doi":"10.1038/s41408-024-00978-z","title":"Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?","year":2024,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Hamilton Health Sciences Foundation; Hamilton Health Sciences","keywords":"Chromosomal translocation; Multiple myeloma; Medicine; Internal medicine; Biology; Genetics; Gene","score_opus":0.0379314257076081,"score_gpt":0.3384788602232021,"score_spread":0.300547434515594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390893554","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03736697,0.026905343,0.000016801394,0.0026436916,0.9293454,0.0016851397,0.0010211084,0.000044423527,0.000971075],"genre_scores_gemma":[0.14935613,0.018573077,0.00011473661,0.00010067259,0.8184863,0.00028961795,0.00016751456,0.00016257542,0.012749404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996712,0.00015346361,0.000729791,0.00036706822,0.001527064,0.0005105704],"domain_scores_gemma":[0.9983236,0.00031368213,0.00028775304,0.0003996606,0.000424355,0.00025090357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004140596,0.00034165775,0.00067171635,0.00029143228,0.00011211664,0.00007374204,0.00032242425,0.00049203995,0.00068394095],"category_scores_gemma":[0.0006757487,0.00019009996,0.00034938025,0.0004551336,0.000118054966,0.00009111718,0.00005906421,0.0020646364,0.00002580422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015814641,0.0005279706,0.004266554,0.0010420304,0.0010437126,0.0006671952,0.0005633704,0.0000069642856,0.00028353187,0.000001425148,0.9761222,0.01389359],"study_design_scores_gemma":[0.020024544,0.0006933916,0.004360099,0.009854401,0.0018341109,0.00037027482,0.00025678592,0.000070295755,0.0065310285,0.000053773776,0.95558417,0.00036712005],"about_ca_topic_score_codex":0.0006103505,"about_ca_topic_score_gemma":0.004490749,"teacher_disagreement_score":0.111989155,"about_ca_system_score_codex":0.00050025835,"about_ca_system_score_gemma":0.0031144752,"threshold_uncertainty_score":0.8969933},"labels":[],"label_agreement":null},{"id":"W4391226400","doi":"10.1038/s41408-024-00985-0","title":"Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Multiple myeloma; Randomized controlled trial; Clinical trial; Medicine; Internal medicine; MEDLINE; Chromosome; Oncology; Bioinformatics; Genetics; Biology; Gene","score_opus":0.2498751381734825,"score_gpt":0.5259056938982104,"score_spread":0.2760305557247279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391226400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014248881,0.9844013,0.000010842209,0.0004526198,0.0007766882,0.014077291,0.00012542614,0.000028962077,0.00011261539],"genre_scores_gemma":[0.00005766147,0.9909722,0.00018171727,0.00018419228,0.0012528586,0.0064397804,0.00010446403,0.00009832655,0.0007087559],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9756777,0.014086286,0.008060386,0.0006330384,0.00088707136,0.00065550016],"domain_scores_gemma":[0.99012125,0.006677711,0.0017994137,0.0006092347,0.00018651709,0.00060590444],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.028237958,0.00069565646,0.018070359,0.0010056276,0.00008070608,0.00017477934,0.00035015255,0.00040511883,0.00043022924],"category_scores_gemma":[0.029640833,0.0003800133,0.0038757077,0.0010039706,0.00011222762,0.00012043274,0.0000932968,0.002876106,0.00022497622],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001810766,0.0006301514,0.000035145826,0.862177,0.005232189,0.0042386204,0.00004208757,2.3689746e-7,1.1900205e-7,0.000008213907,0.00087760185,0.12494786],"study_design_scores_gemma":[0.10241557,0.00012016974,0.000003683737,0.84418935,0.03386434,0.0024918593,0.000008553457,0.00011480475,1.9600273e-7,0.00002217768,0.016514765,0.0002545563],"about_ca_topic_score_codex":0.00012195432,"about_ca_topic_score_gemma":0.0002972154,"teacher_disagreement_score":0.124693304,"about_ca_system_score_codex":0.00067074667,"about_ca_system_score_gemma":0.0035409613,"threshold_uncertainty_score":0.9998652},"labels":[],"label_agreement":null},{"id":"W4391482982","doi":"10.1038/s41408-023-00966-9","title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Medicine; Multiple myeloma; Chimeric antigen receptor; Clinical trial; Adverse effect; Pharmacodynamics; Malignancy; Cytokine release syndrome; Immunotherapy; Oncology; Antigen; Internal medicine; Pharmacokinetics; Immunology; Immune system","score_opus":0.1028294294267789,"score_gpt":0.44232088335920794,"score_spread":0.339491453932429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391482982","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010501579,0.99203265,0.0000379109,0.0008708197,0.00051164365,0.005485606,0.000873187,0.000020009307,0.0001576984],"genre_scores_gemma":[0.000014088634,0.9906043,0.00095795054,0.00009301802,0.0013076076,0.0034388797,0.00011604677,0.000101739344,0.0033664152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972479,0.00011752817,0.0010102696,0.00044276717,0.0006345751,0.00054698077],"domain_scores_gemma":[0.99760187,0.0005389023,0.00061680004,0.00048128772,0.0003826179,0.00037851708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036784515,0.0006285414,0.0027251013,0.0002102364,0.00024398329,0.000055648794,0.00027307638,0.00017707243,0.00041058954],"category_scores_gemma":[0.000284605,0.0002835387,0.0021214536,0.00042406435,0.00010797977,0.000049837494,0.000039400526,0.0005503907,0.00004056393],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017071828,0.0013034765,0.000015133601,0.059114933,0.013379338,0.0002989864,0.00039066625,2.6888438e-7,0.000003343152,0.000012666069,0.0078105046,0.91749996],"study_design_scores_gemma":[0.0043320837,0.0025744655,0.0000046552254,0.102295816,0.023674417,0.0022678988,0.00006244255,0.000014816416,0.000023592804,0.00001586631,0.8645443,0.00018970105],"about_ca_topic_score_codex":0.00012397979,"about_ca_topic_score_gemma":0.000046046134,"teacher_disagreement_score":0.91731024,"about_ca_system_score_codex":0.0005604199,"about_ca_system_score_gemma":0.003166091,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W4392298224","doi":"10.1038/s41408-024-01002-0","title":"Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"Academy of Medical Sciences; Medical Research Council; National Institute for Health and Care Research; Cancer Research UK; European Hematology Association","keywords":"Flow cytometry; T cell; Staining; CD8; Cell; Antibody; Molecular biology; Biology; Antigen; Immunology; Pathology; Medicine; Immune system; Genetics","score_opus":0.015369231450475902,"score_gpt":0.31349333209872715,"score_spread":0.29812410064825123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392298224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8978764,0.0844645,0.011927049,0.0032054908,0.00047940566,0.0010335202,0.0003919195,0.000033456934,0.00058826234],"genre_scores_gemma":[0.99087125,0.0057982956,0.00033212753,0.00013037483,0.0002905219,0.00007075116,0.0000123977525,0.000040263607,0.002454027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984014,0.00006528097,0.00047813734,0.00024169228,0.00049747207,0.00031602208],"domain_scores_gemma":[0.9988217,0.00043939153,0.00014523757,0.00015664348,0.00029156354,0.00014547959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009504631,0.00014856107,0.00025931073,0.00020489152,0.00022101175,0.00016850997,0.00010309493,0.000071755865,0.0001549921],"category_scores_gemma":[0.00015044292,0.000103001934,0.00011242571,0.00032709326,0.0001686603,0.00007882452,0.00003299539,0.00036934178,0.0000026498672],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007365782,0.0003710403,0.0042921724,0.001042516,0.00061100104,0.00016246669,0.003148035,0.00010927922,0.9406603,0.00009202131,0.015628565,0.03314603],"study_design_scores_gemma":[0.01382982,0.0022447351,0.00040092703,0.0008867125,0.0017174366,0.0077748843,0.012201613,0.089973465,0.8491799,0.00055964896,0.020695956,0.00053489214],"about_ca_topic_score_codex":0.000034438435,"about_ca_topic_score_gemma":0.000017215261,"teacher_disagreement_score":0.09299484,"about_ca_system_score_codex":0.00010557203,"about_ca_system_score_gemma":0.0007866488,"threshold_uncertainty_score":0.4200297},"labels":[],"label_agreement":null},{"id":"W4392516550","doi":"10.1038/s41408-024-01018-6","title":"Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Narrative; Medicine; Narrative review; Internal medicine; Bioinformatics; Intensive care medicine; Biology; Literature; Art","score_opus":0.0883671284899405,"score_gpt":0.4293044025224052,"score_spread":0.3409372740324647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392516550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000052306846,0.9917516,0.00006289764,0.00068468746,0.0019718213,0.004771955,0.00047081106,0.000023866163,0.00025710269],"genre_scores_gemma":[0.000012187111,0.9857229,0.0005036454,0.00007879555,0.0018002978,0.0032704503,0.00010451876,0.00008924974,0.008417966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974402,0.00011766825,0.00094772654,0.0004299778,0.0005889396,0.00047544486],"domain_scores_gemma":[0.9975682,0.00062714855,0.000612282,0.00042538022,0.00043047866,0.00033651758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033031366,0.00058453815,0.0024202322,0.000205065,0.000291466,0.000057199337,0.0002183756,0.00017557786,0.00048096947],"category_scores_gemma":[0.00033086663,0.0002740512,0.0019111073,0.00047903098,0.00010025657,0.000052319658,0.000031854725,0.0006028512,0.000038814364],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018728069,0.0011614419,0.000016949394,0.033640835,0.010608515,0.00021263995,0.00035754955,5.3890795e-7,0.0000017360198,0.0000046251953,0.029084235,0.9247236],"study_design_scores_gemma":[0.0036121467,0.0027819064,0.000006051461,0.10130933,0.020615032,0.0040038424,0.00008523,0.00004167333,0.000024122255,0.0000073399956,0.8673317,0.00018162395],"about_ca_topic_score_codex":0.00014675861,"about_ca_topic_score_gemma":0.000066098175,"teacher_disagreement_score":0.924542,"about_ca_system_score_codex":0.0006562976,"about_ca_system_score_gemma":0.003081047,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W4399609630","doi":"10.1038/s41408-024-01071-1","title":"Premature thymic functional senescence is a hallmark of childhood acute lymphoblastic leukemia survivorship","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Université Laval; Centre Hospitalier Universitaire Sainte-Justine; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"Garron Family Cancer Centre; Leukemia and Lymphoma Society; Fonds de Recherche du Québec - Santé; Leukemia and Lymphoma Society of Canada; Hospital for Sick Children; Université de Montréal; Pediatric Oncology Group of Ontario; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Institute of Cancer Research; Cancer Research Society; Ministère de la Santé et des Services sociaux; Ontario Institute for Cancer Research","keywords":"Immunosenescence; Medicine; Cancer; Senescence; Survivorship curve; Immunology; Leukemia; T cell; Internal medicine; Chronic lymphocytic leukemia; Immunophenotyping; Biomarker; Oncology; Biology; Immune system; Flow cytometry","score_opus":0.01808758214467647,"score_gpt":0.2858207302296639,"score_spread":0.26773314808498744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399609630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9409501,0.04291549,0.0011016094,0.008244551,0.0044395006,0.0005161173,0.00027294646,0.00022670878,0.0013329696],"genre_scores_gemma":[0.98804104,0.0035565163,0.00057481765,0.0024998672,0.0036718445,0.000034592103,0.000021066078,0.00010664937,0.0014936129],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961047,0.00018010181,0.0009946998,0.0006168404,0.0014855948,0.0006180326],"domain_scores_gemma":[0.998001,0.000276208,0.00035857208,0.00049220724,0.00036641333,0.0005056336],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009067552,0.00045423658,0.00081361545,0.00035672795,0.00019640203,0.00015456798,0.00032568627,0.00027951697,0.001887779],"category_scores_gemma":[0.00014384353,0.00038571225,0.00057527574,0.00076598773,0.0001690466,0.0003295748,0.000091986025,0.001219458,0.000054364747],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076212697,0.0052335514,0.3135568,0.01778156,0.048262917,0.0058046426,0.060905,0.0011374754,0.10957038,0.0031892282,0.37938926,0.047547948],"study_design_scores_gemma":[0.017817931,0.0025640747,0.8062964,0.032056656,0.013299241,0.043276593,0.001788724,0.0013450242,0.051598012,0.0039741755,0.02352935,0.0024538352],"about_ca_topic_score_codex":0.00044798595,"about_ca_topic_score_gemma":0.00023456808,"teacher_disagreement_score":0.49273962,"about_ca_system_score_codex":0.0005123047,"about_ca_system_score_gemma":0.004308747,"threshold_uncertainty_score":0.99985945},"labels":[],"label_agreement":null},{"id":"W4399859940","doi":"10.1038/s41408-024-01080-0","title":"Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Oncology; Disease; Medicine; Internal medicine; Bioinformatics; Computational biology; Biology","score_opus":0.010928446282557208,"score_gpt":0.28998048298401574,"score_spread":0.2790520367014585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399859940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986373,0.011219227,0.00074021326,0.00051366474,0.00092142506,0.000108994376,0.00007299995,0.000018275072,0.0000321909],"genre_scores_gemma":[0.9934393,0.0040475926,0.00029824337,0.00012572824,0.0013308504,0.000019844514,0.000040329396,0.000019333878,0.0006787608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862486,0.00018043298,0.00039158142,0.00034727913,0.00022967895,0.00022615603],"domain_scores_gemma":[0.99944115,0.000020016068,0.00014438045,0.00019712641,0.00007064231,0.00012669808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005271082,0.00015019003,0.00021713835,0.00022823128,0.00008586026,0.00021567912,0.00020982433,0.00026867335,0.000120039236],"category_scores_gemma":[0.00008792157,0.00012436297,0.00031754572,0.00037924162,0.00005903794,0.000020915324,0.000060208466,0.00063929183,0.000008450409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023567176,0.00041696616,0.8220231,0.0000690492,0.0060650916,0.0002498951,0.0003776381,0.0007996361,0.10604191,0.000049695627,0.042112306,0.021559022],"study_design_scores_gemma":[0.0068515665,0.00074455864,0.6251785,0.00048126117,0.0037243166,0.00015356022,0.00031949347,0.0012272426,0.30355567,0.00051911455,0.056287408,0.0009572652],"about_ca_topic_score_codex":0.00018661814,"about_ca_topic_score_gemma":0.0012339458,"teacher_disagreement_score":0.19751377,"about_ca_system_score_codex":0.000022754755,"about_ca_system_score_gemma":0.00018646312,"threshold_uncertainty_score":0.5071374},"labels":[],"label_agreement":null},{"id":"W4400428906","doi":"10.1038/s41408-024-01084-w","title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Medicine; Cumulative incidence; Internal medicine; Univariate analysis; Incidence (geometry); Progression-free survival; Hematopoietic cell; Surgery; Retrospective cohort study; Hematopoietic stem cell transplantation; Transplantation; Multivariate analysis; Chemotherapy; Haematopoiesis","score_opus":0.027509978119901374,"score_gpt":0.29665129241502913,"score_spread":0.2691413142951278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400428906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936263,0.003977149,0.000005035023,0.00094815803,0.00016104551,0.0004495466,0.00003589581,0.000040092382,0.0007567614],"genre_scores_gemma":[0.99570817,0.00308349,0.000050633116,0.00017457319,0.00018769637,0.000030808973,0.000024905174,0.000048898197,0.0006908324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998252,0.00012318934,0.00034725032,0.00028005795,0.0005547003,0.00044282925],"domain_scores_gemma":[0.9994379,0.000049581264,0.00004686544,0.00017139288,0.000093514274,0.0002007131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030557878,0.00019021967,0.00038637564,0.00039407515,0.000055981203,0.00006026892,0.00012314861,0.00010285024,0.0021593762],"category_scores_gemma":[0.000005779332,0.00012589851,0.0000816396,0.0005488389,0.00005178665,0.00008993215,0.000009601227,0.0009242599,0.0000063730326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055346005,0.0007314117,0.8858428,0.00009325616,0.0002718301,0.0020479988,0.0015777833,0.000041704978,0.022597201,0.0000031896927,0.0005613597,0.08069688],"study_design_scores_gemma":[0.026341168,0.0030004291,0.94474566,0.0027969186,0.00010586156,0.00069428794,0.000054123877,0.00045237946,0.006482588,0.000026241833,0.0150286285,0.00027168376],"about_ca_topic_score_codex":0.00067337876,"about_ca_topic_score_gemma":0.00043655257,"teacher_disagreement_score":0.080425195,"about_ca_system_score_codex":0.00031443126,"about_ca_system_score_gemma":0.00044887236,"threshold_uncertainty_score":0.9987528},"labels":[],"label_agreement":null},{"id":"W4401392108","doi":"10.1038/s41408-024-01111-w","title":"Identification of genetic subtypes in follicular lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Jewish General Hospital; Vector Institute; Princess Margaret Cancer Centre; Queen's University; University of Toronto; University Health Network","funders":"National Cancer Institute; Terry Fox Research Institute; Government of Canada; Deutsche Forschungsgemeinschaft; National Institutes of Health; Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada; F. Hoffmann-La Roche; Génome Québec; Canadian Institutes of Health Research; Else Kröner-Fresenius-Stiftung; Leukemia and Lymphoma Society","keywords":"Identification (biology); Follicular lymphoma; Lymphoma; Medicine; Computational biology; Hematology; Internal medicine; Biology; Bioinformatics; Immunology; Oncology; Genetics; Pathology","score_opus":0.010477757073206589,"score_gpt":0.2798505639844227,"score_spread":0.2693728069112161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401392108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415396,0.057205006,0.000026410427,0.00067777885,0.00029828187,0.00009995464,0.0000057219713,0.000010282511,0.00013696337],"genre_scores_gemma":[0.9938968,0.005510137,0.000113304915,0.000051272094,0.00021656955,0.000029428582,0.0000014426143,0.000010879831,0.00017016828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992436,0.000019039337,0.00031141288,0.00011743158,0.00019385513,0.00011463963],"domain_scores_gemma":[0.9997029,0.000018359024,0.00006332678,0.00010090639,0.000050956758,0.000063555264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001177222,0.00007065979,0.0001534706,0.00013804394,0.00002167634,0.000034731034,0.000041785475,0.000036089077,0.00011341292],"category_scores_gemma":[0.000011906738,0.00005291435,0.00009621488,0.00018845459,0.000017485869,0.00004755921,0.000007821416,0.000044853725,0.0000132323075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008119151,0.0011002945,0.7776253,0.0003035848,0.00080729346,0.002128099,0.00060563546,0.000096981756,0.027040947,0.00034350686,0.0013631957,0.18850398],"study_design_scores_gemma":[0.0026048224,0.00014263878,0.9163316,0.00064132386,0.00057328545,0.0010770198,0.0000432879,0.00024549695,0.07537966,0.00027449496,0.0026182842,0.00006809015],"about_ca_topic_score_codex":0.00011553024,"about_ca_topic_score_gemma":0.000031669933,"teacher_disagreement_score":0.18843588,"about_ca_system_score_codex":0.0001415835,"about_ca_system_score_gemma":0.00029574113,"threshold_uncertainty_score":0.21577847},"labels":[],"label_agreement":null},{"id":"W4402460449","doi":"10.1038/s41408-024-01135-2","title":"Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org; Juravinski Cancer Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Dexamethasone; Subgroup analysis; Multiple myeloma; Internal medicine; Oncology; Medicine; Refractory (planetary science); Lenalidomide; Meta-analysis; Biology","score_opus":0.03603070339032477,"score_gpt":0.32597029922849974,"score_spread":0.28993959583817497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402460449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98095304,0.0152379675,0.00030114446,0.0009207117,0.00075134786,0.0013771524,0.00033806943,0.000033524117,0.000087020686],"genre_scores_gemma":[0.99511147,0.0016301451,0.001049253,0.000097338874,0.0007046917,0.00020871195,0.000036965837,0.000048963568,0.0011124805],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974869,0.00022848086,0.00068462885,0.00040790395,0.0006784113,0.00051366445],"domain_scores_gemma":[0.9979992,0.0007908572,0.0002639176,0.0003603675,0.00022816927,0.00035749562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008681583,0.000266584,0.0007979748,0.0005495988,0.0002469046,0.00011485314,0.00020153717,0.00015858372,0.00023300221],"category_scores_gemma":[0.00060512393,0.00016641559,0.000731747,0.0009758079,0.00015765123,0.00014979702,0.000073440744,0.000569396,0.0000020326563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1970439,0.0044303015,0.41679642,0.001348752,0.07229119,0.0012466726,0.002915252,0.000080455764,0.13990076,0.00021721107,0.009287714,0.15444139],"study_design_scores_gemma":[0.4907873,0.007213315,0.3637565,0.0013802032,0.039868437,0.0010574425,0.00087495026,0.018512944,0.05880657,0.00022690388,0.016753545,0.0007618788],"about_ca_topic_score_codex":0.00024549078,"about_ca_topic_score_gemma":0.00044550293,"teacher_disagreement_score":0.2937434,"about_ca_system_score_codex":0.00018706101,"about_ca_system_score_gemma":0.0006243604,"threshold_uncertainty_score":0.6786231},"labels":[],"label_agreement":null},{"id":"W4402493149","doi":"10.1038/s41408-024-01139-y","title":"Bispecific antibodies in the treatment of multiple myeloma","year":2024,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Antibody; Medicine; Hematology; Immunology; Internal medicine; Oncology; Cancer research","score_opus":0.12383453040322111,"score_gpt":0.4311017220673892,"score_spread":0.3072671916641681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402493149","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00192831,0.9953723,2.824321e-7,0.00051014783,0.00045411912,0.000606313,0.0001573993,0.000008081407,0.00096302526],"genre_scores_gemma":[0.00017996952,0.9945834,0.00005935207,0.0000293264,0.0018423616,0.00009577594,0.000026926053,0.00004112901,0.0031417452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779177,0.0001842579,0.00076682994,0.00026186026,0.0006078707,0.00038739428],"domain_scores_gemma":[0.9990555,0.00024370398,0.00022268786,0.00026695488,0.00008745934,0.00012370922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002999033,0.0003760251,0.0015982746,0.00043522444,0.00008988556,0.000063469386,0.00027734728,0.00015316794,0.00025574377],"category_scores_gemma":[0.000021606793,0.00016483151,0.0009857428,0.00048378384,0.00013487978,0.000029976212,0.000032518205,0.00077029126,0.00005257484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075352196,0.000670113,0.0009381689,0.011720922,0.001393419,0.0018818257,0.0006235126,2.521156e-7,0.000006314485,0.00004761262,0.0033397966,0.9793027],"study_design_scores_gemma":[0.00069666,0.0007466167,0.000337722,0.01825547,0.0029059183,0.0031472687,0.00009620552,0.0000026318758,0.000016935168,0.000026709507,0.97362226,0.00014559942],"about_ca_topic_score_codex":0.00021430344,"about_ca_topic_score_gemma":0.0001565303,"teacher_disagreement_score":0.9791571,"about_ca_system_score_codex":0.00016251598,"about_ca_system_score_gemma":0.00083014916,"threshold_uncertainty_score":0.6721634},"labels":[],"label_agreement":null},{"id":"W4403173763","doi":"10.1038/s41408-024-01153-0","title":"MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"Agencia Estatal de Investigación; European Regional Development Fund; Instituto de Salud Carlos III; Ministerio de Economía y Competitividad; Generalitat de Catalunya; European Commission; Michael Smith Health Research BC","keywords":"Lymphoma; Burkitt's lymphoma; Medicine; Cancer research; Hematology; B cell; Oncology; Internal medicine; Immunology; Antibody","score_opus":0.004214530295685977,"score_gpt":0.22791742188011657,"score_spread":0.2237028915844306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403173763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86470777,0.13242334,0.0000036525994,0.001164273,0.0003768011,0.00030806448,0.000047413185,0.000050979033,0.0009177313],"genre_scores_gemma":[0.98797166,0.0102499835,0.00020280552,0.00043125643,0.0006270106,0.0000669974,0.000017339215,0.000053083084,0.0003798544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983912,0.00005137899,0.00033538858,0.00040967556,0.00040565798,0.00040666948],"domain_scores_gemma":[0.99930257,0.00002284617,0.00010002628,0.00020461732,0.000059143607,0.00031080487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001426174,0.00028932965,0.0003977024,0.00024498557,0.000106786276,0.00023307107,0.00009824888,0.00016490238,0.00010970043],"category_scores_gemma":[0.000015360196,0.00022088092,0.00017072877,0.00029931747,0.000044003405,0.00015655626,0.000039509956,0.00023141931,0.000018334647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036033793,0.0015430864,0.93606836,0.0001958905,0.00091235875,0.006369069,0.0011890839,0.0000029192581,0.0013510814,0.00003832382,0.0035488799,0.048420623],"study_design_scores_gemma":[0.017839363,0.00038262844,0.9577294,0.0023736064,0.000856024,0.012735169,0.00022009091,0.00006502732,0.005945149,0.00006123731,0.0015121032,0.00028017495],"about_ca_topic_score_codex":0.00069213856,"about_ca_topic_score_gemma":0.0001490603,"teacher_disagreement_score":0.123263925,"about_ca_system_score_codex":0.00034038862,"about_ca_system_score_gemma":0.0003922831,"threshold_uncertainty_score":0.90072626},"labels":[],"label_agreement":null},{"id":"W4403400873","doi":"10.1038/s41408-024-01159-8","title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Universitätsklinikum Heidelberg; Deutsches Krebsforschungszentrum","keywords":"Multiple myeloma; Cohort; Medicine; Internal medicine; Oncology","score_opus":0.029946250782767674,"score_gpt":0.3128324942580536,"score_spread":0.2828862434752859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403400873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804072,0.0050485437,0.0000074279833,0.01234202,0.00025513154,0.0013351346,0.0003979257,0.000017020919,0.00018962962],"genre_scores_gemma":[0.9942265,0.0004246033,0.0002478406,0.0035576855,0.0007519439,0.00015585725,0.00026459162,0.00009614361,0.00027483585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709255,0.00010090672,0.00073610706,0.00035477028,0.0012760336,0.0004396538],"domain_scores_gemma":[0.9986089,0.000076890916,0.0005135379,0.00029261815,0.00033991307,0.00016812532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018497987,0.00033759908,0.0008892141,0.00053191575,0.000035307385,0.000027520182,0.0001741508,0.00030303266,0.000137381],"category_scores_gemma":[0.00004752568,0.0002213729,0.0001913985,0.00021251471,0.00006464535,0.00009338868,0.000081481776,0.0018492667,0.000002299605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008269203,0.0005515513,0.96180385,0.0021956698,0.001688983,0.005243325,0.00015433592,0.0000015034831,0.00010278038,9.7180354e-8,0.020799236,0.006631768],"study_design_scores_gemma":[0.0148830535,0.0017040386,0.95058084,0.020307094,0.0005722685,0.00021882146,0.000032101587,0.00002796517,0.003353487,0.00000504152,0.008061556,0.00025376247],"about_ca_topic_score_codex":0.00061489205,"about_ca_topic_score_gemma":0.000080041624,"teacher_disagreement_score":0.018111423,"about_ca_system_score_codex":0.00017334733,"about_ca_system_score_gemma":0.0008474801,"threshold_uncertainty_score":0.9027325},"labels":[],"label_agreement":null},{"id":"W4403458741","doi":"10.1038/s41408-024-01164-x","title":"Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Huntsman Cancer Institute; McMaster University; University of Arkansas for Medical Sciences; Hamilton Health Sciences","keywords":"Multiple myeloma; Retrospective cohort study; Medicine; MEDLINE; Internal medicine; Pediatrics; Oncology; Political science","score_opus":0.05742110478828666,"score_gpt":0.38477372673609556,"score_spread":0.3273526219478089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403458741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95922065,0.0028455104,0.000072895666,0.023916453,0.0009980231,0.0099750515,0.0023961768,0.00008833668,0.0004868838],"genre_scores_gemma":[0.98038435,0.0018681171,0.00021424983,0.004488904,0.0057105767,0.002186655,0.00097203674,0.00019347413,0.0039816555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681205,0.00015167946,0.0006420426,0.000615402,0.0011976083,0.0005812015],"domain_scores_gemma":[0.9978915,0.0003640765,0.0004256543,0.0004184931,0.0006573267,0.00024297195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026745707,0.00055856846,0.0011545306,0.0006477602,0.00017989097,0.00011608952,0.00015366993,0.00033391136,0.00026682927],"category_scores_gemma":[0.00041848954,0.00036135444,0.0008465695,0.00033218993,0.000058203226,0.0000806459,0.000028336199,0.0010829878,0.000013732135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015283101,0.002886474,0.78172225,0.00018924009,0.014431364,0.007045533,0.00051355694,0.000030968684,0.000069866896,9.2041176e-7,0.1856011,0.0059804013],"study_design_scores_gemma":[0.025062352,0.016665267,0.9426377,0.0007800623,0.004350903,0.00021411867,0.000051376945,0.00019732387,0.00046652008,0.00006113737,0.0092199985,0.000293236],"about_ca_topic_score_codex":0.0015630478,"about_ca_topic_score_gemma":0.00052430044,"teacher_disagreement_score":0.17638111,"about_ca_system_score_codex":0.002726486,"about_ca_system_score_gemma":0.0013013761,"threshold_uncertainty_score":0.99988383},"labels":[],"label_agreement":null},{"id":"W4403584947","doi":"10.1038/s41408-024-01160-1","title":"Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Coronavirus disease 2019 (COVID-19); Multiple myeloma; Refractory (planetary science); Medicine; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Internal medicine; Phase (matter); Oncology; Intensive care medicine; Virology; Biology; Disease; Chemistry","score_opus":0.03408087033670494,"score_gpt":0.3724803498232491,"score_spread":0.3383994794865442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403584947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676768,0.0006327638,0.0000014438211,0.028251734,0.00012299452,0.0026985528,0.00049948785,0.000020212297,0.00009597883],"genre_scores_gemma":[0.98081714,0.00009278271,0.000036736343,0.01770369,0.00047087407,0.00030802633,0.00015559825,0.0001160819,0.00029904314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534166,0.00048323817,0.0007463024,0.0005726408,0.0020892348,0.0007669343],"domain_scores_gemma":[0.9977944,0.00050640793,0.00046764352,0.0007011928,0.00020412171,0.00032627274],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00053228723,0.00063593907,0.0011188536,0.0010809436,0.000109908055,0.00010632729,0.00042174428,0.00028549277,0.0002073765],"category_scores_gemma":[0.00027825177,0.00029030355,0.00026613407,0.0006609421,0.0001395866,0.00012407769,0.000050044095,0.0045088083,0.000009372673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0093539,0.009429099,0.9179559,0.0003179071,0.0027086248,0.022449782,0.0015918459,0.00003566791,0.000003063696,1.448997e-7,0.034332797,0.0018212702],"study_design_scores_gemma":[0.10184975,0.024460273,0.8657621,0.0012698105,0.00086207554,0.00023195069,0.00039037858,0.000006727745,0.000006131594,0.0000055484807,0.004845718,0.00030950303],"about_ca_topic_score_codex":0.002532637,"about_ca_topic_score_gemma":0.0017845043,"teacher_disagreement_score":0.09249585,"about_ca_system_score_codex":0.0013444407,"about_ca_system_score_gemma":0.0025105672,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W4403946959","doi":"10.1038/s41408-024-01166-9","title":"Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML","year":2024,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Core binding factor; Internal medicine; Genetics; Bioinformatics; Biology; Computational biology; Gene; Transcription factor","score_opus":0.054128508804982337,"score_gpt":0.3452643679558103,"score_spread":0.29113585915082796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403946959","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78605473,0.0124384165,7.0069956e-7,0.19945867,0.0010958173,0.00050119055,0.00019173279,0.000044073942,0.00021468043],"genre_scores_gemma":[0.31192726,0.13990748,0.0018504026,0.44382593,0.037780747,0.00073539466,0.00059480104,0.001855657,0.061522305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974478,0.000103085746,0.0005476592,0.00044941987,0.0006032209,0.0008488322],"domain_scores_gemma":[0.9990248,0.00020125396,0.00020620234,0.00025371808,0.000094659976,0.00021935688],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033343938,0.00043624008,0.00079477084,0.00080618623,0.00011200571,0.00017546969,0.0002889577,0.0008198094,0.0009275916],"category_scores_gemma":[0.000082300816,0.00032140856,0.0002151404,0.00029313428,0.00012878941,0.00008021232,0.000112957656,0.0074220276,0.000050780087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012188755,0.00015267136,0.2817398,0.00094427564,0.00618527,0.035637416,0.0022449892,0.0000041408002,0.017949153,0.0000059856934,0.6426008,0.011316663],"study_design_scores_gemma":[0.06715389,0.0027946038,0.10870132,0.0059334566,0.0025763002,0.01777148,0.0005337216,0.00019182882,0.0044619143,0.0002758612,0.7874693,0.0021362805],"about_ca_topic_score_codex":0.00018840158,"about_ca_topic_score_gemma":0.000029125244,"teacher_disagreement_score":0.47412744,"about_ca_system_score_codex":0.0017211582,"about_ca_system_score_gemma":0.0024490159,"threshold_uncertainty_score":0.9999857},"labels":[],"label_agreement":null},{"id":"W4403947139","doi":"10.1038/s41408-024-01165-w","title":"Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Leukemia and Lymphoma Society; U.S. Department of Health and Human Services","keywords":"CD34; Medicine; Plerixafor; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Autologous stem-cell transplantation; Melphalan; Haematopoiesis; Propensity score matching; Internal medicine; Urology; Stem cell; Surgery; Oncology; CXCR4; Biology","score_opus":0.019294930824064492,"score_gpt":0.27803633748950685,"score_spread":0.2587414066654424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403947139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203694,0.0057915403,0.00022834695,0.00022323224,0.00041905075,0.00054634496,0.000053352975,0.000070162096,0.0006310442],"genre_scores_gemma":[0.995681,0.0024173907,0.0009515415,0.000059078968,0.00016916957,0.00007012001,0.00004184501,0.000051456285,0.00055842154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978208,0.000117086165,0.0005096524,0.0003509558,0.0006007439,0.00060077955],"domain_scores_gemma":[0.999084,0.00017681914,0.000102316844,0.0001663201,0.00010002881,0.0003705264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019977445,0.00025961708,0.00035598752,0.00035907756,0.0001493545,0.0001324482,0.00012592779,0.0001261982,0.0002134588],"category_scores_gemma":[0.000013880321,0.00021108423,0.0001604639,0.0002820941,0.000041794567,0.00023075854,0.0000255818,0.0006345571,0.00006562789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029370214,0.003487937,0.8785305,0.0042042728,0.0007461516,0.015104879,0.009463738,0.0022698583,0.01260415,0.000012101878,0.0010054498,0.069633946],"study_design_scores_gemma":[0.07286444,0.003425251,0.80462134,0.0043139467,0.0013220104,0.0020807844,0.0013461577,0.012650302,0.0954818,0.000059653757,0.00095853576,0.0008757472],"about_ca_topic_score_codex":0.00014001604,"about_ca_topic_score_gemma":0.00027933792,"teacher_disagreement_score":0.08287765,"about_ca_system_score_codex":0.0003807123,"about_ca_system_score_gemma":0.00075140805,"threshold_uncertainty_score":0.8607765},"labels":[],"label_agreement":null},{"id":"W4404222964","doi":"10.1038/s41408-024-01177-6","title":"Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Lenalidomide; Multiple myeloma; Dexamethasone; Bortezomib; Medicine; Internal medicine; Hematology; Induction therapy; Oncology; Chemotherapy","score_opus":0.021626995701039278,"score_gpt":0.3043724535718073,"score_spread":0.28274545787076805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404222964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464184,0.0027032918,0.000021912983,0.00092125114,0.00018097476,0.00059609814,0.00082370016,0.000029288582,0.000081620914],"genre_scores_gemma":[0.99755895,0.0010886953,0.00033040074,0.000057902507,0.00067971344,0.00003770877,0.000113187714,0.00004007874,0.0000933844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978561,0.00016552235,0.000455937,0.0003901831,0.0007379845,0.00039431313],"domain_scores_gemma":[0.9979769,0.00079675147,0.0002630264,0.00035468687,0.00023901758,0.00036963949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035246788,0.00027000133,0.0003927349,0.000147183,0.00018896264,0.00012931175,0.00012461861,0.00010177415,0.00013794762],"category_scores_gemma":[0.00051160203,0.00013968717,0.00018040545,0.00028084603,0.00015809477,0.0001811749,0.000037148446,0.0007082469,0.0000051228817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028960468,0.0012943756,0.8733343,0.00006576656,0.004673527,0.0009251055,0.001220849,0.00015122084,0.0034475748,0.0000055042024,0.004661634,0.081259705],"study_design_scores_gemma":[0.03720107,0.0041144677,0.9512272,0.0016476162,0.0005611938,0.00019703081,0.00013297076,0.00022624519,0.004250805,0.00003657783,0.00024675744,0.00015806718],"about_ca_topic_score_codex":0.0034874214,"about_ca_topic_score_gemma":0.00028518328,"teacher_disagreement_score":0.08110164,"about_ca_system_score_codex":0.00025978073,"about_ca_system_score_gemma":0.0006140468,"threshold_uncertainty_score":0.56962776},"labels":[],"label_agreement":null},{"id":"W4404719809","doi":"10.1038/s41408-024-01187-4","title":"RSK1 dependency in FLT3-ITD acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Edward P. Evans Foundation; National Heart, Lung, and Blood Institute; McGill University; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; MPN Research Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Cancer research; Fms-Like Tyrosine Kinase 3; Leukemia; Biology; Cycloheximide; Immunology; Cell culture; Mutation; Genetics; Gene","score_opus":0.017955739931584908,"score_gpt":0.3294307861238656,"score_spread":0.3114750461922807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404719809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9419936,0.039081875,0.0002280301,0.007398443,0.001389929,0.00042429485,0.000035253823,0.00014919897,0.009299365],"genre_scores_gemma":[0.96077406,0.020328682,0.0017085321,0.0009970713,0.0036332295,0.00009373667,0.000012146184,0.00013244827,0.012320077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719095,0.00009624303,0.0005619548,0.0004361594,0.00089066254,0.00082401],"domain_scores_gemma":[0.99885374,0.00009070863,0.00007319499,0.0003237333,0.00016492889,0.0004936781],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075197616,0.0002742445,0.0004519559,0.000637037,0.00013054932,0.00021237669,0.0003462133,0.00021558134,0.0022243862],"category_scores_gemma":[0.000089086876,0.00022077895,0.00022806939,0.00085323676,0.00008656381,0.00034412494,0.000119267665,0.0025811067,0.00027470294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017672627,0.0007417989,0.09635864,0.0013203358,0.006250406,0.10106592,0.0038768544,0.00025306962,0.14355871,0.001207007,0.14861959,0.4949804],"study_design_scores_gemma":[0.051729217,0.005285122,0.14068848,0.014613388,0.008568903,0.17240424,0.0016576198,0.017146168,0.13377975,0.009044513,0.44143865,0.003643947],"about_ca_topic_score_codex":0.00040610245,"about_ca_topic_score_gemma":0.00021681527,"teacher_disagreement_score":0.49133644,"about_ca_system_score_codex":0.002251524,"about_ca_system_score_gemma":0.0055455947,"threshold_uncertainty_score":0.99972},"labels":[],"label_agreement":null},{"id":"W4404828842","doi":"10.1038/s41408-024-01192-7","title":"Molecular monitoring in CML—a modern example of an old proverb","year":2024,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Department of Medicine, University of Toronto; University of Toronto","keywords":"Medicine; Computational biology; MEDLINE; Bioinformatics; Biology; Intensive care medicine; Biochemistry","score_opus":0.015990089796937803,"score_gpt":0.3082338323487274,"score_spread":0.29224374255178964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404828842","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35943782,0.03067778,0.000011400337,0.000067270244,0.6086974,0.00049666036,0.00022532941,0.00004737641,0.00033892965],"genre_scores_gemma":[0.048666216,0.0052913,0.0007812538,0.000018802639,0.94319797,0.00013402195,0.0001163421,0.00025019227,0.0015438927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996609,0.000077709075,0.0007641738,0.00057104864,0.0014566085,0.00052148],"domain_scores_gemma":[0.9984011,0.0000934072,0.00038270015,0.0005372685,0.00027631712,0.00030921935],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00038880587,0.00044274103,0.00091549725,0.00038390173,0.000042187155,0.00007440172,0.00030327812,0.00066434866,0.00010361115],"category_scores_gemma":[0.00015256017,0.0003931351,0.0002601379,0.0002603579,0.000043899687,0.00014414877,0.000094171286,0.0025044768,0.0000056430777],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019838098,0.003453073,0.007851654,0.00848695,0.008934135,0.028897285,0.0044250223,0.0017354158,0.038683977,0.000027545113,0.8195408,0.07598035],"study_design_scores_gemma":[0.054095417,0.0047370805,0.0012335199,0.041034184,0.0129125025,0.001921801,0.0002891607,0.001245572,0.09304659,0.0020093978,0.7852286,0.0022461528],"about_ca_topic_score_codex":0.0034480593,"about_ca_topic_score_gemma":0.00016664264,"teacher_disagreement_score":0.33450055,"about_ca_system_score_codex":0.0023050716,"about_ca_system_score_gemma":0.005030642,"threshold_uncertainty_score":0.99985206},"labels":[],"label_agreement":null},{"id":"W4407238709","doi":"10.1038/s41408-025-01212-0","title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Seagen","keywords":"Medicine; Pomalidomide; Context (archaeology); Clinical trial; Multiple myeloma; Oncology; Internal medicine; Dexamethasone; Daratumumab; Clinical endpoint; Lenalidomide","score_opus":0.1447630802165594,"score_gpt":0.4704130007054941,"score_spread":0.3256499204889347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407238709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045396267,0.99263245,0.0000019255929,0.00042875332,0.0006016591,0.0013514686,0.00006047624,0.000011693315,0.00037194762],"genre_scores_gemma":[0.0017319605,0.9928059,0.00069812103,0.00003466702,0.00035965905,0.00027686992,0.00003276673,0.0000570069,0.004003032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937308,0.0011721277,0.0029077253,0.0004964756,0.0008644149,0.00082845625],"domain_scores_gemma":[0.99505097,0.0026792772,0.0011132351,0.0005109513,0.00021525646,0.00043030837],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030024627,0.00051332795,0.0026695856,0.0007359808,0.00023538178,0.000058217633,0.0005978227,0.00039719814,0.00014953167],"category_scores_gemma":[0.0020421504,0.00027982876,0.00062562304,0.00081309123,0.0001523794,0.00005914558,0.00021169023,0.0033448322,0.000015273448],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009117957,0.0015526469,0.01656853,0.0055264416,0.001315471,0.0021643606,0.00015248022,6.907772e-7,6.662158e-7,0.0000046285904,0.0016203879,0.9701819],"study_design_scores_gemma":[0.015978567,0.00034140592,0.02065032,0.08997665,0.0011325554,0.00079009606,0.00015577543,0.0000054000707,0.00002036719,0.000009825637,0.8706116,0.0003274255],"about_ca_topic_score_codex":0.00029329053,"about_ca_topic_score_gemma":0.0076496303,"teacher_disagreement_score":0.9698545,"about_ca_system_score_codex":0.0008774726,"about_ca_system_score_gemma":0.013981007,"threshold_uncertainty_score":0.99996537},"labels":[],"label_agreement":null},{"id":"W4408310298","doi":"10.1038/s41408-025-01242-8","title":"Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; Hôpital Charles-Le Moyne; Université de Sherbrooke; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; McGill University; Université Laval; Centre Hospitalier de l’Université de Montréal; The Quebec Population Health Research Network; Université du Québec à Montréal; Université du Québec; Centre hospitalier universitaire de Québec; Université de Montréal; Institut universitaire en santé mentale de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Affect (linguistics); Medicine; Intensive care medicine; Prospective cohort study; Family medicine; Internal medicine; Psychology","score_opus":0.013173212410804247,"score_gpt":0.2912117035899546,"score_spread":0.2780384911791503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408310298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85967255,0.008117373,0.000012790334,0.12781148,0.0013198041,0.0023108271,0.00027967524,0.00011644838,0.0003590779],"genre_scores_gemma":[0.79976875,0.014263232,0.00022813784,0.13251126,0.012092478,0.000935551,0.0000914876,0.0003961237,0.03971296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569017,0.00031763632,0.0008192682,0.0011464608,0.0011770717,0.0008493997],"domain_scores_gemma":[0.99766624,0.00017579917,0.0008357373,0.000804154,0.00027402584,0.00024401708],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003327897,0.0009385001,0.0016253516,0.00033505078,0.00049106777,0.00033930232,0.0004210609,0.0006366092,0.00027726695],"category_scores_gemma":[0.000053130338,0.0006707989,0.00036471462,0.00030401113,0.00010773835,0.00022875355,0.0001418319,0.0048844297,0.0000028246045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015419936,0.0014209825,0.59838223,0.0016829899,0.018656693,0.00979468,0.007334107,0.0000054769807,0.011540908,0.0000026503826,0.3420213,0.0076159933],"study_design_scores_gemma":[0.20485434,0.005839785,0.39687064,0.020596307,0.017186191,0.0064026727,0.0034889905,0.000056867444,0.06873456,0.0002822788,0.2699437,0.0057436614],"about_ca_topic_score_codex":0.012503898,"about_ca_topic_score_gemma":0.0031510147,"teacher_disagreement_score":0.20331234,"about_ca_system_score_codex":0.003095415,"about_ca_system_score_gemma":0.0022248027,"threshold_uncertainty_score":0.9995743},"labels":[],"label_agreement":null},{"id":"W4408868147","doi":"10.1038/s41408-025-01243-7","title":"Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","year":2025,"lang":"en","type":"erratum","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Drug development; Internal medicine; Drug; Oncology; Intensive care medicine; Pharmacology; Biology","score_opus":0.07078477127089412,"score_gpt":0.39924263271318067,"score_spread":0.32845786144228656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408868147","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6386059,0.10944432,0.000058363894,0.025631702,0.15597369,0.0077887424,0.000546404,0.00016730776,0.06178355],"genre_scores_gemma":[0.27842954,0.065032825,0.0011367544,0.0005378402,0.005213002,0.00041641938,0.00024447707,0.00015835912,0.6488308],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99471194,0.0007805533,0.0020638984,0.00054632575,0.0011252776,0.00077203644],"domain_scores_gemma":[0.99676746,0.001037894,0.00092041545,0.000510342,0.00037950402,0.0003843763],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021526646,0.00047694184,0.0014073559,0.00081872445,0.00024591983,0.000057568137,0.0005164901,0.00059311447,0.0005975986],"category_scores_gemma":[0.001890017,0.0002950639,0.00035359175,0.0007762765,0.00017481612,0.000075834236,0.0001902,0.0065594246,0.000012763315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038954609,0.0027539188,0.1804667,0.000371717,0.0013155254,0.0030067214,0.0007858222,0.0000121173725,0.00001688793,0.0000016425182,0.7183467,0.08902675],"study_design_scores_gemma":[0.026371108,0.0006579021,0.6022682,0.012612891,0.0005377702,0.0010547661,0.0008057959,0.0002246173,0.00038332547,0.000012817884,0.3546867,0.00038407993],"about_ca_topic_score_codex":0.0014060055,"about_ca_topic_score_gemma":0.031019574,"teacher_disagreement_score":0.5870473,"about_ca_system_score_codex":0.000994016,"about_ca_system_score_gemma":0.01331059,"threshold_uncertainty_score":0.9999502},"labels":[],"label_agreement":null},{"id":"W4408957812","doi":"10.1038/s41408-025-01263-3","title":"Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; AbbVie","keywords":"Azacitidine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Medicine; Myeloid leukemia; Venetoclax; Leukemia; Antecedent (behavioral psychology); Internal medicine; Myeloid; Oncology; Immunology; Chronic lymphocytic leukemia; Bone marrow; Psychology; Psychotherapist; Biology","score_opus":0.013960923690989883,"score_gpt":0.2738220891699498,"score_spread":0.25986116547895993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408957812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93034697,0.016228545,0.00002491975,0.048142035,0.0008956404,0.0032715313,0.0004250952,0.00018625383,0.00047902975],"genre_scores_gemma":[0.40232015,0.28265467,0.0012325868,0.21527094,0.012333934,0.0022497077,0.0037535913,0.0020220191,0.078162394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99298763,0.0003841805,0.0015351379,0.001370692,0.0017217624,0.0020006006],"domain_scores_gemma":[0.99664676,0.00044203887,0.000819271,0.0008610064,0.00068826013,0.00054268044],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00043548504,0.0013901626,0.0022957458,0.001888745,0.00037885673,0.00030208935,0.0007583396,0.0016316137,0.0010947791],"category_scores_gemma":[0.0001283275,0.000967567,0.00029092617,0.0017068076,0.0005055215,0.00033317963,0.00027579578,0.009116102,0.000031249063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019431585,0.00068096264,0.05965749,0.005397218,0.032533716,0.12247769,0.001243727,0.0014782107,0.001332025,0.0000075667654,0.6785141,0.077245675],"study_design_scores_gemma":[0.29806542,0.034635622,0.15425168,0.064954504,0.019742874,0.051578045,0.00023201382,0.0058108885,0.0044658226,0.00020290002,0.35829496,0.0077652847],"about_ca_topic_score_codex":0.0009509717,"about_ca_topic_score_gemma":0.00031381234,"teacher_disagreement_score":0.5280268,"about_ca_system_score_codex":0.024624357,"about_ca_system_score_gemma":0.02900519,"threshold_uncertainty_score":0.9998849},"labels":[],"label_agreement":null},{"id":"W4409083304","doi":"10.1038/s41408-025-01234-8","title":"Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada); Hôpital Charles-Le Moyne; Université de Sherbrooke; Bausch Health (Canada); Cegep de Saint Jerome; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier de l'Université Laval; Montreal Heart Institute; St. Jerome's University; Cégep de Lévis; Centre hospitalier universitaire de Québec; Hôpital du Sacré-Cœur de Montréal; McGill University; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Université Laval; Université de Montréal; McGill-Queen's University Press; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Internal medicine; Medicine; Hematology; Oncology; Gerontology","score_opus":0.04317865656157713,"score_gpt":0.3873996564677468,"score_spread":0.3442209999061697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409083304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89491063,0.004571527,0.0000028594452,0.09580835,0.0013621771,0.002455933,0.0007023708,0.000013899131,0.00017224507],"genre_scores_gemma":[0.9469686,0.014584562,0.000086125525,0.026428286,0.008281954,0.00063989044,0.00091389514,0.00015387381,0.0019427723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919318,0.0026461326,0.0018544012,0.000947131,0.0017853357,0.0008352288],"domain_scores_gemma":[0.9929784,0.004085688,0.00078897394,0.00067365705,0.0011959402,0.0002773403],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019206061,0.0006977516,0.0019937656,0.0004826976,0.00038488966,0.00022227442,0.0004917999,0.0008724133,0.00028190835],"category_scores_gemma":[0.00067722984,0.00042956902,0.00036316304,0.00057828694,0.0003796795,0.00013818151,0.0003371101,0.0077431714,0.000006062225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007555755,0.002264608,0.82326627,0.0000732304,0.0038965603,0.00082997995,0.0025931576,0.000011046505,6.696244e-7,0.000015504622,0.1600017,0.006291673],"study_design_scores_gemma":[0.021444771,0.005204741,0.95906,0.0028670873,0.0020116093,0.000054335083,0.0021787742,0.0001990069,0.000007994688,0.00015236126,0.006404905,0.0004144268],"about_ca_topic_score_codex":0.06732217,"about_ca_topic_score_gemma":0.10118493,"teacher_disagreement_score":0.1535968,"about_ca_system_score_codex":0.001086375,"about_ca_system_score_gemma":0.0021803363,"threshold_uncertainty_score":0.9998156},"labels":[],"label_agreement":null},{"id":"W4409147719","doi":"10.1038/s41408-025-01259-z","title":"Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Cilag; Pharmacyclics; Genentech; National Institutes of Health; National Cancer Institute; University College London; National Institute for Health and Care Research; Ascentage Pharma; SkylineDx; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Celgene; Swedish Orphan Biovitrum; Array BioPharma; Kite Pharma; Gilead Sciences; BeiGene; Sanofi; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Progression-free survival; Dosing; Oncology; Surgery; Gastroenterology; Chemotherapy","score_opus":0.08100113878727644,"score_gpt":0.40975673512727917,"score_spread":0.32875559634000273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409147719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934024,0.0023129603,0.00011329048,0.0002970374,0.0006704638,0.0022101484,0.00005779663,0.0000158794,0.0009200007],"genre_scores_gemma":[0.99566066,0.001938519,0.000708055,0.000021319342,0.00048700577,0.0005446722,0.000035432695,0.000024017712,0.0005802874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750084,0.00023052825,0.0006405111,0.00028320096,0.0010556682,0.00028923393],"domain_scores_gemma":[0.99776256,0.00044372148,0.00040707263,0.0004175686,0.00083196524,0.00013709054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010582731,0.00020373038,0.0004173775,0.000403373,0.0002363999,0.000042631305,0.00025114475,0.000058019166,0.00018239846],"category_scores_gemma":[0.00021293291,0.00013109721,0.0002319584,0.0003291208,0.000083685634,0.00014450196,0.000030472569,0.00018816507,6.802862e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033112364,0.0062040607,0.58950347,0.000033985394,0.0032966486,0.00002870785,0.00094333466,0.000101809535,0.003220721,0.000057977948,0.00008154528,0.39321652],"study_design_scores_gemma":[0.03883728,0.004177864,0.9391941,0.0003457119,0.0026113733,0.000025470566,0.0011555183,0.0043596756,0.0061153723,0.00011406916,0.0029539834,0.00010960142],"about_ca_topic_score_codex":0.00088508095,"about_ca_topic_score_gemma":0.0032397727,"teacher_disagreement_score":0.39310694,"about_ca_system_score_codex":0.0006985452,"about_ca_system_score_gemma":0.00073592516,"threshold_uncertainty_score":0.5345989},"labels":[],"label_agreement":null},{"id":"W4409578902","doi":"10.1038/s41408-025-01288-8","title":"Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Affect (linguistics); Medicine; Prospective cohort study; Intensive care medicine; Internal medicine; Psychology","score_opus":0.013395953033813964,"score_gpt":0.2998396381446816,"score_spread":0.28644368511086765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409578902","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32581744,0.0048101814,0.000018059485,0.6652881,0.0009174789,0.0021519987,0.00066801754,0.000084548155,0.00024421158],"genre_scores_gemma":[0.121612504,0.014189714,0.000112774665,0.8511717,0.0022609576,0.0007662776,0.00015265879,0.00024387226,0.009489561],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522763,0.0005329394,0.00083859486,0.0012156791,0.0013457115,0.000839439],"domain_scores_gemma":[0.9975028,0.00028929068,0.00086361414,0.0008524951,0.00022396515,0.0002678602],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00048776326,0.0010448884,0.0016015865,0.00026867646,0.00046612415,0.00034739263,0.00044162563,0.000509386,0.00022958728],"category_scores_gemma":[0.00004371551,0.00075526873,0.0003371211,0.00024534695,0.00010769091,0.00018773097,0.00014460944,0.0055309907,0.0000027604735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075007655,0.0009773056,0.050489534,0.00035845765,0.0061267964,0.0018372508,0.0020682227,0.0000035223861,0.0027091247,0.0000032075734,0.9332629,0.0014136261],"study_design_scores_gemma":[0.04937047,0.0022281932,0.011419208,0.0058578225,0.0020410067,0.0006695891,0.00053986564,0.000012860566,0.018734373,0.000040721323,0.9077071,0.0013788225],"about_ca_topic_score_codex":0.014764773,"about_ca_topic_score_gemma":0.0018538396,"teacher_disagreement_score":0.20420492,"about_ca_system_score_codex":0.0041368385,"about_ca_system_score_gemma":0.0015758544,"threshold_uncertainty_score":0.9996861},"labels":[],"label_agreement":null},{"id":"W4411396441","doi":"10.1038/s41408-025-01286-w","title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Fluorescence in situ hybridization; Risk stratification; Medicine; Multiple myeloma; Internal medicine; Oncology; Family medicine; Biology; Genetics; Chromosome","score_opus":0.22496739292696086,"score_gpt":0.42518130795705555,"score_spread":0.2002139150300947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411396441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016043724,0.97814393,0.00035056242,0.00015607689,0.00038961935,0.003924116,0.0009129801,0.000006885908,0.00007211558],"genre_scores_gemma":[0.017245343,0.96210796,0.019134857,0.00000832643,0.000490132,0.0007006652,0.000036891146,0.000045100584,0.00023070544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941688,0.00013268454,0.004523449,0.00042074252,0.0004200436,0.00033423348],"domain_scores_gemma":[0.98103607,0.0031642541,0.013447181,0.00058411254,0.0016626898,0.00010568687],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026435188,0.0003150222,0.0015878441,0.00014954251,0.0003095179,0.000030543142,0.00028024116,0.00017489374,0.000001966292],"category_scores_gemma":[0.018174509,0.00017323764,0.00059136236,0.0003488248,0.00014754444,0.000027175094,0.00009591373,0.0004189348,2.3161816e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043795008,0.00016044085,0.026544878,0.020251328,0.0019411381,0.000029731615,0.00012190242,0.00022881698,0.00096482737,0.0000023671673,0.0002779542,0.9490387],"study_design_scores_gemma":[0.057677742,0.0027664867,0.04089666,0.35416308,0.10215403,0.01066899,0.0015305704,0.018021826,0.051884916,0.00035532055,0.35792476,0.0019556272],"about_ca_topic_score_codex":0.000721275,"about_ca_topic_score_gemma":0.00061179773,"teacher_disagreement_score":0.94708306,"about_ca_system_score_codex":0.00014869827,"about_ca_system_score_gemma":0.0036526674,"threshold_uncertainty_score":0.99009585},"labels":[],"label_agreement":null},{"id":"W4412820579","doi":"10.1038/s41408-025-01329-2","title":"Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Sanofi; Kyowa Hakko Kirin; Cilag; Italfarmaco; Seagen; Celltrion; Pfizer; Incyte; BeiGene; Astex Pharmaceuticals; Kite Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; Leukemia and Lymphoma Society; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen","keywords":"Brentuximab vedotin; Oncology; Medicine; Internal medicine; Chemotherapy; Subgroup analysis; Anaplastic large-cell lymphoma; Lymphoma; Front line; Clinical trial; Hodgkin lymphoma; Meta-analysis","score_opus":0.013720827726550729,"score_gpt":0.28571803154387887,"score_spread":0.2719972038173281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412820579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744626,0.022877395,0.0001301809,0.00032858702,0.0006444952,0.0013181872,0.00018710637,0.000008845018,0.000042602],"genre_scores_gemma":[0.99401927,0.003791101,0.000037735317,0.000107693,0.00014362848,0.0002535743,0.0000106116895,0.00002121988,0.0016151539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983424,0.00008950158,0.00062036596,0.00025903032,0.00039092827,0.0002977801],"domain_scores_gemma":[0.99845946,0.00029749487,0.00047967955,0.00050000625,0.00018406099,0.00007932648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025640114,0.00024006117,0.0008840117,0.0001962687,0.00020611974,0.000022049364,0.00022026827,0.00007010104,0.00009985446],"category_scores_gemma":[0.00001892235,0.00012391013,0.0008276845,0.00054499257,0.000045927307,0.000024123088,0.000036895453,0.000053115302,0.0000012191389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035030488,0.022820365,0.91323686,0.00023142078,0.036671493,0.0000486221,0.005460597,0.0005913805,0.0012324759,0.000019118945,0.0012650611,0.014919552],"study_design_scores_gemma":[0.15424907,0.0037660722,0.75648713,0.000515225,0.05612423,0.000052344218,0.0020446328,0.002112469,0.022720195,0.000009803382,0.0017327141,0.00018614462],"about_ca_topic_score_codex":0.0005925732,"about_ca_topic_score_gemma":0.0018689055,"teacher_disagreement_score":0.15674976,"about_ca_system_score_codex":0.0010761791,"about_ca_system_score_gemma":0.00056346034,"threshold_uncertainty_score":0.50529087},"labels":[],"label_agreement":null},{"id":"W4413629863","doi":"10.1038/s41408-025-01353-2","title":"Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Refractory (planetary science); Medicine; Single Center; Center (category theory); Internal medicine; Oncology; Chemistry; Biology","score_opus":0.023582005949821728,"score_gpt":0.290717206242874,"score_spread":0.26713520029305227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413629863","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17264907,0.006650538,0.000025812624,0.8048992,0.0013155445,0.0009559934,0.0059411684,0.000081311104,0.0074813687],"genre_scores_gemma":[0.19637622,0.006785009,0.00077633624,0.74890107,0.010971622,0.00037648642,0.010390707,0.00043471524,0.024987828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99496084,0.00040895073,0.0011852031,0.00083862053,0.0011908974,0.001415483],"domain_scores_gemma":[0.99689186,0.00027459042,0.00047326,0.0007816144,0.0008191913,0.0007594668],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040721844,0.0006324935,0.0015725356,0.004343179,0.00032915294,0.00035157913,0.00074293785,0.0012446061,0.0031140086],"category_scores_gemma":[0.00027696593,0.0006237252,0.0005841301,0.0026206104,0.00013571502,0.00022606672,0.000115286806,0.0078158425,0.00003816673],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013546711,0.0005547106,0.04341914,0.00013114866,0.007920307,0.00897799,0.00036951658,0.00006773285,0.00015441004,0.000004774428,0.93434656,0.0039182375],"study_design_scores_gemma":[0.018329982,0.000633284,0.045065984,0.0039028607,0.010333746,0.00066314754,0.00014704588,0.0003648054,0.00029226748,0.000113467606,0.9191046,0.0010488114],"about_ca_topic_score_codex":0.23831557,"about_ca_topic_score_gemma":0.31747198,"teacher_disagreement_score":0.07915641,"about_ca_system_score_codex":0.0047596856,"about_ca_system_score_gemma":0.007168121,"threshold_uncertainty_score":0.9996214},"labels":[],"label_agreement":null},{"id":"W4413807594","doi":"10.1038/s41408-025-01352-3","title":"Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study","year":2025,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Saskatchewan Cancer Agency; McMaster University; Ottawa Hospital; Institute of Cancer Research; Saskatoon Medical Imaging; University of Alberta; University of Calgary; University of Ottawa","funders":"Janssen Pharmaceuticals","keywords":"Multiple myeloma; Incidence (geometry); Medicine; Retrospective cohort study; Observational study; Population; Cohort; Cohort study; Internal medicine; Environmental health","score_opus":0.0452434986231261,"score_gpt":0.35435939692169266,"score_spread":0.30911589829856656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413807594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698056,0.0012385376,0.000029870927,0.026610652,0.0003428713,0.0017915354,0.00012137874,0.000022325847,0.00003720898],"genre_scores_gemma":[0.9800651,0.0006785174,0.0016225108,0.013345532,0.0023027542,0.000276465,0.00004781951,0.00003592811,0.0016253545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627787,0.00036530185,0.001083808,0.00051343907,0.0014076883,0.00035190332],"domain_scores_gemma":[0.99732745,0.0004372698,0.0008471834,0.0004389961,0.0008106791,0.00013843944],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00094352564,0.00031995255,0.00069620897,0.00017787052,0.000323628,0.000082198036,0.00030774352,0.00027453623,0.00011521006],"category_scores_gemma":[0.0013758219,0.00021528346,0.00017015978,0.00030529496,0.00014841567,0.00012220067,0.00016297626,0.002359144,7.296732e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037474174,0.00019334875,0.99049765,0.00034712334,0.0018226834,0.00067198643,0.00017792886,0.000020986054,0.00009846708,0.0000013160675,0.0050452733,0.0007485229],"study_design_scores_gemma":[0.0039144563,0.0007982923,0.9915464,0.001006313,0.0013213636,0.0004838679,0.000028529616,0.0004304156,0.000101628655,0.000074758966,0.00012822016,0.00016575865],"about_ca_topic_score_codex":0.0010823647,"about_ca_topic_score_gemma":0.0002979737,"teacher_disagreement_score":0.01326512,"about_ca_system_score_codex":0.00027833553,"about_ca_system_score_gemma":0.00091274356,"threshold_uncertainty_score":0.9999425},"labels":[],"label_agreement":null},{"id":"W4414853478","doi":"10.1038/s41408-025-01356-z","title":"Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Pomalidomide; Dexamethasone; Cyclophosphamide; Multiple myeloma; Clinical endpoint; Adverse effect; Lenalidomide; Refractory (planetary science)","score_opus":0.04355623544536998,"score_gpt":0.38981062880104506,"score_spread":0.3462543933556751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414853478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98387414,0.007318167,0.00009138195,0.00037687298,0.0013019416,0.00598088,0.00003091979,0.00008497597,0.00094072893],"genre_scores_gemma":[0.9932522,0.0016269548,0.0022977125,0.00012764859,0.00072840025,0.0008498986,0.000021499096,0.000116001494,0.0009796537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9900514,0.003301663,0.002491976,0.0010720225,0.0016320137,0.0014509427],"domain_scores_gemma":[0.99424726,0.0018587108,0.0010240452,0.0012247898,0.00064993225,0.0009952612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004929173,0.0008295342,0.003239621,0.0011013501,0.0004506057,0.0001524061,0.000672837,0.00029308765,0.0006725574],"category_scores_gemma":[0.0029768306,0.00062020094,0.0004761021,0.0022367719,0.00030731875,0.0004966995,0.00024617527,0.0017858412,0.000008762616],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7000724,0.03456113,0.1938758,0.00011841056,0.007928003,0.0089582205,0.0029698939,0.0002581147,0.0006862185,0.000019602658,0.00034195036,0.05021028],"study_design_scores_gemma":[0.8266015,0.014617301,0.14312066,0.0007786341,0.0035326155,0.00021558594,0.009039669,0.00023784625,0.0010841842,0.00008475559,0.0002086838,0.0004785533],"about_ca_topic_score_codex":0.003149262,"about_ca_topic_score_gemma":0.0064960453,"teacher_disagreement_score":0.12652913,"about_ca_system_score_codex":0.00074648333,"about_ca_system_score_gemma":0.002055837,"threshold_uncertainty_score":0.9996249},"labels":[],"label_agreement":null},{"id":"W4415521520","doi":"10.1038/s41408-025-01387-6","title":"35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience","year":2025,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Multiple myeloma; French; Autologous stem-cell transplantation; Clinical trial; Transplantation; Stem cell; Standard of care","score_opus":0.09186293333158163,"score_gpt":0.3964676674332405,"score_spread":0.3046047341016589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415521520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06411092,0.9337437,0.000020072956,0.00013409904,0.00070940546,0.001094013,0.000113478476,0.000013480454,0.000060805192],"genre_scores_gemma":[0.028049618,0.9705441,0.000072689305,0.00006779767,0.00076324673,0.00019582987,0.000011709256,0.000032893073,0.0002620992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970588,0.00069576304,0.0010312174,0.0003238495,0.00055514765,0.00033520412],"domain_scores_gemma":[0.997688,0.0010583184,0.00070923864,0.00026332674,0.00008552182,0.00019562458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082517543,0.00034420562,0.0019316244,0.00029637647,0.0001558918,0.000044892968,0.00029175877,0.00027256925,0.00014252498],"category_scores_gemma":[0.000067848094,0.0001969632,0.00043338886,0.00036015027,0.00013509186,0.00006888466,0.000031786112,0.0011569039,0.000003779308],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074057205,0.00013695458,0.00013775149,0.0037176602,0.00082659425,0.0004592585,0.0013630276,8.6551586e-7,0.00009490107,0.0000039282995,0.00012425888,0.9923942],"study_design_scores_gemma":[0.08740859,0.0072469665,0.027859043,0.30593267,0.015172134,0.011406353,0.0018877198,0.000016749527,0.007863862,0.00013967154,0.5331065,0.0019597448],"about_ca_topic_score_codex":0.00009822428,"about_ca_topic_score_gemma":0.000006089143,"teacher_disagreement_score":0.99043447,"about_ca_system_score_codex":0.00011746835,"about_ca_system_score_gemma":0.00097408576,"threshold_uncertainty_score":0.8031926},"labels":[],"label_agreement":null},{"id":"W4416690579","doi":"10.1038/s41408-025-01416-4","title":"Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Juravinski Cancer Centre; Hamilton Health Sciences; Population Health Research Institute; McMaster University","funders":"Government of Ontario; Leukemia and Lymphoma Society of Canada; Cancer Research Society; Johns Hopkins Children's Center","keywords":"Stem cell; Transplantation; Hematology; Hematopoietic stem cell transplantation; Myeloid; Haematopoiesis; MEDLINE","score_opus":0.022391468870450293,"score_gpt":0.35069953915330787,"score_spread":0.3283080702828576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416690579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998122,0.00038132435,0.00017934211,0.00015592943,0.00019179385,0.00061148254,0.000037998194,0.000016747634,0.00030339495],"genre_scores_gemma":[0.99893796,0.0004286301,0.00009041301,0.000070208844,0.00012342702,0.00004220066,0.000018571121,0.00002597499,0.00026259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979471,0.00023763432,0.0005866741,0.0002613415,0.00059285975,0.00037440247],"domain_scores_gemma":[0.9991004,0.00016890562,0.0002010941,0.00022202471,0.00015978479,0.0001477935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006418058,0.00020777485,0.0004989967,0.00077289087,0.00010495163,0.00003289131,0.00017686418,0.00011442505,0.00009544545],"category_scores_gemma":[0.000016067224,0.00016601373,0.00020224831,0.0006880157,0.000019289837,0.00009201711,0.000015298921,0.0007588934,0.0000019757722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002387573,0.0007797423,0.96322864,0.00013557877,0.0005656486,0.0004252277,0.0005754327,0.006347977,0.022228066,0.0000035675735,0.00006302515,0.0032595433],"study_design_scores_gemma":[0.015124112,0.0017111375,0.96661496,0.0005021402,0.0006458371,0.000047252564,0.00040875305,0.0003895065,0.014411203,0.000010657968,0.0000030539163,0.00013138032],"about_ca_topic_score_codex":0.0017381725,"about_ca_topic_score_gemma":0.00042960962,"teacher_disagreement_score":0.012736539,"about_ca_system_score_codex":0.0021749805,"about_ca_system_score_gemma":0.002758524,"threshold_uncertainty_score":0.67698437},"labels":[],"label_agreement":null},{"id":"W7117694170","doi":"10.1038/s41408-025-01444-0","title":"Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hematology; Clinical trial; MEDLINE; Chemotherapy; Text mining","score_opus":0.019761591039750934,"score_gpt":0.34972406755008556,"score_spread":0.3299624765103346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117694170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970745,0.00053435465,0.000012986507,0.0007347273,0.0002435401,0.0011312541,0.00002768275,0.0000061733504,0.00023479729],"genre_scores_gemma":[0.99520475,0.0042585665,0.000035174216,0.0002191722,0.000071391325,0.00009166877,0.0000018459895,0.000017390708,0.00010001713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804306,0.000464652,0.0005410621,0.0002375056,0.0005007223,0.00021301722],"domain_scores_gemma":[0.99799603,0.0011448521,0.0003205116,0.00025580268,0.00018768225,0.000095143245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080700376,0.00022394507,0.000727188,0.00016016295,0.000087636945,0.000013844843,0.00012157455,0.00010087694,0.0003326914],"category_scores_gemma":[0.00014151401,0.00009734578,0.00019348437,0.00030032385,0.000086464024,0.00006118524,0.000014730959,0.0005606652,0.0000011143286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025087968,0.0041029295,0.8681308,0.000080633945,0.0009980189,0.000026018404,0.00017179076,0.000018363917,0.0007865455,0.00001044562,0.0001786029,0.100407876],"study_design_scores_gemma":[0.03858728,0.017155048,0.76847696,0.0011257854,0.00048056635,0.0000063625503,0.000013423098,0.000009237654,0.17386949,0.000011558396,0.0001697947,0.00009447685],"about_ca_topic_score_codex":0.00018915437,"about_ca_topic_score_gemma":0.00020624307,"teacher_disagreement_score":0.17308295,"about_ca_system_score_codex":0.000088919114,"about_ca_system_score_gemma":0.000563289,"threshold_uncertainty_score":0.39696455},"labels":[],"label_agreement":null}]}